<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD002292.pub3" GROUP_ID="SKIN" ID="881602111516193983" MERGED_FROM="" MODIFIED="2016-02-10 10:49:39 +0000" MODIFIED_BY="Helen Scott" NOTES="&lt;p&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.1&lt;br&gt;Exported from Review Manager 4.2&lt;br&gt;from GK, 18 feb03&lt;/p&gt;&lt;p&gt;19feb03 - corrected as per PM's suggestions and started general editing&lt;/p&gt;&lt;p&gt;Hvae also changed labels as per sally's suggestion&lt;/p&gt;&lt;p&gt;literature up-date March 2003 by GK, FD and Ingrid Riphagen&lt;/p&gt;&lt;p&gt;submitted for peer-review by GK on 6th may 2003&lt;/p&gt;&lt;p&gt;14 may 03 - EP began copy-editing for publication, incl. HW's suggestions.&lt;br&gt;Sally Hollis had wrong identifier - changed to correct (SH02). Phillippa Middleton's contact details are missing.&lt;br&gt;Abstract is over word limit (722 vs. 400) - returning to Gudula for revision.&lt;/p&gt;&lt;p&gt;19may03 - EP continued copy-editing, corrected spelling to UK English throughout, numbers in results to match metaview where number of decimal places was inconsistent, changed journal titles to full. Noted problem with Rook 1998 citation, asked gudula for correction.&lt;/p&gt;&lt;p&gt;20may03 - EP made alterations to this version as those made by Gudula in version sent on 20may03. These included: revised abstract, revised contributions of reviewers. Also, Rook 1998 citation updated, now the ID is Wojnarowska.&lt;/p&gt;&lt;p&gt;ready for CLIB&lt;/p&gt;&lt;p&gt;28may03 - still looks OK!&lt;/p&gt;&lt;p&gt;16may05 - TL added to what's new 'The skin group TSC has searched the Skin Group Specialised Register, the Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE to May 2005 and sent the trials found to the lead author who has checked them and decided that there are no new RCTs.'&lt;br&gt;I have called this a substantial update - check if this is correct - yes&lt;/p&gt;&lt;p&gt;25may05 - asked Kavita to check warnings and edit style if time&lt;br&gt;25 May 05 (KJ) Warnings addressed, headings reformatted&lt;br&gt;13 Aug 07 (DAH) Citation for Murrell D changed to DF upon request of author&lt;/p&gt;&lt;p&gt;Converted to RM5 by CB 8/8/08&lt;/p&gt;" NOTES_MODIFIED="2016-02-10 10:46:14 +0000" NOTES_MODIFIED_BY="Helen Scott" REVIEW_NO="#18" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="13.0">
<COVER_SHEET MODIFIED="2016-02-10 10:49:39 +0000" MODIFIED_BY="Helen Scott">
<TITLE>Interventions for bullous pemphigoid</TITLE>
<CONTACT MODIFIED="2016-02-10 10:49:39 +0000" MODIFIED_BY="Helen Scott"><PERSON ID="16372" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Gudula</FIRST_NAME><LAST_NAME>Kirtschig</LAST_NAME><POSITION>Dermatologist</POSITION><EMAIL_1>g.kirtschig@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Institute of General Medicine and Interprofessional Care</DEPARTMENT><ORGANISATION>University of Tübingen</ORGANISATION><CITY>Tübingen</CITY><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>0049-7071 36 59 700</PHONE_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2016-02-10 10:49:39 +0000" MODIFIED_BY="Helen Scott"><PERSON ID="16372" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Gudula</FIRST_NAME><LAST_NAME>Kirtschig</LAST_NAME><POSITION>Dermatologist</POSITION><EMAIL_1>g.kirtschig@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Institute of General Medicine and Interprofessional Care</DEPARTMENT><ORGANISATION>University of Tübingen</ORGANISATION><CITY>Tübingen</CITY><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>0049-7071 36 59 700</PHONE_1></ADDRESS></PERSON><PERSON ID="4841" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Philippa</FIRST_NAME><LAST_NAME>Middleton</LAST_NAME><POSITION>Principal Research Fellow</POSITION><EMAIL_1>philippa.middleton@adelaide.edu.au</EMAIL_1><EMAIL_2>mpm@ozemail.com.au</EMAIL_2><ADDRESS><ORGANISATION>Healthy Mothers, Babies and Children, South Australian Health and Medical Research Institute</ORGANISATION><ADDRESS_1>Women's and Children's Hospital</ADDRESS_1><ADDRESS_2>72 King William Road</ADDRESS_2><CITY>Adelaide</CITY><ZIP>5006</ZIP><REGION>South Australia</REGION><COUNTRY CODE="AU">Australia</COUNTRY></ADDRESS></PERSON><PERSON ID="828110F882E26AA200E51E67E25FC1CF" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Cathy</FIRST_NAME><LAST_NAME>Bennett</LAST_NAME><POSITION>Visiting Professor</POSITION><EMAIL_1>info@systematicresearch.uk</EMAIL_1><EMAIL_2>cmt.bennett@ntlworld.com</EMAIL_2><ADDRESS><DEPARTMENT>Centre for Technology Enabled Health Research (CTEHR)</DEPARTMENT><ORGANISATION>Coventry University</ORGANISATION><ADDRESS_1>Priory Street</ADDRESS_1><CITY>Coventry</CITY><ZIP>CV1 5FB</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON><PERSON ID="16382" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Dedee</FIRST_NAME><MIDDLE_INITIALS>F</MIDDLE_INITIALS><LAST_NAME>Murrell</LAST_NAME><POSITION>Professor of Dermatology</POSITION><EMAIL_1>D.Murrell@unsw.edu.au</EMAIL_1><ADDRESS><DEPARTMENT>Department of Dermatology</DEPARTMENT><ORGANISATION>St George Hospital &amp; University of New South Wales</ORGANISATION><ADDRESS_1>Belgrave St</ADDRESS_1><ADDRESS_2>Kogarah</ADDRESS_2><CITY>Sydney</CITY><ZIP>2217</ZIP><REGION>NSW</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 29 350 2543</PHONE_1><FAX_1>+61 29 350 29906</FAX_1></ADDRESS></PERSON><PERSON ID="16426" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Fenella</FIRST_NAME><LAST_NAME>Wojnarowska</LAST_NAME><EMAIL_1>fenella@northtregeare.com</EMAIL_1><ADDRESS><DEPARTMENT>Nuffield Department of Clinical Medicine</DEPARTMENT><ORGANISATION>University of Oxford</ORGANISATION><CITY>Oxford</CITY><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON><PERSON ID="16371" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Nonhlanhla</FIRST_NAME><MIDDLE_INITIALS>P</MIDDLE_INITIALS><LAST_NAME>Khumalo</LAST_NAME><POSITION>Dermatologist</POSITION><EMAIL_1>n.khumalo@uct.ac.za</EMAIL_1><ADDRESS><DEPARTMENT>Department of Dermatology</DEPARTMENT><ORGANISATION>Groote Schuur Hospital</ORGANISATION><ADDRESS_1>Anzio Road</ADDRESS_1><ADDRESS_2>Observatory</ADDRESS_2><CITY>Cape Town</CITY><ZIP>7925</ZIP><REGION>Western Cape</REGION><COUNTRY CODE="ZA">South Africa</COUNTRY><PHONE_1>+27 21 4049 111 ext: 3376</PHONE_1><FAX_1>+27 21 4478 232</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2011-11-07 12:09:19 +0000" MODIFIED_BY="Laura Prescott">
<UP_TO_DATE>
<DATE DAY="10" MONTH="8" YEAR="2010"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="10" MONTH="8" YEAR="2010"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="2" YEAR="2012"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2000"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2003"/>
<LAST_CITATION_ISSUE ISSUE="10" YEAR="2010"/>
</DATES>
<WHATS_NEW MODIFIED="2015-10-07 11:13:58 +0100" MODIFIED_BY="Helen Scott">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2015-10-07 11:13:58 +0100" MODIFIED_BY="Helen Scott">
<DATE DAY="7" MONTH="10" YEAR="2015"/>
<DESCRIPTION>
<P>Author information (affiliation) updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2015-10-07 11:13:25 +0100" MODIFIED_BY="Helen Scott">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2015-10-07 11:13:25 +0100" MODIFIED_BY="Helen Scott">
<DATE DAY="11" MONTH="9" YEAR="2013"/>
<DESCRIPTION>
<P>Contact author's out-of-date email address removed and current email address and second affiliation added. Another author's affiliation also updated</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-09-11 11:12:33 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="7" MONTH="11" YEAR="2011"/>
<DESCRIPTION>
<P>Correction made to the data relating to the Beissert 2007 study ('1000' mg MMF amended to '2000' mg MMF)</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2011-11-07 12:18:54 +0000" MODIFIED_BY="Laura  Prescott">
<DATE DAY="6" MONTH="9" YEAR="2010"/>
<DESCRIPTION>
<P>Change in authorship</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2011-11-07 12:18:56 +0000" MODIFIED_BY="Laura  Prescott">
<DATE DAY="6" MONTH="9" YEAR="2010"/>
<DESCRIPTION>
<P>Review updated with 3 new studies</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2013-09-11 11:12:38 +0100" MODIFIED_BY="Finola M Delamere">
<DATE DAY="5" MONTH="2" YEAR="2010"/>
<DESCRIPTION>
<P>New studies found and included or excluded, authors changed</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-09-11 11:12:40 +0100" MODIFIED_BY="Finola M Delamere">
<DATE DAY="5" MONTH="2" YEAR="2010"/>
<DESCRIPTION>
<P>Updated</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-09-11 11:12:42 +0100" MODIFIED_BY="Cathy Bennett">
<DATE DAY="8" MONTH="8" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2013-09-11 11:12:39 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="5" MONTH="6" YEAR="2008"/>
<DESCRIPTION>
<P>New studies found and included or excluded</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2013-09-11 11:12:34 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="16" MONTH="5" YEAR="2005"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-09-11 11:12:36 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="5" MONTH="6" YEAR="2003"/>
<DESCRIPTION>
<P>Minor update</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Nuffield Trust Fellowship scheme</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2011-11-07 12:16:46 +0000" MODIFIED_BY="Finola M Delamere">
<SUMMARY MODIFIED="2010-09-08 07:50:49 +0100" MODIFIED_BY="Finola M Delamere">
<TITLE MODIFIED="2008-08-11 09:57:22 +0100" MODIFIED_BY="Cathy Bennett">Treatments for bullous pemphigoid</TITLE>
<SUMMARY_BODY MODIFIED="2010-09-08 07:50:49 +0100" MODIFIED_BY="Finola M Delamere">
<P>Bullous pemphigoid (BP) is the most common autoimmune blistering disease in the West. Incidence figures are not available for most parts of the world but BP appears to be rarer in the Far East. Bullous pemphigoid is usually a disease of the elderly but it can also affect younger people and children. Both sexes are similarly affected. While BP usually resolves within five years, there is a moderate death rate associated with the disease and its treatment. Oral corticosteroid drugs are the most common treatment, but may be associated with serious adverse effects, including some deaths. The most common adverse effects of oral steroids, include weight gain and high blood pressure. Long-term use is associated with an increased risk of diabetes mellitus and decreased bone density. Topical steroids are also associated with adverse effects, such as thinning of the skin and easy bruising. The risk of experiencing adverse effects of topical steroids depends on the strength of the steroid, how long it is used for, which area of the body it is applied to, and the kind of skin problem; if a high-strength, potent steroid is used, enough may be absorbed through the skin to cause adverse effects in the rest of the body.</P>
<P>Other treatments include azathioprine, mycophenolate mofetil, dapsone, methotrexate, cyclosporin, cyclophosphamide, plasma exchange, erythromycin, and tetracycline and nicotinamide. Some of these drugs or interventions have the potential for severe adverse effects such as increased susceptibility to serious infections, liver and kidney damage, and bone marrow suppression; and many are very expensive.</P>
<P>Three new studies were included in this update of the review published in 2005 making a total of 10 randomised controlled trials with a total of 1049 participants. All studies involved different comparisons, none had a placebo group. Different doses and formulations of corticosteroids plus azathioprine showed no significant differences in disease control, although azathioprine reduced the amount of prednisone required for disease control. There were no significant differences in healing or disease-free intervals in participants taking azathioprine compared with mycophenolate mofetil, or in disease response comparing tetracycline plus nicotinamide with prednisolone. One small study using Chinese traditional medicine, 'Jingui Shenqi Pill' (JSP), plus prednisone did not show any benefit in favour of adding this traditional Chinese herbal remedy. Most of the deaths were in participants taking high doses of oral corticosteroids.</P>
<P>The review of trials concluded that lower doses of oral steroids and strong steroid creams seem safe and effective. However, the use of steroid creams in extensive disease may be limited by side-effects and the practicality of applying creams to large areas of the skin. Milder regimens of topical steroids are safe and effective in moderate BP. More research is needed on treatments for BP, in particular, the effectiveness of adding plasma exchange, azathioprine or mycophenolate mofetil to corticosteroids, and the treatment with tetracyclines and nicotinamide.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2010-09-08 07:53:15 +0100" MODIFIED_BY="Finola M Delamere">
<ABS_BACKGROUND MODIFIED="2010-09-08 07:52:40 +0100" MODIFIED_BY="Finola M Delamere">
<P>Bullous pemphigoid (BP) is the most common autoimmune blistering disease in the West. Oral steroids are the standard treatment.This is an update of the review published in 2005.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2010-02-23 10:33:07 +0000" MODIFIED_BY="Cathy Bennett">
<P>To assess treatments for bullous pemphigoid.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2010-09-03 13:50:29 +0100" MODIFIED_BY="Laura  Prescott">
<P>In August 2010 we updated our searches of the Cochrane Skin Group Specialised Register, the Cochrane Central Register of Controlled Trials (Clinical Trials)<I>,</I> MEDLINE, EMBASE, and the Ongoing Trials registers.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2010-03-25 13:54:35 +0000" MODIFIED_BY="Finola M Delamere">
<P>Randomised controlled trials of treatments for participants with immunofluorescence-confirmed bullous pemphigoid.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2010-08-10 13:43:32 +0100" MODIFIED_BY="Finola M Delamere">
<P>At least two authors evaluated the studies for the inclusion criteria, and extracted data independently.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2010-09-08 07:53:15 +0100" MODIFIED_BY="Finola M Delamere">
<P>We included 10 randomised controlled trials (with a total of 1049 participants) of moderate to high risk of bias. All studies involved different comparisons, none had a placebo group. In 1 trial plasma exchange plus prednisone gave significantly better disease control at 1 month (0.3 mg/kg: RR 18.78, 95% CI 1.20 to 293.70) than prednisone alone (1.0 mg/kg: RR 1.79, 95% CI 1.11 to 2.90), while another trial showed no difference in disease control at 6 months.</P>
<P>No differences in disease control were seen for different doses or formulations of prednisolone (one trial each), for azathioprine plus prednisone compared with prednisone alone (one trial), for prednisolone plus azathioprine compared with prednisolone plus plasma exchange (one trial), for prednisolone plus mycophenolate mofetil or plus azathioprine (one trial), for tetracycline plus nicotinamide compared with prednisolone (one trial). Chinese traditional medicine plus prednisone was not effective in one trial.</P>
<P>There were no significant differences in healing in a comparison of a standard regimen of topical steroids (clobetasol) with a milder regimen (RR 1.00, 95% 0.97 to 1.03) in one trial. In another trial, clobetasol showed significantly more disease control than oral prednisolone in people with extensive and moderate disease (RR 1.09, 95% CI 1.02 to 1.17), with significantly reduced mortality and adverse events (RR 1.06, 95% CI 1.00 to 1.12).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2010-09-06 15:35:43 +0100" MODIFIED_BY="Finola M Delamere">
<P>Very potent topical steroids are effective and safe treatments for BP, but their use in extensive disease may be limited by side-effects and practical factors. Milder regimens (using lower doses of steroids) are safe and effective in moderate BP. Starting doses of prednisolone greater than 0.75 mg/kg/day do not give additional benefit, lower doses may be adequate to control disease and reduce the incidence and severity of adverse reactions. The effectiveness of adding plasma exchange, azathioprine or mycophenolate mofetil to corticosteroids, and combination treatment with tetracycline and nicotinamide needs further investigation. </P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2011-11-07 12:16:46 +0000" MODIFIED_BY="Finola M Delamere">
<BACKGROUND MODIFIED="2010-09-08 07:54:40 +0100" MODIFIED_BY="Finola M Delamere">
<CONDITION MODIFIED="2010-09-08 07:52:50 +0100" MODIFIED_BY="Finola M Delamere">
<SUBSECTION>
<HEADING LEVEL="3">Definition and epidemiology</HEADING>
<P>Bullous pemphigoid (BP) is an acquired autoimmune disorder in which disease-specific autoantibodies are directed against components of the basement membrane zone of the skin (<LINK REF="REF-Morrison-1990" TYPE="REFERENCE">Morrison 1990</LINK>; <LINK REF="REF-Wojnarowska-1998" TYPE="REFERENCE">Wojnarowska 1998</LINK>). It is the most common autoimmune blistering disease in the West with an estimated incidence of six to seven cases per million population per year in France and Germany (<LINK REF="REF-Bernard-1995" TYPE="REFERENCE">Bernard 1995</LINK>; <LINK REF="REF-Zillikens-1995" TYPE="REFERENCE">Zillikens 1995</LINK>). The figures are probably similar or higher in the United Kingdom. Incidence figures are not available for most parts of the world but bullous pemphigoid appears to be rarer in the Far East (<LINK REF="REF-Adam-1992" TYPE="REFERENCE">Adam 1992</LINK>; <LINK REF="REF-Jin-1993" TYPE="REFERENCE">Jin 1993</LINK>; <LINK REF="REF-Tham-1998" TYPE="REFERENCE">Tham 1998</LINK>). Bullous pemphigoid is usually a disease of the elderly but it can also affect younger people and children (<LINK REF="REF-Kirtschig-1994" TYPE="REFERENCE">Kirtschig 1994</LINK>; <LINK REF="REF-Orange-1989" TYPE="REFERENCE">Orange 1989</LINK>; <LINK REF="REF-Nemeth-1991" TYPE="REFERENCE">Nemeth 1991</LINK>). Both sexes are similarly affected.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Clinical picture</HEADING>
<P>The characteristic clinical picture is the development of tense blisters, which may arise on inflamed skin or skin of normal appearance. This may be heralded by an urticarial or eczematous rash. The degree of itch varies from none to intense and may precede the appearance of blisters, which contain either clear or bloodstained fluid. The blisters are usually generalised on the body with a tendency to appear on the creases of the limbs. Localised forms also occur. Bullous pemphigoid may affect mucosal surfaces such as the mouth; scarring is usually not observed.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Investigation and diagnosis</HEADING>
<P>The most reliable test to achieve a diagnosis is a skin biopsy for immunopathological investigation. A direct immunofluorescence technique (IF) (on skin) demonstrates deposits of IgG autoantibodies and complement (C3) at the dermo-epidermal junction. Indirect IF (using serum) demonstrates circulating autoantibodies directed against basement membrane proteins (<LINK REF="REF-Morrison-1990" TYPE="REFERENCE">Morrison 1990</LINK>; <LINK REF="REF-Wojnarowska-1998" TYPE="REFERENCE">Wojnarowska 1998</LINK>). When skin tissue is incubated in one molar sodium chloride, separation of the dermis from the epidermis occurs within the lamina lucida level of the basement membrane (visualised on electron microscopic examination). Immunofluorescence techniques performed on such split skin was first shown in the late 1980s to result in a more precise localisation of the antigen-antibody-binding site. This helps to separate other autoimmune bullous diseases such as epidermolysis bullosa acquisita and bullous systemic lupus erythematosus (in which fluorescence is at the floor of the blister: dermal binding) from BP (in which fluorescence is usually at the roof: epidermal binding) (<LINK REF="REF-Logan-1987" TYPE="REFERENCE">Logan 1987</LINK>). Immunoelectron microscopy and immunoblotting are more specific investigations and in some cases can lead to a change in the diagnosis (<LINK REF="REF-Kirtschig-1994" TYPE="REFERENCE">Kirtschig 1994</LINK>). The latter investigations are not yet available for routine clinical use, being largely limited to research centres.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Natural history</HEADING>
<P>The natural history of both treated and untreated BP is of a persistent disease with eventual remission occurring in the majority of cases. Remission is likely to occur within five years, although relapses and exacerbations may occur (<LINK REF="REF-Ahmed-1977" TYPE="REFERENCE">Ahmed 1977</LINK>; <LINK REF="REF-Hadi-1988" TYPE="REFERENCE">Hadi 1988</LINK>; <LINK REF="REF-Nemeth-1991" TYPE="REFERENCE">Nemeth 1991</LINK>; <LINK REF="REF-Person-1977" TYPE="REFERENCE">Person 1977</LINK>). The mortality rate in the initial 30 cases reported by Lever was 24% at 1 year. This was prior to the use of oral corticosteroids (<LINK REF="REF-Lever-1953" TYPE="REFERENCE">Lever 1953</LINK>). The mortality rate in other studies ranges from about 10% to 40% at 1 year (<LINK REF="REF-Colbert-2004" TYPE="REFERENCE">Colbert 2004</LINK>; <LINK REF="REF-Venning-1992" TYPE="REFERENCE">Venning 1992</LINK>; <LINK REF="REF-Savin-1979" TYPE="REFERENCE">Savin 1979</LINK>; <LINK REF="REF-Savin-1987" TYPE="REFERENCE">Savin 1987</LINK>; <LINK REF="REF-Roujeau-1998" TYPE="REFERENCE">Roujeau 1998</LINK>; <LINK REF="REF-Gudi-2005" TYPE="REFERENCE">Gudi 2005</LINK>), despite the use of topical and systemic treatments. This might suggest that treatment is at best suppressive (without really altering the prognosis of the disease) or at worst contributes to mortality (e.g. from sepsis secondary to immunosuppression) whilst relieving itch and preventing blisters. Savin suggested that death seemed to be more commonly related to underlying illness in the elderly, debilitation associated with severe illness, or the adverse effects of treatment. The study by Parker et al supports this view, they evaluated 223 participants with pemphigoid and compared mortality data with the general population in the United States (<LINK REF="REF-Parker-2008" TYPE="REFERENCE">Parker 2008</LINK>). There was no difference between pemphigoid participants and age-matched controls in expected mortality. They conclude that mortality of participants with bullous pemphigoid is more likely related to advanced age and associated medical conditions than disease-specific factors and treatment will not alter the natural disease history but the quality of life.</P>
</SUBSECTION>
</CONDITION>
<INTERVENTION MODIFIED="2010-09-08 07:54:00 +0100" MODIFIED_BY="Finola M Delamere">
<P>Current treatments include oral steroids (e.g. prednisone or prednisolone), azathioprine, mycophenolate mofetil, dapsone, methotrexate, cyclosporin, cyclophosphamide, plasma exchange, erythromycin, and tetracycline and nicotinamide. Some of these drugs or interventions have the potential for severe adverse effects such as increased susceptibility to serious infections, liver and kidney damage, and bone marrow suppression; and some are very expensive.</P>
<P>High-potency topical steroids (clobetasol propionate cream) have been demonstrated to improve survival in patients with bullous pemphigoid (<LINK REF="STD-Joly-2002" TYPE="STUDY">Joly 2002</LINK>). These topical steroids may be safer and more effective than high-dose oral corticosteroids for controlling BP and therefore may be suitable for treating those patients, often the elderly, who have a poor prognosis because they are at high risk of developing adverse effects with systemic treatments. Topical steroids are not without risk of adverse effects, both locally (increased susceptibility of the skin to damage like skin atrophy and bruising and infections of the skin) and systemically if enough steroid is absorbed through the skin, leading, for example, to Cushing syndrome with fluid retention, increased blood pressure and diabetes mellitus, and adrenal gland suppression.</P>
<P>Prednisone is an inactive drug precursor that is metabolised by the liver and converted to biologically active prednisolone. The two forms are virtually identical therapeutically and can be used interchangeably in many situations. As prednisone is rapidly converted to prednisolone, prednisolone may be preferred in some patients who have liver disease or some other metabolic disorder. There are some differences in the appearance and taste of the two formulations: prednisolone sodium phosphate is very soluble with a not unpleasant taste, whereas prednisone is bitter and poorly soluble. Some reports have suggested that the use of prednisone is preferable to prednisolone in the treatment of BP (<LINK REF="REF-Lebrun_x002d_Vignes-1999" TYPE="REFERENCE">Lebrun-Vignes 1999</LINK>) and this may account for differences in use of the drug, for example, in France. For the purposes of this review, prednisone and prednisolone are regarded as bio-equivalent, however, for each of our included studies we have used the drug name which was quoted in the report of the study.</P>
<P>There are emerging reports of some BP cases being treated with biological therapies, in particular, anti-CD20 monoclonal antibodies (rituximab) (<LINK REF="REF-Hertl-2008" TYPE="REFERENCE">Hertl 2008</LINK>). CD20 is a molecule which is expressed on the surface of B lymphocytes (the immune cells which produce antibodies) including the autoantibodies which are directed at the skin in BP. Rituximab, a monoclonal antibody, binds specifically to this transmembranous CD20 antigen and the resulting lysis (breaking down) of the B lymphocyte is induced via a number of immune pathways. This limits the immune system's attack by depleting the number of B lymphocytes available to produce antibodies. Rituximab could be used either as an alternative to standard treatments for bullous pemphigoid, in patients that are refractory to standard treatment (<LINK REF="REF-Reguia_x00ef_-2009" TYPE="REFERENCE">Reguiaï 2009</LINK>) or if the patient is unable to tolerate other treatments.</P>
</INTERVENTION>
<IMPORTANCE MODIFIED="2010-09-08 07:54:40 +0100" MODIFIED_BY="Finola M Delamere">
<P>Mortality figures, based on uncontrolled studies, have not improved much since the introduction of systemic treatments. This may suggest that BP is a self-limiting condition (occurring in older people with a higher mortality than the general population) and that the prognosis is not altered by treatment. It is also possible that improved skin care and medical support currently available,compared with the times of Lever (<LINK REF="REF-Lever-1953" TYPE="REFERENCE">Lever 1953</LINK>) do significantly lower the mortality rate and that this benefit is masked by the adverse effects of systemic treatments. However, this does not tell us about morbidity and the quality of life of these affected people and whether treatment alters the duration of the lesions. There is also variation in the long-term toxicity of systemic agents ranging from very little (e.g. antibiotics) to a lot (e.g. prednisolone or cyclophosphamide). Use of very potent topical steroid treatment may be adequate in localised disease and has minimal side-effects. There is wide variation in practice among clinicians as to which drugs or interventions are used and in what order or combinations.</P>
<P>This review aims to establish:</P>
<OL>
<LI>which are the most effective drugs or interventions, with the least adverse effects;</LI>
<LI>whether combination therapy (e.g. azathioprine plus steroids) offers any advantages over single drugs (e.g. oral steroids alone);</LI>
<LI>whether antibiotics such as tetracyclines, erythromycin, dapsone, or sulphonamides are useful; and</LI>
<LI>whether systemic treatment is better than topical or no treatment.</LI>
</OL>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES>
<P>To assess the effects of treatments for bullous pemphigoid.</P>
</OBJECTIVES>
<METHODS MODIFIED="2010-09-05 12:17:19 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2010-09-03 14:17:50 +0100" MODIFIED_BY="Laura  Prescott">
<CRIT_STUDIES>
<P>Randomised controlled trials.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>People of any age who have received treatment for a diagnosis of bullous pemphigoid, confirmed by immunofluorescence studies. </P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Any therapeutic intervention used to treat bullous pemphigoid.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2010-09-03 14:17:50 +0100" MODIFIED_BY="Laura  Prescott">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2010-09-03 14:16:03 +0100" MODIFIED_BY="Laura  Prescott">
<P>(a) Regression or healing of the skin lesions at time periods specified by individual trials.</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2010-09-03 14:17:50 +0100" MODIFIED_BY="Laura  Prescott">
<P>(a) Effect on the quality of life, e.g. relief of soreness or itching.</P>
<P>(b) Duration of remissions after stopping treatment.</P>
<P>(c) Complications of the primary disease (BP), e.g. localised skin infection.</P>
<P>(d) Systemic infection.</P>
<P>(e) Adverse effects of treatment:</P>
<P>i) organ failure</P>
<P>ii) allergic reactions.</P>
<P>f) Mortality.</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2010-09-05 12:13:25 +0100" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2010-09-05 12:13:25 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the following databases up to 10th August 2010:</P>
<UL>
<LI>The Cochrane Skin Group Specialised Register using the search terms in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>; and</LI>
<LI>The Cochrane Central Register of Controlled Trials (Clinical Trials) within <I>The Cochrane Library</I> using the search strategy in <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>; and</LI>
<LI>MEDLINE and EMBASE using the strategies in <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK> and <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK> respectively.</LI>
</UL>
<SUBSECTION>
<HEADING LEVEL="4">Ongoing Trials</HEADING>
<P>We searched the following Ongoing Trials registers in August 2010 using the term 'bullous pemphigoid'.</P>
<UL>
<LI>The metaRegister of Controlled Trials <A HREF="http://www.controlled-trials.com/">www.controlled-trials.com</A>.</LI>
<LI>The U.S. National Institutes of Health ongoing trials register <A HREF="http://www.clinicaltrials.gov/">www.clinicaltrials.gov</A>.</LI>
<LI>The Australian and New Zealand Clinical Trials Registry <A HREF="http://www.anzctr.org.au/">www.anzctr.org.au</A>.</LI>
<LI>The World Health Organization International Clinical Trials Registry platform <A HREF="http://www.who.int/trialsearch">www.who.int/trialsearch</A>.</LI>
<LI>The Ongoing Skin Trials Register on <A HREF="http://www.nottingham.ac.uk/ongoingskintrials">www.nottingham.ac.uk/ongoingskintrials</A>.</LI>
</UL>
</SUBSECTION>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2010-07-29 13:33:01 +0100" MODIFIED_BY="Cathy Bennett">
<SUBSECTION>
<HEADING LEVEL="4">References from published studies</HEADING>
<P>We searched the bibliographies from identified studies.</P>
</SUBSECTION>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2010-09-05 12:17:19 +0100" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2010-09-03 14:12:28 +0100" MODIFIED_BY="Laura  Prescott">
<P>We screened the abstracts of potentially relevant studies and obtained full articles if necessary. We assessed articles that were possible RCTs for eligibility using inclusion criteria outlined in the protocol. This was done independently by at least two authors (NP, PM, and GK).</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2010-09-05 12:15:08 +0100" MODIFIED_BY="[Empty name]">
<P>We extracted details of eligible studies and summarised them using a data extraction sheet that was based on the outcome measures. Two authors (GK, PM) extracted data independently and subsequently checked for discrepancies. The data of the Chinese article was kindly extracted by Dr Ching-Chi Chi from Taiwan. We had planned to resolve disagreements by discussion with the other authors (DM and FW), but this was not necessary because there were very few small studies.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2010-09-05 12:16:45 +0100" MODIFIED_BY="[Empty name]">
<P>Risk of bias for the new studies identified by the updated search was independently assessed by two authors (CB and GK) and we resolved any differences by consensus.</P>
<P>We made an assessment of the risk of bias which includes an evaluation of the following components for each included study, using the criteria outlined in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>) (details are available in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> ('Risk of bias') for each study):</P>
<P>(a) the method of generation of the randomisation sequence;<BR/>(b) the method of allocation concealment - it was considered 'adequate' if the assignment could not be foreseen;<BR/>(c) who was blinded or not blinded (participants, clinicians, outcome assessors); and<BR/>(d) how many participants dropped out of the study overall, and whether participants were analysed in the groups to which they were originally randomised (intention-to-treat analysis).</P>
<P>The original protocol of this review stated that the Jadad quality assessment scale would be used, which also similarly assesses randomisation, blinding, withdrawals, and dropouts (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>). We assessed all these aspects but reported them individually (see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>) rather than as a summary score.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2010-07-29 13:34:59 +0100" MODIFIED_BY="Cathy Bennett">
<P>We presented dichotomous measures as risk ratios (RR) with 95% confidence intervals (CI); and continuous measures were presented as mean differences with 95% CI.</P>
</EFFECT_MEASURES>
<MISSING_DATA MODIFIED="2010-05-12 15:56:04 +0100" MODIFIED_BY="Cathy Bennett">
<P>We contacted trial investigators to obtain missing data and clarify the specifics of the trial conditions when this was not clear to us from the published report of the trial.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2010-09-05 12:17:07 +0100" MODIFIED_BY="[Empty name]">
<P>For an assessment of heterogeneity we used the I² statistic. If we found moderate to high levels of heterogeneity (I² &gt; 50%) for the primary outcomes, we explored the possible sources of heterogeneity.</P>
</HETEROGENEITY_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2010-09-05 12:17:19 +0100" MODIFIED_BY="[Empty name]">
<P>We had planned to divide data analysis into two groups:<BR/>(a) trials where the diagnosis of BP was confirmed by immunofluorescence (IF) using intact skin; and<BR/>(b) trials where split skin was used for IF (this procedures helps, although not completely, to distinguish true BP participants from those with other subepidermal immunobullous diseases), however, this was unnecessary as only one of the studies used IF on split skin (<LINK REF="STD-Beissert-2007" TYPE="STUDY">Beissert 2007</LINK>).</P>
<P>We conducted a narrative synthesis of included trials, and present the characteristics of the trials and results in tables and figures. We were unable to pool data in a meta-analysis as the studies were heterogenous especially in terms of the treatments used. We did, however, present some of the data in Review Manager 5 (RevMan) in the form of risk ratios and 95% confidence intervals for the results of single trials.</P>
<P>The adverse events are summarised in a separate table "Adverse events in the included studies; <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>"; some columns are left empty, it would have been misleading to enter "zero" when a paper was silent about a particular adverse event, because we are not sure that all adverse events have been reported.</P>
</DATA_SYNTHESIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2011-11-07 12:16:46 +0000" MODIFIED_BY="Finola M Delamere">
<STUDY_DESCRIPTION MODIFIED="2010-09-08 08:22:18 +0100" MODIFIED_BY="Finola M Delamere">
<SEARCH_RESULTS MODIFIED="2010-09-08 08:22:18 +0100" MODIFIED_BY="Finola M Delamere">
<P>We identified 73 abstracts from MEDLINE, 27 from EMBASE, and 7 from the Cochrane Central Register of Controlled Trials (Clinical Trials) at our initial searches. For this update we searched the Cochrane Skin Group Specialised Register, <I>The Cochrane Library</I> (Issue 1, 2009), MEDLINE, and EMBASE on 16th March 2009 and 31 abstracts were identified. Prior to publication we ran another search on 10th August 2010 of the listed databases but found no potentially eligible studies. We assessed 28 of these for eligibility and they were clearly either not RCTs or the participants did not have a diagnosis of bullous pemphigoid. Therefore as none of the studies appeared to meet the eligibility criteria on the surface, no studies appear in the excluded studies table. We included 3 new RCTs in this update (<LINK REF="STD-Beissert-2007" TYPE="STUDY">Beissert 2007</LINK>; <LINK REF="STD-Joly-2009" TYPE="STUDY">Joly 2009</LINK>; <LINK REF="STD-Liu-2006" TYPE="STUDY">Liu 2006</LINK>), therefore there are 10 completed RCTs with a total of 1049 participants included in this review; details of all the studies are included in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
<P>We identified seven ongoing trials from the above mentioned Ongoing Trial registers. We are aware that two of these are ongoing RCTs (<LINK REF="STD-ISRCTN13704604" TYPE="STUDY">ISRCTN13704604</LINK>; <LINK REF="STD-NCT00809822" TYPE="STUDY">NCT00809822</LINK>). The remaining five trials will be assessed for eligibility when more details become available.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2010-09-06 14:56:32 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Design</HEADING>
<P>Six of the studies in this review were multicentre French studies (<LINK REF="STD-Dreno-1993" TYPE="STUDY">Dreno 1993</LINK>; <LINK REF="STD-Guillaume-1993" TYPE="STUDY">Guillaume 1993</LINK>; <LINK REF="STD-Joly-2002" TYPE="STUDY">Joly 2002</LINK>; <LINK REF="STD-Joly-2009" TYPE="STUDY">Joly 2009</LINK>; <LINK REF="STD-Morel-1984" TYPE="STUDY">Morel 1984</LINK>; <LINK REF="STD-Roujeau-1984" TYPE="STUDY">Roujeau 1984</LINK>). Morel was a co-author in two (<LINK REF="STD-Morel-1984" TYPE="STUDY">Morel 1984</LINK>; <LINK REF="STD-Roujeau-1984" TYPE="STUDY">Roujeau 1984</LINK>), Guillaume in three (<LINK REF="STD-Guillaume-1993" TYPE="STUDY">Guillaume 1993</LINK>; <LINK REF="STD-Roujeau-1984" TYPE="STUDY">Roujeau 1984</LINK>; <LINK REF="STD-Joly-2009" TYPE="STUDY">Joly 2009</LINK>), three trial authors (Crickx, Labeille, and Guillot) were in the same two trials (<LINK REF="STD-Roujeau-1984" TYPE="STUDY">Roujeau 1984</LINK>; <LINK REF="STD-Guillaume-1993" TYPE="STUDY">Guillaume 1993</LINK>), Dreno in three (<LINK REF="STD-Dreno-1993" TYPE="STUDY">Dreno 1993</LINK>; <LINK REF="STD-Joly-2002" TYPE="STUDY">Joly 2002</LINK>; <LINK REF="STD-Joly-2009" TYPE="STUDY">Joly 2009</LINK>), and Roujeau in four studies (<LINK REF="STD-Guillaume-1993" TYPE="STUDY">Guillaume 1993</LINK>; <LINK REF="STD-Joly-2002" TYPE="STUDY">Joly 2002</LINK>; <LINK REF="STD-Roujeau-1984" TYPE="STUDY">Roujeau 1984</LINK>; <LINK REF="STD-Joly-2009" TYPE="STUDY">Joly 2009</LINK>). It is not clear if any of the studies included the same groups of participants.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Sample sizes</HEADING>
<P>There were 1049 participants in total. There were 8 small studies (between 20 and 100 participants in each) and 2 larger RCTs including more than half of the participants (653) in this review (<LINK REF="STD-Joly-2002" TYPE="STUDY">Joly 2002</LINK>; <LINK REF="STD-Joly-2009" TYPE="STUDY">Joly 2009</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Setting</HEADING>
<P>Only four studies in this review were done in centres outside France. <LINK REF="STD-Burton-1978" TYPE="STUDY">Burton 1978</LINK> was conducted in the UK, <LINK REF="STD-Fivenson-1994" TYPE="STUDY">Fivenson 1994</LINK> in the USA, <LINK REF="STD-Liu-2006" TYPE="STUDY">Liu 2006</LINK> in China, and <LINK REF="STD-Beissert-2007" TYPE="STUDY">Beissert 2007</LINK> in Germany. The studies were carried out in hospital settings, although it is unclear what the setting was in <LINK REF="STD-Liu-2006" TYPE="STUDY">Liu 2006</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Participants</HEADING>
<P>All participants had confirmed bullous pemphigoid (confirmed by immunofluorescence, except <LINK REF="STD-Liu-2006" TYPE="STUDY">Liu 2006</LINK>, in which this is unclear). The participants were older men and women (range of mean ages at baseline quoted in the included studies was 65.4 to 84.8 years of age).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Interventions</HEADING>
<P>None of the studies included a placebo group. The interventions tested in the included studies included, oral steroids, with or without other interventions, topical steroids, and tetracycline and nicotinamide (versus prednisolone). All used different interventions with only five studies overlapping; therefore classification by intervention is intended to assist the reader, rather than to attempt to fit different interventions in to broad classification groups. A brief summary of the type of interventions used is presented below. Full details of each trial are given in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="5">Oral steroid with or without other interventions, including plasma exchange</HEADING>
<P>
<LINK REF="STD-Beissert-2007" TYPE="STUDY">Beissert 2007</LINK> used oral methylprednisolone plus azathioprine versus (vs) oral methylprednisolone plus mycophenolate mofetil; and <LINK REF="STD-Dreno-1993" TYPE="STUDY">Dreno 1993</LINK> administered prednisolone versus methylprednisolone. <LINK REF="STD-Morel-1984" TYPE="STUDY">Morel 1984</LINK> looked at prednisolone at two doses (0.75 mg/kg versus 1.25 mg/kg). <LINK REF="STD-Liu-2006" TYPE="STUDY">Liu 2006</LINK> compared a traditional Chinese medicine, 'Jingui Shenqi Pill' (JSP), plus prednisone (0.5 to 1.0 mg/kg/day) to prednisone alone (0.5 to 1.0 mg/kg/day). In <LINK REF="STD-Guillaume-1993" TYPE="STUDY">Guillaume 1993</LINK> participants received prednisolone versus prednisolone and azathioprine, versus plasma exchange and prednisolone, and <LINK REF="STD-Roujeau-1984" TYPE="STUDY">Roujeau 1984</LINK> also investigated plasma exchange and prednisolone. <LINK REF="STD-Burton-1978" TYPE="STUDY">Burton 1978</LINK> compared azathioprine plus prednisone versus prednisone alone. We have used the drug names as reported in the included studies (i.e. prednisone or prednisolone); for the purposes of this review, prednisone and prednisolone are regarded as bio-equivalent.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Topical steroid treatment</HEADING>
<P>
<LINK REF="STD-Joly-2002" TYPE="STUDY">Joly 2002</LINK> used topical clobetasol propionate versus oral prednisolone, and in <LINK REF="STD-Joly-2009" TYPE="STUDY">Joly 2009</LINK> investigated 2 different regimens of topical clobetasol propionate cream: 40 g clobetasol propionate cream/day versus a mild regimen of 10 to 30 g/day, depending on the body weight, were compared in a large, randomised study. The regimen was chosen according to disease severity.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Tetracycline and nicotinamide</HEADING>
<P>
<LINK REF="STD-Fivenson-1994" TYPE="STUDY">Fivenson 1994</LINK> used prednisolone versus nicotinamide and tetracycline.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcomes</HEADING>
<P>We specified a number of outcomes of interest for this review in <LINK TAG="CRIT_OUTCOMES" TYPE="SECTION">Types of outcome measures</LINK>. Our primary outcome of regression or healing of skin lesions was reported in all the included studies. Effects of the interventions on quality of life were reported in <LINK REF="STD-Dreno-1993" TYPE="STUDY">Dreno 1993</LINK>, <LINK REF="STD-Guillaume-1993" TYPE="STUDY">Guillaume 1993</LINK>, and <LINK REF="STD-Roujeau-1984" TYPE="STUDY">Roujeau 1984</LINK>. The duration of remission after stopping treatment was reported in <LINK REF="STD-Beissert-2007" TYPE="STUDY">Beissert 2007</LINK> and <LINK REF="STD-Joly-2009" TYPE="STUDY">Joly 2009</LINK>.</P>
<P>Adverse effects were recorded in <LINK REF="STD-Beissert-2007" TYPE="STUDY">Beissert 2007</LINK>, <LINK REF="STD-Joly-2002" TYPE="STUDY">Joly 2002</LINK>, and <LINK REF="STD-Joly-2009" TYPE="STUDY">Joly 2009</LINK>, while mortality was reported in <LINK REF="STD-Burton-1978" TYPE="STUDY">Burton 1978</LINK>, <LINK REF="STD-Joly-2002" TYPE="STUDY">Joly 2002</LINK>, and <LINK REF="STD-Joly-2009" TYPE="STUDY">Joly 2009</LINK>. The remaining review outcomes of complications of the primary disease and systemic infection were not reported in any of the included studies.</P>
<P>The reports of the included studies focused on a variety of outcomes, including disease control, survival, and cumulative steroid doses which are summarised as follows:</P>
<UL>
<LI>The outcomes reported in <LINK REF="STD-Beissert-2007" TYPE="STUDY">Beissert 2007</LINK> were complete healing (complete re-epithelialisation of all lesions), and cumulative steroid dose. Secondary outcomes were duration of remission (disease-free interval) and safety.</LI>
<LI>
<LINK REF="STD-Dreno-1993" TYPE="STUDY">Dreno 1993</LINK> reported the number of blisters, intensity of erythema, and the intensity of pruritus (itch) at days five and ten.</LI>
<LI>
<LINK REF="STD-Fivenson-1994" TYPE="STUDY">Fivenson 1994</LINK> reported the number of bullous, crusted, urticarial lesions as the total highest score possible on each visit per participant.</LI>
<LI>Only <LINK REF="STD-Burton-1978" TYPE="STUDY">Burton 1978</LINK> did not have clearly stated outcome measures. The following outcome measures were obtained from the published report, and include cumulative dose of prednisone in both groups necessary for disease control, mortality, and adverse effects, including whether azathioprine and prednisolone (synergistic immunosuppression) was associated with increased risk of malignancy.</LI>
<LI>
<LINK REF="STD-Guillaume-1993" TYPE="STUDY">Guillaume 1993</LINK> reported disease control in terms of blister formation, resolution of erythema, and no more than minimal pruritus at four weeks and six months after starting treatment.</LI>
<LI>
<LINK REF="STD-Joly-2002" TYPE="STUDY">Joly 2002</LINK> and <LINK REF="STD-Joly-2009" TYPE="STUDY">Joly 2009</LINK> both reported survival after one year, disease control at three weeks, and occurrence of severe adverse events during the follow-up year; <LINK REF="STD-Joly-2009" TYPE="STUDY">Joly 2009</LINK> also reported occurrence of relapses during follow-up and cumulative doses of steroid cream.</LI>
<LI>
<LINK REF="STD-Liu-2006" TYPE="STUDY">Liu 2006</LINK> reported compete healing at four weeks; <LINK REF="STD-Morel-1984" TYPE="STUDY">Morel 1984</LINK> assessed new blister formation at days 21 and 51, and <LINK REF="STD-Roujeau-1984" TYPE="STUDY">Roujeau 1984</LINK> assessed the cumulative and daily corticosteroid dose to achieve disease control in terms of blister formation. Other parameters of disease control were intensity of pruritus and extent of erythema and urticarial lesions.</LI>
</UL>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2010-09-03 14:33:15 +0100" MODIFIED_BY="Laura  Prescott">
<P>A search of the abstracts of potential RCTs for the initial published version of this review and for this update indicated that there were no studies that should be listed in the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table, e.g. no RCTs that dealt with closely related conditions.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2010-09-06 15:57:16 +0100" MODIFIED_BY="Finola M Delamere">
<ALLOCATION MODIFIED="2010-09-05 12:28:19 +0100" MODIFIED_BY="[Empty name]">
<P>Some attempt at randomisation was made in all of the studies. Randomisation was not described in detail by <LINK REF="STD-Burton-1978" TYPE="STUDY">Burton 1978</LINK>, <LINK REF="STD-Fivenson-1994" TYPE="STUDY">Fivenson 1994</LINK>, or <LINK REF="STD-Liu-2006" TYPE="STUDY">Liu 2006</LINK>.</P>
<P>Only <LINK REF="STD-Joly-2009" TYPE="STUDY">Joly 2009</LINK> was assessed as having adequate randomisation as both sequence generation and allocation concealment were adequate.</P>
<P>It was not explicitly stated in <LINK REF="STD-Burton-1978" TYPE="STUDY">Burton 1978</LINK> that the 25 participants were initially randomised, but this was implied in other sections of the article in that each participant was described as being assigned to treatment by the ward sister who drew a marked paper from an envelope. Since there are no details about how the envelopes were marked, the sequence generation was rated as unclear.</P>
<P>
<LINK REF="STD-Morel-1984" TYPE="STUDY">Morel 1984</LINK> randomised 50 participants using a table of numbers, but allocation concealment was unclear.</P>
<P>The study reported by <LINK REF="STD-Dreno-1993" TYPE="STUDY">Dreno 1993</LINK> was randomised, but the method was not described.</P>
<P>Similarly, in <LINK REF="STD-Fivenson-1994" TYPE="STUDY">Fivenson 1994</LINK> randomisation was mentioned but the method used was not explained. A full translation of the study of <LINK REF="STD-Liu-2006" TYPE="STUDY">Liu 2006</LINK> provided no details about the randomisation method used.</P>
<P>The prednisolone and plasma exchange versus prednisolone-only study (<LINK REF="STD-Roujeau-1984" TYPE="STUDY">Roujeau 1984</LINK>) had an adequate method of sequence generation (computer-generated), but allocation was unclear.</P>
<P>The <LINK REF="STD-Joly-2002" TYPE="STUDY">Joly 2002</LINK> study on topical versus oral corticosteroids studies (<LINK REF="STD-Joly-2002" TYPE="STUDY">Joly 2002</LINK>), had an adequate sequence generation method, but seemed marginal for allocation concealment therefore we coded it as unclear.</P>
<P>A three-arm study (<LINK REF="STD-Guillaume-1993" TYPE="STUDY">Guillaume 1993</LINK>) comparing the efficacy of azathioprine or plasma exchange when added to prednisolone used an adequate method of sequence generation (pre-established lists). But <LINK REF="STD-Guillaume-1993" TYPE="STUDY">Guillaume 1993</LINK> was also marginal regarding allocation concealment as it was not clear if the study co-ordinator was or was not involved in the allocation process; therefore we have coded it as unclear.</P>
<P>
<LINK REF="STD-Beissert-2007" TYPE="STUDY">Beissert 2007</LINK> had adequate sequence generation by centrally-generated random numbers to receive oral methylprednisolone plus azathioprine or mycophenolate mofetil.</P>
</ALLOCATION>
<BLINDING MODIFIED="2010-09-03 14:39:02 +0100" MODIFIED_BY="Laura  Prescott">
<P>Most of the studies had no blinding of either participants or outcome assessors (see <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). <LINK REF="STD-Dreno-1993" TYPE="STUDY">Dreno 1993</LINK> employed a double-blind method although the two products used as interventions were of a different appearance, the supply of the products to the participants was made by a person other than the investigator. Additionally clinical follow-up after the end of the study was done by a blinded investigator .</P>
<P>Two regimens of very potent topical corticosteroids, a standard regimen of 40 g clobetasol propionate cream/day versus a mild regimen of 10 to 30 g/d depending on the body weight, were compared in a large, randomised study (<LINK REF="STD-Joly-2009" TYPE="STUDY">Joly 2009</LINK>). Blinding was not deemed necessary as the primary outcome was event-free survival.</P>
<P>The studies by <LINK REF="STD-Burton-1978" TYPE="STUDY">Burton 1978,</LINK> <LINK REF="STD-Guillaume-1993" TYPE="STUDY">Guillaume 1993</LINK>, <LINK REF="STD-Fivenson-1994" TYPE="STUDY">Fivenson 1994,</LINK> <LINK REF="STD-Liu-2006" TYPE="STUDY">Liu 2006,</LINK> and <LINK REF="STD-Roujeau-1984" TYPE="STUDY">Roujeau 1984</LINK> were also not blinded. In <LINK REF="STD-Guillaume-1993" TYPE="STUDY">Guillaume 1993</LINK> blinding could be considered by some as unethical (this was given as a reason for not blinding in one study) because it would mean an invasive procedure (intravenous line) in the control group as well. <LINK REF="STD-Joly-2002" TYPE="STUDY">Joly 2002</LINK> was not blinded, however, the primary outcome was survival at one year which was unlikely to be biased by lack of blinding (this was given as the reason for not blinding). However, assessments for disease control and complications were also made which might potentially have been biased by the lack of blinding. In <LINK REF="STD-Beissert-2007" TYPE="STUDY">Beissert 2007</LINK> complete healing defined as complete re-epithelialisation of the lesions and cumulative steroid dose at complete healing were primary end points, judgement may have been biased because of the lack of blinding.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2010-09-06 15:57:06 +0100" MODIFIED_BY="Finola M Delamere">
<P>There was one dropout in <LINK REF="STD-Dreno-1993" TYPE="STUDY">Dreno 1993</LINK>: treatment was stopped after eight days of treatment as the participant was in a coma unrelated to treatment.</P>
<P>In <LINK REF="STD-Morel-1984" TYPE="STUDY">Morel 1984</LINK> four participants were excluded from the analysis, two because they did not fit the inclusion criteria and two due to protocol deviation.</P>
<P>
<LINK REF="STD-Burton-1978" TYPE="STUDY">Burton 1978</LINK> and <LINK REF="STD-Liu-2006" TYPE="STUDY">Liu 2006</LINK> seemed to have no dropouts but the reports were short and no details were given.</P>
<P>In <LINK REF="STD-Roujeau-1984" TYPE="STUDY">Roujeau 1984</LINK> the number and reasons for dropouts, two from each arm of the study, were listed.</P>
<P>In the prednisone (6 participants) versus tetracycline and nicotinamide (14 participants) trial, the report of the trial states that 18 of 20 participants enrolled in the study were treated, the 2 that were unavailable for follow up at 8 weeks were both in the tetracycline/nicotinamide group. The reasons for dropout were not given (<LINK REF="STD-Fivenson-1994" TYPE="STUDY">Fivenson 1994</LINK>).</P>
<P>
<LINK REF="STD-Guillaume-1993" TYPE="STUDY">Guillaume 1993</LINK> had 3 arms, prednisolone-only (32 participants with 1 dropout), prednisolone and azathioprine (36 participants, no dropouts) and prednisolone and plasma exchange (32 participants with 1 dropout), the reasons for the 2 dropouts were not given.</P>
<P>
<LINK REF="STD-Joly-2002" TYPE="STUDY">Joly 2002</LINK> stated reasons for dropouts. This study was the largest study including 341 participants.</P>
<P>In <LINK REF="STD-Joly-2009" TYPE="STUDY">Joly 2009</LINK> the intention-to-treat analysis was not fulfilled, as only 150 of 153 randomised participants of the standard regimen were analysed, however, this is only a small deviation.</P>
<P>In <LINK REF="STD-Beissert-2007" TYPE="STUDY">Beissert 2007</LINK> one participant was lost. Two died of causes not related to the treatment, they were included in the intention-to-treat analysis.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2010-09-03 14:40:54 +0100" MODIFIED_BY="Laura  Prescott">
<P>All the prospectively stated outcomes were reported in all of the studies except for <LINK REF="STD-Burton-1978" TYPE="STUDY">Burton 1978</LINK> and <LINK REF="STD-Guillaume-1993" TYPE="STUDY">Guillaume 1993</LINK>. In <LINK REF="STD-Burton-1978" TYPE="STUDY">Burton 1978</LINK> the prospectively stated outcome measures were unclear. In <LINK REF="STD-Guillaume-1993" TYPE="STUDY">Guillaume 1993</LINK> outcome measurements of controlled disease were stated to be no more than one new blister occurring four weeks after starting treatment, resolution of erythema, and no more than minimal pruritus. However, only the composite measure of controlled disease was reported.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2010-09-06 15:57:16 +0100" MODIFIED_BY="Finola M Delamere">
<P>
<LINK REF="STD-Dreno-1993" TYPE="STUDY">Dreno 1993</LINK> only had a very short (10 days) follow-up, which limits the applicability of results to clinical practice, especially in a chronic disease such as BP.</P>
<P>Initial diagnosis confirmed by immunofluorescence was performed in all but one study (a pathological test was mentioned but not described further in <LINK REF="STD-Liu-2006" TYPE="STUDY">Liu 2006</LINK>).</P>
<P>More participants in the azathioprine group in <LINK REF="STD-Beissert-2007" TYPE="STUDY">Beissert 2007</LINK> had severe disease; 53% had &#8805;20% body surface area involvement compared to only 27% in the mycophenolate mofetil (MMF) group, and more participants had raised liver enzyme tests. However, a test to check for thiopurinemethyltransferase activity was not performed. Additionally, only those participants who were likely to attend for follow up were recruited. Eligibility was also determined by the consultant doctor after baseline testing.</P>
<P>In <LINK REF="STD-Fivenson-1994" TYPE="STUDY">Fivenson 1994</LINK> the study was originally designed to randomise 96 participants, but enrolment was terminated when 20 participants were enrolled. No reasons were given for this.</P>
<P>The <LINK REF="STD-Guillaume-1993" TYPE="STUDY">Guillaume 1993</LINK> study was stopped after the interim analysis became available; this showed no appreciable benefit resulting from the addition of azathioprine or plasma exchange to prednisolone.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2011-11-07 12:16:46 +0000" MODIFIED_BY="Finola M Delamere">
<P>The assessment and reporting of disease control, symptoms, and adverse effects of medication were recorded in varying detail in the different trials. Mortality is the only outcome measure documented in all the studies, however, this was not a stated outcome of interest in most studies and it is not always clear whether the deaths were related to treatment.</P>
<P>The following effects of interventions section is organised by comparison, followed by the primary and secondary outcomes stated in the <LINK TAG="METHODS" TYPE="SECTION">Methods</LINK> section of this review (<A HREF="https://webmail.vumc.nl/Exchange/G.Kirtschig/Inbox/RE:%20%2318%20BP-2.EML/">Types of outcome measures</A>).</P>
<SUBSECTION>
<HEADING LEVEL="3">Higher versus lower doses of prednisolone</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Regression or healing of skin lesions</HEADING>
<P>The study <LINK REF="STD-Morel-1984" TYPE="STUDY">Morel 1984</LINK> comparing the starting dose of prednisolone 0.75 mg/kg (26 participants) versus prednisolone 1.25 mg/kg (24 participants) reported that 51% versus 64% of participants were clear of skin lesions at day 21 and 33% versus 55% at day 51 (no significant difference in effectiveness, comparing each dose at 21 days and 51 days, data not shown). This was the case for analyses based on completers only as well as on an intention-to-treat basis (assuming unknown = not healed). There were no significant differences between doses of prednisolone at 21 days in terms of disease control (healing of skin lesions) (RR 1.20, 95% CI 0.77 to 1.87), or 51 days (RR 1.38, 95% CI 0.69 to 2.79, <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Mortality</HEADING>
<P>At day 51, there were 3 deaths out of 22 participants in the higher dose compared to 2 deaths out of 24 participants in the lower dose (RR 1.64, 95% CI 0.30 to 8.90, <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>) (<LINK REF="STD-Morel-1984" TYPE="STUDY">Morel 1984</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Methylprednisolone versus prednisolone</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Regression or healing of skin lesions</HEADING>
<P>The study comparing different formulations of steroids, methylprednisolone (n = 28) with prednisolone (n = 29) (<LINK REF="STD-Dreno-1993" TYPE="STUDY">Dreno 1993</LINK>), found a large reduction in the number of blisters in both groups. At day 10 the mean number of blisters was 6.0 (SD 19) for methylprednisolone and 13.0 (SD 35) for prednisolone (mean difference -7.00) (95% CI -21.55 to 7.55, <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>).</P>
<P>Collective figures of overall improvement (22 of 28 participants in the methylprednisolone group, 78.6%, versus 18 of 29 participants in the prednisolone group, 62.1%) were reported (RR 1.27, 95% CI 0.90 to 1.79, <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>). This was not statistically significant.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Effect on the quality of life</HEADING>
<P>Erythema and pruritus (itch) were each measured by the participant on a scale from zero (absent) to three (severe). No significant difference was seen between the groups for either score: erythema 0.59 (SD 0.69) versus 0.93 (SD 0.72), mean difference -0.34 (95% CI -0.71 to 0.03, <LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>), and pruritus 0.59 (SD 0.8) versus 0.86 (SD 0.8), mean difference -0.27 (95% CI -0.69 to 0.15, <LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>). The study investigators report that the only statistically significant result was a reduction in pruritis; the statistical significance for this outcome (pruritus) was given as 0.042 by the study investigators, but it was unclear which statistical test they used.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Mortality</HEADING>
<P>There were no deaths recorded in this study, but the follow-up period was only 10 days.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Prednisone plus azathioprine versus prednisone</HEADING>
<P>This comparison was evaluated in two small studies, <LINK REF="STD-Burton-1978" TYPE="STUDY">Burton 1978</LINK> with a three-year follow-up, and <LINK REF="STD-Guillaume-1993" TYPE="STUDY">Guillaume 1993</LINK> with a six-month follow-up.</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Regression or healing of skin lesions</HEADING>
<P>The <LINK REF="STD-Guillaume-1993" TYPE="STUDY">Guillaume 1993</LINK> study failed to show improvements in disease control (14/36 vs 13/31; RR 0.93, 95% CI 0.52 to 1.66, <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
<P>In <LINK REF="STD-Burton-1978" TYPE="STUDY">Burton 1978</LINK>, the prednisone plus azathioprine group, 9/12 participants had their disease controlled at 3 years (7 participants off treatment and 2 still on treatment), and 9/13 participants in the prednisone-only group had their disease controlled (4 participants off treatment and 5 still on treatment) (RR 1.08, 95% CI 0.67 to 1.76, <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>) (P = 0.75: not statistically significant). This study found a 45% reduction in the amount of prednisone required for disease control by the azathioprine group over a 3-year period (mean total dose 3688 mg in the azathioprine group versus 6732 mg in the prednisone-only group), which was statistically significant (P &lt; 0.01). The statistical test that was used was not reported.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Adverse effects</HEADING>
<P>In <LINK REF="STD-Burton-1978" TYPE="STUDY">Burton 1978</LINK> one of the off-treatment participants who was originally assigned to the prednisone-only group withdrew from the prednisone group due to adverse effects and was subsequently successfully treated with azathioprine. In <LINK REF="STD-Guillaume-1993" TYPE="STUDY">Guillaume 1993</LINK> severe complications were more often noted in the azathioprine group (RR 1.29, 95% CI 0.68 to 2.45, <LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>) (not statistically significant). Unfortunately, the adverse effects were not given in detail for each group (see Adverse Events; <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). The study investigators stated that "most of the adverse events could be attributed to corticosteroids". The chief adverse effect associated with azathioprine was a reduction in the white cell count (2 of 12 participants in the <LINK REF="STD-Burton-1978" TYPE="STUDY">Burton 1978</LINK> trial and 4 of 36 participants in the <LINK REF="STD-Guillaume-1993" TYPE="STUDY">Guillaume 1993</LINK> trial).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Mortality</HEADING>
<P>There was no statistical significance in mortality at 6 months between the prednisone and the prednisone plus azathioprine group in <LINK REF="STD-Guillaume-1993" TYPE="STUDY">Guillaume 1993</LINK> (RR 1.03, 95% CI 0.35 to 3.06, <LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>). The <LINK REF="STD-Burton-1978" TYPE="STUDY">Burton 1978</LINK> study had the longest follow-up (3 years) and an overall mortality of 7/25 participants (28%). There were 3 deaths in the prednisone plus azathioprine group (n = 12) and 4 in the prednisone-only group (n = 13) (RR 0.81, 95% CI 0.23 to 2.91, <LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>) (P = 0.75) after 3 years of treatment.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Prednisolone plus plasma exchange versus prednisolone</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Regression or healing of skin lesions</HEADING>
<P>This comparison was evaluated in two small studies: <LINK REF="STD-Roujeau-1984" TYPE="STUDY">Roujeau 1984</LINK> with a one-month follow-up, and <LINK REF="STD-Guillaume-1993" TYPE="STUDY">Guillaume 1993</LINK> with a six-month follow-up.</P>
<P>In the study comparing prednisolone versus prednisolone and plasma exchange (<LINK REF="STD-Roujeau-1984" TYPE="STUDY">Roujeau 1984</LINK>), all participants were started on a low dose of prednisolone (0.3 mg/kg/day) which was increased (max 2 mg/kg/day methylprednisolone intramuscular + 2 mg/kg/day oral cyclophosphamide) until disease control was achieved. The addition of plasma exchange appeared to reduce the amount of prednisolone required to achieve disease control. Disease control was achieved with a dose of 0.3 mg/kg/day in 13/22 participants in the prednisolone plus plasma exchange group but in none of the 15 participants in the prednisolone-only group (risk ratio in favour of prednisolone plus plasma exchange: RR 18.78, 95% CI 1.20 to 293.70, <LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>) (P = 0.04). This is statistically significant, although the confidence intervals are very wide.</P>
<P>Significantly more participants also achieved disease control with prednisolone doses less than or equal to 1 mg/kg: 21/22 for prednisolone plus plasma exchange and 8/15 for prednisolone-only (RR 1.79, 95% CI 1.11 to 2.90, <LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>) (P = 0.02). Disease control was achieved with less than half the total prednisolone dose in the plasma exchange group; significantly lower doses of prednisolone were required to achieve disease control, both in terms of the cumulative dose (mean difference -1.53 g: 95% CI -2.40 to -0.66, <LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>) and the average daily dose: 0.52 (SD 0.28) mg/kg in the plasma exchange group versus 0.97 (SD 0.33) mg/kg in the prednisolone-only group. They found a similar side-effect profile in both groups and the disease was controlled within about four weeks in both groups.</P>
<P>However, this favourable effect of adding plasma exchange was not seen in the <LINK REF="STD-Guillaume-1993" TYPE="STUDY">Guillaume 1993</LINK> study for disease control at 6 months: 9/31 prednisolone plus plasma exchange vs 13/31 prednisolone (RR 0.69, 95% CI 0.35 to 1.38, <LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>: see Analysis 4.1.3). The report of the study indicates that the trial was "interrupted after the interim analysis showed no appreciable benefit resulting from the addition of azathioprine or plasma exchange to prednisolone" at four weeks or at six weeks follow-up.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Mortality and adverse effects</HEADING>
<P>In <LINK REF="STD-Guillaume-1993" TYPE="STUDY">Guillaume 1993</LINK> mortality at 6 months was assessed as mortality alone (3/31 vs 5/31, RR 0.60, 95% CI 0.16 to 2.30, <LINK REF="CMP-004.04" TYPE="ANALYSIS">Analysis 4.4</LINK>: see analysis 4.4.3), or total adverse events including mortality (10 major adverse events including 5 deaths in the prednisolone, versus 6 major adverse events including 3 deaths in the plasma exchange group) (RR 0.60, 95% CI 0.25 to 1.45, <LINK REF="CMP-004.03" TYPE="ANALYSIS">Analysis 4.3</LINK>) (<LINK REF="STD-Guillaume-1993" TYPE="STUDY">Guillaume 1993</LINK>).</P>
<P>In <LINK REF="STD-Roujeau-1984" TYPE="STUDY">Roujeau 1984</LINK> no deaths occurred during the treatment period (<LINK REF="CMP-004.04" TYPE="ANALYSIS">Analysis 4.4</LINK>). There were only 25 of the participants available for follow up, that is after the initial treatment period which included 41 original participants, of which only 37 were analysed by the trial authors because they were lost early in the treatment period. Of those 25 participants available for follow up, 2 participants died in the prednisolone group, and 1 in the prednisolone plus plasma exchange group (the calculation for the worst case scenario includes the 4 lost participants, 2 in each group).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Prednisolone plus azathioprine versus prednisolone plus plasma exchange</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Regression or healing of skin lesions</HEADING>
<P>Comparing the prednisolone plus azathioprine group with the prednisolone plus plasma exchange group (<LINK REF="STD-Guillaume-1993" TYPE="STUDY">Guillaume 1993</LINK>), no significant differences were found for disease control at 6 months:14/36 and 9/31 respectively (RR 1.34, 95% CI 0.67 to 2.66, <LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Mortality and adverse effects</HEADING>
<P>Mortality at 6 months in <LINK REF="STD-Guillaume-1993" TYPE="STUDY">Guillaume 1993</LINK> was 6/36 (azathioprine) versus 3/31 (plasma exchange) (RR 1.72, 95% CI 0.47 to 6.32, <LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK>). Total adverse events including deaths were more often noted in the azathioprine group (15/36 total adverse effects (including 6 deaths) versus 6/31 (including 3 death) in the plasma exchange group). The results almost reach statistical significance with regard to total adverse events, including mortality at 6 months in favour of the plasma exchange plus prednisolone group (RR 2.15, 95% CI 0.95 to 4.87, <LINK REF="CMP-005.03" TYPE="ANALYSIS">Analysis 5.3</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Prednisone versus tetracycline and nicotinamide</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Regression or healing of skin lesions</HEADING>
<P>Comparing prednisone with tetracycline and nicotinamide (<LINK REF="STD-Fivenson-1994" TYPE="STUDY">Fivenson 1994</LINK>), 1 complete and 5 partial responders were reported in the steroid group (n = 6), compared with 5 complete, 5 partial responders, 1 non-responder, and 1 disease progression in the tetracycline group (n = 12). Two participants in the tetracycline group were unavailable for follow-up at 8 weeks (together n = 14). The results are not statistically significant for either complete response (RR 2.50, 95% CI 0.37 to 16.89, <LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>) or complete and/or partial response (RR 0.87, 95% CI 0.62 to 1.22, <LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>). The data for the non-responder (n = 1), the participant whose disease progressed (n = 1), and the two participants that were lost to follow up (n = 2) in the tetracycline group are not shown in the table.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Duration of remissions</HEADING>
<P>Of the participants available for long-term follow-up in <LINK REF="STD-Fivenson-1994" TYPE="STUDY">Fivenson 1994</LINK>, all 5 in the tetracycline group remained disease-free (mean 17.5 weeks) while 2 of the 3 in the steroid group had repeated flare-up with tapered off treatment (mean 21.3 weeks). Unfortunately, this trial included very few participants, two thirds of whom were in the tetracycline group (14 of 20 participants). The randomisation in this study was unclear and there was a high dropout rate (2/20 at 8 weeks and a further 10 participants at the end of study). At 10 months there were only 3 participants left in the steroid group (2 of whom had multiple recurrences with tapering of medication), and only 5 participants remained in the nicotinamide plus tetracycline group, all of whom remained disease-free during medication tapering.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse effects</HEADING>
<P>The report of the study states that "fewer short-term and long-term adverse effects occurred in the participants treated with the nicotinamide/tetracycline combination compared with prednisone therapy" (there was also one death due to sepsis in the prednisone group (<LINK REF="CMP-006.02" TYPE="ANALYSIS">Analysis 6.2</LINK>)). Most of the side-effects in the tetracycline/nicotinamide group in <LINK REF="STD-Fivenson-1994" TYPE="STUDY">Fivenson 1994</LINK> were mild (two participants developed gastrointestinal symptoms which resolved after substitution of tetracycline with minocycline, one of them developed tinnitus on minocycline which resolved despite continuing treatment. One participant in the latter group developed severe tubular necrosis. He had been enrolled in the study with elevated serum creatinine (159 which peaked at 654 micromol/L: normal 60 to 120 micromol/L) and was also taking nonsteroidal anti-inflammatory drugs (ibuprofen and aspirin). This participant's renal function returned to normal within two weeks of stopping treatment.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Very potent topical steroids (clobetasol propionate) versus prednisone</HEADING>
<P>The largest study had two study groups with the study stratified by severity of disease (<LINK REF="STD-Joly-2002" TYPE="STUDY">Joly 2002</LINK>):</P>
<OL>
<LI>Moderate disease (less than 10 new blisters a day): topical steroids (initial dose of 40 g of 0.05% clobetasol propionate twice daily applied to entire body surface) (77 participants), and oral prednisone 0.5 mg/kg (76 participants).</LI>
<LI>Extensive disease (more than 10 new blisters a day): topical steroids (93 participants), and oral prednisone 1 mg/kg (95 participants).</LI>
</OL>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Regression or healing of skin lesions</HEADING>
<P>In the moderate disease group differences were seen between the topical steroid and 0.5 mg/kg oral steroid groups in terms of rate of disease control at 3 weeks: 100% vs 94% (RR 1.06, 95% CI 1.00 to 1.12, <LINK REF="CMP-007.01" TYPE="ANALYSIS">Analysis 7.1,</LINK>: see Analysis 7.1.1) (P = 0.07).</P>
<P>Both interventions resulted in nearly 100% of participants experiencing disease control. The disease was controlled in 99% of the participants with extensive disease using topical steroids versus 91% of those on oral steroids at 3 weeks. This reached statistical significance (RR 1.09, 95% CI 1.02 to 1.17, <LINK REF="CMP-007.01" TYPE="ANALYSIS">Analysis 7.1</LINK>: see Analysis 7.1.2) (P = 0.01), although this outcome was not assessed blindly, and therefore the possibility of bias exists.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Adverse effects</HEADING>
<P>The incidence of severe complications was reported for people with extensive disease: 29% for topical steroids versus 54% for oral steroids (RR 0.54, 95% CI 0.37 to 0.78, P = 0.001), which is statistically significant, i.e. there were fewer adverse events due to clobetasol (<LINK REF="CMP-007.02" TYPE="ANALYSIS">Analysis 7.2</LINK>: see analysis 7.2.2). But this was not statistically significant in the moderate disease group (32% vs 38%, RR 0.85, 95% CI 0.55 to 1.31, <LINK REF="CMP-007.02" TYPE="ANALYSIS">Analysis 7.2</LINK>) (P = 0.46) (<LINK REF="STD-Joly-2002" TYPE="STUDY">Joly 2002</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Mortality (survival)</HEADING>
<P>The major outcome in this study was survival, the study being designed to have 80% power to detect a reduction in the 1-year mortality rate for both moderate and extensive bullous pemphigoid. To achieve this power, 75 participants were needed in each treatment group, which was accomplished.</P>
<P>In the extensive disease group, those using topical steroids had a better survival rate at 1 year compared to those on oral steroids (76% versus 58%, RR 0.58, 95% CI 0.37 to 0.89, <LINK REF="CMP-007.03" TYPE="ANALYSIS">Analysis 7.3</LINK>: see analysis 7.3.2) (statistically significant: P = 0.01). This was consistent with the incidence of severe complications in the people with extensive disease. In the moderate disease group no significant differences were seen between the topical steroid and 0.5 mg/kg oral steroid groups in terms of overall survival (30% vs 30%, RR 0.99, 95% CI 0.61 to 1.60, <LINK REF="CMP-007.03" TYPE="ANALYSIS">Analysis 7.3</LINK>) (<LINK REF="STD-Joly-2002" TYPE="STUDY">Joly 2002</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Standard dose (40 g/day) of very potent topical steroids versus mild dose (10 to 30 g/day)</HEADING>
<P>A second large study from the same French group was recently published to compare two different regimens of topical steroids (<LINK REF="STD-Joly-2009" TYPE="STUDY">Joly 2009</LINK>). In the mild regimen of <LINK REF="STD-Joly-2009" TYPE="STUDY">Joly 2009</LINK>, participants received different amounts of clobetasol propionate cream depending on their body weight and severity of the disease (moderate disease (&#8804; 10 new blisters/day): 69 participants received 20 g/day if their body weight was &gt; 45 kg and 10 g/day if &lt; 45 kg) (severe disease (&gt; 10 new blisters/day): 90 participants received 30 g/day if their body weight was &gt; 45 kg and 20 g/day if &lt; 45 kg), in the standard regimen all participants received 40 g of the cream/day (moderate disease n = 65, severe disease n = 88).</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Regression or healing of skin lesions</HEADING>
<P>The report of the study has a discrepancy in the number of participants who were evaluated at 21 days and states that 150/153 participants were evaluable, as 3 included participants were lost to follow up early after the initiation of treatment and were not available for evaluation of efficacy at day 21. However, disease control rates at 21 days are given for 153/153 participants. We wrote to the study investigator for clarification (<LINK REF="REF-Joly-2010" TYPE="REFERENCE">Joly 2010</LINK>), who confirmed that the published report contains a typographical error. The correct figures are: 153 participants randomised, 150 analysed. We carried out an analysis of the results using the randomised number of participants (n = 153). In the mild regimen 156/159 participants were controlled by day 21 and in the standard regimen 150/153 (RR 1.00, 95% CI 0.97 to 1.03, <LINK REF="CMP-008.01" TYPE="ANALYSIS">Analysis 8.1</LINK>: see Analysis 8.1.1) (not statistically significant P = 0.96).</P>
<P>In the report of the study, participants and their responses to the treatment regimens were stratified by severity of disease. Using the correct figures supplied by the study investigator (<LINK REF="REF-Joly-2010" TYPE="REFERENCE">Joly 2010</LINK>), of those with moderate disease, disease control was achieved in 68/69 using the mild regimen, and with the standard regimen 63/65 were controlled (RR 1.02, 95% CI 0.97 to 1.07, <LINK REF="CMP-008.01" TYPE="ANALYSIS">Analysis 8.1</LINK>: see Analysis 8.1.2). Of those with extensive disease, 88/90 achieved disease control in the mild regimen and 87/88 were controlled with the standard regimen (RR 0.99, 95% CI 0.95 to 1.03, <LINK REF="CMP-008.01" TYPE="ANALYSIS">Analysis 8.1</LINK>: see Analysis 8.1.3).</P>
<P>The median cumulative doses of cream used during the study period were 5760 g in the standard regimen versus 1314 g (mild regimen), which is a 70% reduction in cumulative doses of corticosteroid.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Duration of remissions</HEADING>
<P>There were 67 relapses in 159 participants in the mild regimen and 52 in 153 participants in the standard regimen (RR 1.24, 95% CI 0.93 to 1.65, <LINK REF="CMP-008.02" TYPE="ANALYSIS">Analysis 8.2</LINK>). This was not significantly different between the two groups. There is insufficient evidence to say that one treatment regimen is different from the other in terms of effectiveness.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse effects</HEADING>
<P>Eighty-nine participants in each group had severe adverse events. This consisted of 194 events in 89 participants in the mild regimen group and 227 in the standard regimen group. There were 42 life-threatening adverse effects in 33 participants. The main severe side-effects in both groups were diabetes mellitus (n = 34 standard, n = 18 mild), cardiovascular and neurovascular disorders in n = 35 (standard) and n = 21 participants (mild), and severe infections in 32 and 27 participants, in the standard and mild regimen groups respectively. There were also cutaneous side-effects which included purpura, severe skin atrophy, and striae.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Mortality</HEADING>
<P>In the mild regimen 60/159 participants had died by year 1 (moderate disease 19/69, severe disease 41/90) and in the standard regimen 58/153 (moderate disease 21/65, severe disease 37/88). This was not statistically significant between the 2 groups for those participants with moderate (RR 0.85, 95% CI 0.51 to 1.43) or extensive (RR 1.08, 95% CI 0.78 to 1.51) disease (<LINK REF="CMP-008.03" TYPE="ANALYSIS">Analysis 8.3</LINK>).</P>
<P>The report of the study gives an adjusted analysis (Cox model adjusted for age and Karnofsky score), after which a beneficial effect of the mild regimen was observed in participants with moderate BP, with an almost twofold decrease in the risk of death or life-threatening adverse events relative to the standard regimen (hazard ratio = 0.54, 95% confidence interval, 0.30 to 0.97; P = 0.039).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Jingui Shenqi Pill (JSP) 1# bid plus prednisone versus prednisone</HEADING>
<P>The Jingui Shenqi Pill (JSP) 1# bid plus prednisone 0.5 to 1.0 mg/kg/day was compared to prednisone alone 0.5 to 1.0 mg/kg/day in a small trial (<LINK REF="STD-Liu-2006" TYPE="STUDY">Liu 2006</LINK>). Thirty participants with bullous pemphigoid were included, the primary clinical outcome was healing of the skin lesions after 4 weeks treatment.</P>
<P>A cure was defined as &gt; 90% of the total number of lesions being healed, moderate healing if only 60% to 89% of the affected area had healed, improved if 30% to 59% of the lesions had healed, and not effective if less than 30% of the lesions had healed.</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Regression or healing of skin lesions</HEADING>
<P>Complete healing of the lesions at 4 weeks was achieved in 1 participant receiving the Jingui Shenqi Pill (1/15) and none in the prednisone group (0/15) (RR 3.00, 95% CI 0.13 to 68.26, <LINK REF="CMP-009.01" TYPE="ANALYSIS">Analysis 9.1</LINK>). Partial healing was achieved in 13 of 15 with JSP treatment compared with 11 of 15 participants with prednisone-only treatment (RR 1.18, 95% CI 0.82 to 1.70, <LINK REF="CMP-009.01" TYPE="ANALYSIS">Analysis 9.1</LINK>) .</P>
<P>Overall, the treatment was effective (some degree of healing) in 14/15 participants (93.33%) of the treatment group compared to 11/15 (73.33%) of the prednisone group (RR 1.27, 95% CI 0.91 to 1.78, <LINK REF="CMP-009.01" TYPE="ANALYSIS">Analysis 9.1</LINK>). None of the results were statistically significant.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Mortality</HEADING>
<P>No deaths were reported during the four-week follow-up (<LINK REF="STD-Liu-2006" TYPE="STUDY">Liu 2006</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Azathiopine plus corticosteroid versus mycophenolate mofetil plus corticosteroid</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Regression or healing of skin lesions</HEADING>
<P>Comparing azathioprine (2 mg/kg/day) and mycophenolate mofetil (MMF) (2000 mg twice/day) both in addition to oral methylprednisolone (0.5 mg/kg/day), all participants achieved some degree of healing (either partial or complete).</P>
<P>In this trial complete healing and disease remission was defined as complete re-epithelialisation of all lesions. 35/38 of the azathioprine group and 35/35 of the MMF group showed complete healing (92% vs 100%) (RR 0.92, 95% CI 0.83 to 1.03, <LINK REF="CMP-010.01" TYPE="ANALYSIS">Analysis 10.1</LINK>) (<LINK REF="STD-Beissert-2007" TYPE="STUDY">Beissert 2007</LINK>). Participants showed complete healing after 23.8 ± 18.9 days and 42.0 ± 55.3 days for azathioprine and mycophenolate mofetil respectively, but this difference was not statistically significant (unpaired t-test).</P>
<P>Three participants in the azathioprine group showed partial healing (RR 6.46, 95% CI 0.35 to 120.81, <LINK REF="CMP-010.01" TYPE="ANALYSIS">Analysis 10.1</LINK>) (not statistically significant), 2 of whom died of unrelated cause, leading to premature discontinuation of the treatment, and 1 was lost to follow up before treatment was completed.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Duration of remissions (weeks)</HEADING>
<P>The disease-free interval between complete remission and recurrence of lesions (new blister formation) was 23.5 weeks ± 19.4 weeks for azathioprine and 18 weeks ± 12.8 weeks for MMF, that is 5.50 more weeks of remission for those participants treated with azathioprine, but this difference was not statistically significant (unpaired t-test).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse effects</HEADING>
<P>Nine (24%) grade 3/4 adverse effects are described in the azathioprine group, and 6 (17%) in the MMF group. There were more elevated liver function tests in the azathioprine group (6/37 vs 1/35), however, participants were not checked for thiopurinemethyltransferase activity prior to treatment. There was no statistical difference between treatments for any of the outcomes.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Mortality</HEADING>
<P>There were two deaths in the azathioprine group, described as not treatment-related.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2010-09-08 08:57:50 +0100" MODIFIED_BY="Finola M Delamere">
<SUMMARY_OF_RESULTS MODIFIED="2010-09-05 12:57:19 +0100" MODIFIED_BY="[Empty name]">
<P>Ten studies were included in this review (7 studies were previously included; in this updated review 3 new studies were found and included: <LINK REF="STD-Beissert-2007" TYPE="STUDY">Beissert 2007,</LINK> <LINK REF="STD-Joly-2009" TYPE="STUDY">Joly 2009,</LINK> and <LINK REF="STD-Liu-2006" TYPE="STUDY">Liu 2006</LINK>). The studies in this review used oral prednisolone or prednisone in the control group (there were no comparisons with placebo) and were all small trials apart from two studies comparing different amounts of topical steroids and oral steroids (<LINK REF="STD-Joly-2002" TYPE="STUDY">Joly 2002</LINK>; <LINK REF="STD-Joly-2009" TYPE="STUDY">Joly 2009</LINK>). For the purposes of this review prednisone and prednisolone are regarded as bio-equivalent.</P>
<P>No meta-analysis was possible because of the clinical heterogeneity of the studies in terms of interventions, measures of disease control, and follow-up. The three studies that had overlapping treatments compared prednisone versus prednisone plus azathioprine (<LINK REF="STD-Burton-1978" TYPE="STUDY">Burton 1978</LINK>), prednisolone versus prednisolone plus plasma exchange (<LINK REF="STD-Roujeau-1984" TYPE="STUDY">Roujeau 1984</LINK>), and prednisolone alone, with azathioprine and with plasma exchange (<LINK REF="STD-Guillaume-1993" TYPE="STUDY">Guillaume 1993</LINK>), but they were heterogenous especially in terms of the doses of treatment used.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2010-09-08 07:59:58 +0100" MODIFIED_BY="Finola M Delamere">
<P>The outcome measures in these studies are very varied, as can be seen when looking at the definition of disease control and the interventions used (see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>). Our primary outcome was regression or healing of skin lesions; we did not pre-specify the follow-up times in our protocol as there is no established optimum treatment for BP (<LINK REF="REF-Wojnarowska-2002" TYPE="REFERENCE">Wojnarowska 2002</LINK>) and we did not want to exclude potentially effective therapies from our analyses because they did not meet strict inclusion criteria in relation to follow up times. We found that there were relatively few reports of trials for this rare disease and that there is variation in the time points reported.</P>
<P>Some of the included studies reported short follow-up periods (only 10 days in <LINK REF="STD-Dreno-1993" TYPE="STUDY">Dreno 1993</LINK>), which makes judgment of the practical significance of the results difficult, especially in view of the chronic nature of this disease. One study (<LINK REF="STD-Morel-1984" TYPE="STUDY">Morel 1984</LINK>) compared the starting dose of prednisolone, and reported results at 21 and 51 days, so perhaps the follow-up of 51 days may be more reasonable. We reported the results of that study at both time points in this review, although there were no significant differences in healing when the length of time or the dose given were compared. The <LINK REF="STD-Burton-1978" TYPE="STUDY">Burton 1978</LINK> trial had the longest follow-up period but unfortunately details on how disease control was evaluated are not given and few clinical data were available. Participants with contraindications to oral steroids or azathioprine and those "unlikely to attend follow-up" were excluded from the trial.</P>
<P>The <LINK REF="STD-Fivenson-1994" TYPE="STUDY">Fivenson 1994</LINK> study had an unclear method of randomisation, a high dropout rate, and small numbers, but may suggest some merit in the use of tetracycline and nicotinamide. However, further study is needed to confirm these findings.</P>
<P>Probably the most interesting feature of the <LINK REF="STD-Roujeau-1984" TYPE="STUDY">Roujeau 1984</LINK> study was the lower doses of prednisolone used in both treatment groups. Strict measures of disease control were used (complete disappearance of blisters, pruritus, and erythema) and in both groups the disease was controlled within about 4 weeks in all participants; however, higher doses than the initial low dose of 0.3 mg/kg prednisone were needed in all participants of the prednisolone-only group and in two thirds of the participants in the plasma exchange group to achieve disease control. There were no deaths during the study but this may be partly because of the exclusion of participants older than 80 years of age. This study found that the plasma exchange group required much less prednisolone than the prednisolone-only group. This benefit was, however, not confirmed by <LINK REF="STD-Guillaume-1993" TYPE="STUDY">Guillaume 1993</LINK>. This latter study also failed to confirm the benefit of the addition of azathioprine to prednisolone. <LINK REF="STD-Beissert-2007" TYPE="STUDY">Beissert 2007</LINK> added either azathioprine or mycophenolate mofetil to an initial dose of 0.5 mg methylprednisolone/kg/day; there was no difference in effectiveness. The cumulative steroid dose until the end of the documentation (&gt; 720 days) was 4967 ± 12191mg for the azathioprine group and 5754 ± 9693mg for the MMF group. The similarity between the two groups possibly reflects a comparable immunosuppressive effect of the two drugs. Interestingly, there were more participants with severe disease in the azathioprine group: 53% had &#8805; 20% body surface area involvement compared to only 27% in the MMF group.</P>
<P>In a small, methodologically unclear trial <LINK REF="STD-Liu-2006" TYPE="STUDY">Liu 2006</LINK> added the Jingui Shenqi Pill to oral steroids and described a beneficial effect after four weeks treatment compared to the control group. They found an increased expression of glucocorticosteroid receptor (GCr) &#945; and a decreased expression of GCr &#946; in skin lesions of the treatment group which may improve the sensitivity of the skin to glucocorticosteroids. However, the effectiveness of this intervention was not proven in our analyses.</P>
<P>As it is unlikely that future studies on interventions for bullous pemphigoid including a placebo group would be ethically justifiable, a comparison of low-dose prednisolone with tetracyclines and nicotinamide (or potent topical corticosteroids, for mild and/or localised disease) may prove a worthy alternative. Uncontrolled studies have suggested the successful use of topical steroids as first-line for the treatment of both localised and mild disease (<LINK REF="REF-Garg-1994" TYPE="REFERENCE">Garg 1994</LINK>; <LINK REF="REF-Rollin-1993" TYPE="REFERENCE">Rollin 1993</LINK>; <LINK REF="REF-Zimmermann-1999" TYPE="REFERENCE">Zimmermann 1999</LINK>), and two recent randomised controlled trials (<LINK REF="STD-Joly-2002" TYPE="STUDY">Joly 2002</LINK>; <LINK REF="STD-Joly-2009" TYPE="STUDY">Joly 2009</LINK>) confirm this view. The use of potent topical steroids is favoured because they have minimal side-effects and a limited number of contraindications. <LINK REF="STD-Joly-2002" TYPE="STUDY">Joly 2002</LINK> showed a significant benefit of 40 g 0.05% clobetasol propionate cream/day over 1 mg/kg of prednisone in extensive disease for disease control, adverse events, and mortality. No statistically significant differences between clobetasol propionate cream and 0.5 mg/kg prednisone were found in the moderate disease group for disease control, adverse events, and mortality.</P>
<P>However, even though there were less severe adverse effects (pneumonia, diabetes requiring insulin, myocardial infarction, psychiatric symptoms, stroke, thrombosis, bone fracture) noted in the group of participants treated with prednisone 1 mg/kg, it is not mentioned if participants in the different groups had similar adverse effects regarding, for example, blood pressure and bone mineral density. Also, the effort needed in applying the creams twice daily to the whole body is a major limitation in people with BP, who are mostly elderly and may have other co-existing disease. Another aspect is that topical preparations may be more costly than oral cortisone preparations and nursing care may be costly too.</P>
<P>It is likely that very potent topical corticosteroids applied in such large quantities may have systemic effects (perhaps comparable to 0.5 mg/kg/day prednisone). However, we do expect that there is also a local immunosuppressive and anti-inflammatory effect of the topically applied corticosteroids, because there are reports of participants with localised BP effectively treated with potent topical steroids only. In fact, a later trial by the same group shows that less topical steroids (&#8804; 30 g 0.05% clobetasol propionate cream/day) are as effective in disease control after 21 days, and that the mean cumulative dose was 71% lower in a mild treatment regimen than in a standard treatment regimen. The mild regimen was associated with less severe adverse effects (<LINK REF="STD-Joly-2009" TYPE="STUDY">Joly 2009</LINK>).</P>
<P>An important research question for the future is to evaluate whether a lower dose of steroid (0.5 mg/kg/day) would be adequate for disease control in extensive disease when compared with standard higher doses.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2010-09-08 08:57:50 +0100" MODIFIED_BY="Finola M Delamere">
<P>Most of the studies were very small and of poor methodological quality because of:</P>
<UL>
<LI>an unclear method of randomisation;</LI>
<LI>lack of blinding in the majority of studies; and</LI>
<LI>exclusion of dropouts from the analysis in most studies.</LI>
</UL>
<P>This is summarised in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>.</P>
<P>Some studies which did not describe the method of randomisation were published some time ago (e.g. <LINK REF="STD-Burton-1978" TYPE="STUDY">Burton 1978;</LINK> <LINK REF="STD-Dreno-1993" TYPE="STUDY">Dreno 1993</LINK>; <LINK REF="STD-Morel-1984" TYPE="STUDY">Morel 1984</LINK>); we did not attempt to gain further information as it was unlikely that further details of the studies would be available.</P>
<P>The main concern with <LINK REF="STD-Liu-2006" TYPE="STUDY">Liu 2006</LINK> is that in the published report of this study it was not absolutely clear that the diagnosis of BP was confirmed by immunofluorescence. The report of the trial was translated from Chinese and refers to the confirmation of the diagnosis listing the usual clinical features, histology, direct immunofluorescence, indirect IF on salt split skin and immuno EM, using a method given in a reference. The source of the methods in the reference was translated but it was unclear which of the methods listed were used. We contacted the trial investigators on two occasions, regarding the method used to confirm diagnosis, but did not receive a reply. Given that the description of the diagnosis of BP in the published report is not precise, it is possible that inclusion of the trial into a meta-analysis could introduce bias. However, Chinese traditional medicine plus prednisone was not shown to be effective in this single trial.</P>
<P>In <LINK REF="STD-Burton-1978" TYPE="STUDY">Burton 1978</LINK> there may have been selection bias, as participants were "started on oral prednisone 30 to 80 mg/day, to suppress new blisters" and only then "did the consultant decide whether to include the participant in the trial". Also <LINK REF="STD-Joly-2002" TYPE="STUDY">Joly 2002</LINK> switched three participants from one intervention group to another because of side-effects of treatment, although this was done in accordance with the study protocol.</P>
<P>The <LINK REF="STD-Guillaume-1993" TYPE="STUDY">Guillaume 1993</LINK> study was stopped after the interim analysis became available which showed no appreciable benefit resulting from the addition of azathioprine or plasma exchange to prednisolone. The trial investigators calculated that "the inclusion of 120 participants as initially scheduled, could not change these negative results". The <LINK REF="STD-Fivenson-1994" TYPE="STUDY">Fivenson 1994</LINK> study was terminated after 20 participants were enrolled (the study was originally designed to randomise 96 participants in 4 centres). No reasons were given for this early ending but a further randomised, double-blind, multicentre trial was mentioned as being 'underway' in the published report of the trial. We have attempted to contact the trial investigators but have been unsuccessful in obtaining any further details or data from the later study.</P>
<P>Overall, there were relatively few included studies of and these were of variable methodological quality, therefore some caution should be exercised in interpreting the results. Additionally no statistical pooling of the data was possible because of the clinical heterogeneity of the studies in terms of interventions, measures of disease control, and follow-up.</P>
</QUALITY_OF_EVIDENCE>
<AGREEMENT MODIFIED="2010-09-08 08:03:23 +0100" MODIFIED_BY="Finola M Delamere">
<P>The last published version<I> (</I>
<LINK REF="REF-Khumalo-2005" TYPE="REFERENCE">Khumalo 2005</LINK>
<I>) </I>of this review had seven included randomised controlled trials. The authors concluded at that time that oral corticosteroid drugs were the most common treatment, but may have been associated with serious adverse effects, including some deaths. The review concluded that more research was needed on treatments for BP; however, strong corticosteroid creams appeared safe and effective and lower doses of oral corticosteroids could be effective also in severe disease with fewer adverse effects than usual doses.</P>
<P>Since the review was last updated we have found and included three new RCTs but our conclusions have not changed greatly: very potent topical steroids are effective and safe treatments for bullous pemphigoid. Their use in extensive disease may be limited by side-effects and practical factors; new evidence suggests that milder regimens are safe and effective in moderate BP (<LINK REF="STD-Joly-2009" TYPE="STUDY">Joly 2009</LINK>). Starting doses of prednisolone greater than 0.75 mg/kg/day do not give additional benefit; lower doses may be adequate to control disease and reduce the incidence and severity of adverse reactions. One new included study investigated the addition of a Chinese herbal medicine (Jinqui Shui pill) to prednisone, but this was not more effective (<LINK REF="STD-Liu-2006" TYPE="STUDY">Liu 2006</LINK>). The third newly included study, <LINK REF="STD-Beissert-2007" TYPE="STUDY">Beissert 2007</LINK>, compared oral methylprednisolone plus azathioprine versus oral methylprednisolone plus mycophenolate mofetil, but no significant differences between the two therapies were observed. The effectiveness of adding plasma exchange, or azathioprine to corticosteroids has therefore not been established, a conclusion which is unchanged from the previous published version of this review. There was no new information about combination treatment with tetracycline and nicotinamide to add to this review, therefore further research is needed to determine if this therapy might be helpful.</P>
<P>We identified seven ongoing trials from the updated searches: <LINK REF="STD-ACTRN12607000104459" TYPE="STUDY">ACTRN12607000104459</LINK> (rituximab), <LINK REF="STD-NCT00286325" TYPE="STUDY">NCT00286325</LINK> (rituximab), <LINK REF="STD-NCT00472030" TYPE="STUDY">NCT00472030</LINK> (omalizumab), <LINK REF="STD-NCT00525616" TYPE="STUDY">NCT00525616</LINK> (rituximab (Mabthéra)), <LINK REF="STD-NCT00802243" TYPE="STUDY">NCT00802243</LINK> (leflunomide), <LINK REF="STD-NCT00809822" TYPE="STUDY">NCT00809822</LINK> (NPB-01(intravenous immunoglobulin)), and <LINK REF="STD-ISRCTN13704604" TYPE="STUDY">ISRCTN13704604</LINK> (doxycycline versus prednisolone).</P>
<P>The latter study (<LINK REF="STD-ISRCTN13704604" TYPE="STUDY">ISRCTN13704604</LINK>) investigates the effectiveness of doxycycline versus 0.5 mg/day prednisolone in the treatment of bullous pemphigoid. The primary outcomes are effectiveness measured by a blinded blister count at week six and safety, measured by the number of adverse events related to the trial medication which occur during the year of follow-up; results will be available by October 2013. </P>
<P>Monoclonal antibody therapies could offer alternatives to long-term steroid use, or may permit the dose of steroids or immune suppressive drugs to be reduced. Four of these ongoing studies are investigating the use of such biological agents. The use of rituximab as an adjuvant treatment in BP is being studied in <LINK REF="STD-ACTRN12607000104459" TYPE="STUDY">ACTRN12607000104459</LINK>, and the efficacy and tolerance of a single cycle of rituximab in the control of bullous pemphigoid is being examined in <LINK REF="STD-NCT00525616" TYPE="STUDY">NCT00525616</LINK>. The safety and efficacy of omalizumab is being tested in <LINK REF="STD-NCT00472030" TYPE="STUDY">NCT00472030,</LINK> and the safety of treatment of bullous pemphigoid in participants resistant to therapy with systemic corticosteroids, with rituximab plus systemic corticosteroids in <LINK REF="STD-NCT00286325" TYPE="STUDY">NCT00286325</LINK>. However, results from randomised controlled trials were not available at the time of this update, and while monoclonal antibody therapy may have a role to play in treatment of BP, it is not without adverse reactions including infusion reactions, fever, neutropenia, chills, increased risk of infection, weakness, and fatigue. Participants would potentially also require re-treatment with monoclonal antibodies, and there is a risk of neutralising antibodies that would interfere with therapeutic efficacy. Furthermore, it is a very costly treatment and will probably be reserved for treatment-resistant cases. The efficacy and safety of newer biology therapies (monoclonal antibodies) such as rituximab should be investigated in the context of randomised controlled trials.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2010-09-03 15:12:45 +0100" MODIFIED_BY="Laura  Prescott">
<IMPLICATIONS_PRACTICE MODIFIED="2010-09-03 15:12:45 +0100" MODIFIED_BY="Laura  Prescott">
<UL>
<LI>Starting doses of prednisolone greater than 0.75 mg/kg/day do not seem to give additional benefit, and it would appear that lower doses (0.5 mg/kg/day) may be adequate for disease control in more participants than was previously believed. This would be expected to reduce the incidence and severity of adverse reactions (especially death) associated with treatment.</LI>
<LI>Very potent topical steroids (clobetasol propionate) are an effective treatment for bullous pemphigoid. They seem to have less serious adverse effects compared to high-dose systemic steroids, however, their use in extensive disease may be limited by practical factors (ability of participant or availability of carer to apply the treatment). When feasible they should be considered for first-line treatment, especially in localised disease. However, if large quantities are needed to be applied topically, they may be associated with systemic absorption and adverse events. It would be helpful to determine serum cortisol levels with the use of topical steroid therapies.</LI>
<LI>The effectiveness of the addition of plasma exchange, azathioprine, or mycophenolate mofetil to prednisolone or prednisone, has not been established. The addition of a Chinese traditional herbal medicine to prednisone was not beneficial.</LI>
<LI>Combination treatment with tetracycline and nicotinamide may be useful, although this needs further validation.</LI>
</UL>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2010-09-03 15:10:36 +0100" MODIFIED_BY="Laura  Prescott">
<UL>
<LI>Double-blind studies are needed to confirm the appropriate oral steroid doses for the treatment of bullous pemphigoid.</LI>
<LI>Blinded RCTs comparing topical steroids with low doses of prednisolone/prednisone and with (less toxic) systemic treatments such as tetracycline and nicotinamide are needed.</LI>
<LI>The efficacy and safety of newer biologic therapies (monoclonal antibodies) such as rituximab, should be investigated in the context of randomised controlled trials.</LI>
</UL>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2010-09-08 08:08:50 +0100" MODIFIED_BY="Finola M Delamere">
<P>The authors thank Tina Leonard and Hywel Williams for their patience, without whose help the original review may never have been completed. Nonhlanhla P Khumalo thanks the Nuffield Trust Fellowship Scheme for the financial support in the preparation of this review. Sally Hollis contributed to the first version of the review as follows: extraction of the data, analysis of the results (statistics), and writing of the systematic review. The editorial base would like to thank the following people who were the external referees for this review: Grant Anhalt, Vicky Werth (content experts), and Jean Sangster (consumer).</P>
<P>GK thanks the "Deutsche Forschungsgemeinschaft" (DFG) for their financial support in the past, which enabled her to build up her knowledge of autoimmune blistering diseases. This knowledge was of great value when conducting this review.</P>
<P>For this update of the review the authors would like to thank Dr Ching-Chi Chi from Taiwan who translated the Chinese article by Liu 2009 and extracted the data of this article; Dr Ningning Dang, Consultant Dermatologist, Jinan Hospital, Department of Dermatology, China who translated the Chinese textbook section on the diagnosis of bullous pemphigoid, and Ingrid I. Riphagen, Medisch Informatiespecialist, VUmc Amsterdam, Netherlands who assisted in updating the review.</P>
<P>The Cochrane Skin Group editorial base would also like to thank Sue Jessop and Jo Leonardi-Bee who acted as the Key and Statistical Editors respectively, Vicky Werth who was the clinical referee and Alison Devine who was the consumer referee.<BR/>
</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2010-09-06 15:12:48 +0100" MODIFIED_BY="[Empty name]">
<P>GK contributed to the writing of the protocol, extraction of data, analysis of the results, the writing of the systematic review, and updating the review.</P>
<P>PM contributed to the extraction of the data, analysis of the results (statistics), writing of the systematic review, and provided comments on the updated review.</P>
<P>CB contributed to the 'Risk of bias' tables for the updated review, corresponded with trial investigators, contributed to writing and editing the text, revised some of the analyses, and (with GK) responded to the peer referees' comments.</P>
<P>DFM contributed to the writing of the protocol, extraction of data, and analysis of the results of the first version of the systematic review and editing the text of the current version.</P>
<P>FW contributed to the writing of protocol and analysis of the results of the first version of the systematic review.</P>
<P>NPK was the first author of the first version of the systematic review and was the main contributor to that version of the review.<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2010-09-03 15:15:23 +0100" MODIFIED_BY="Laura  Prescott">
<P>We changed the wording of the primary outcome "regression or healing of skin lesions" which referred to the "rate of" and "when/how soon?" as these are time-to-event measures which are complicated to measure and analyse (and not often reported in trials). We added "at time periods specified by individual trials".</P>
<P>We made minor changes to the secondary outcomes of systemic infection and mortality. We had originally intended to look at systemic infection and mortality as a result of the primary disease and as a result of treatment. At the time of the first published version of the review, we decided that these data were unlikely to be available and we no longer include them.</P>
<P>The original protocol of this review stated that the Jadad quality assessment scale would be used, which also similarly assesses randomisation, blinding, withdrawals, and dropouts (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>). We assessed all these aspects but reported them individually (see 'Risk of bias' tables in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>) rather than as a summary score, as the use of scales for assessing quality or risk of bias is explicitly discouraged in Cochrane reviews (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>; section 8.3.3) .</P>
<P>We have reclassified the outcomes as primary and secondary outcomes.</P>
<P>We have changed the measures of treatment effect to risk ratio (RR) from odds ratio (OR) in accordance with Cochrane Skin Group policy.<BR/>
</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2011-11-07 15:25:57 +0000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2010-09-05 00:03:19 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2010-09-03 18:38:28 +0100" MODIFIED_BY="Laura  Prescott">
<STUDY DATA_SOURCE="PUB" ID="STD-Beissert-2007" MODIFIED="2010-09-02 11:41:00 +0100" MODIFIED_BY="Liz Doney" NAME="Beissert 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-09-02 11:41:00 +0100" MODIFIED_BY="Liz Doney" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Beissert S, Werfel T, Frieling U, Böhm M, Sticherling M, Stadler R, et al</AU>
<TI>A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid</TI>
<SO>Archives of Dermatology</SO>
<YR>2007</YR>
<VL>143</VL>
<NO>12</NO>
<PG>1536-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Burton-1978" NAME="Burton 1978" YEAR="1978">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Burton JL, Harman RR, Peachy RD, Warin RP</AU>
<TI>Azathioprine plus prednisone in treatment of pemphigoid</TI>
<SO>British Medical Journal</SO>
<YR>1978</YR>
<VL>2</VL>
<PG>1190-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dreno-1993" MODIFIED="2010-09-03 18:35:44 +0100" MODIFIED_BY="Laura  Prescott" NAME="Dreno 1993" YEAR="1993">
<REFERENCE MODIFIED="2010-09-03 18:35:44 +0100" MODIFIED_BY="Laura  Prescott" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dreno B, Sassolas B, Lacour P, Montpoint S, Lota I, Giordano F, et al</AU>
<TI>Methylprednisolone versus prednisolone methylsulfobenzoate in pemphigoid: A comparative multicenter study</TI>
<SO>Annales de Dermatologie et de Vénéréologie</SO>
<YR>1993</YR>
<VL>120</VL>
<PG>518-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fivenson-1994" MODIFIED="2010-09-02 11:58:00 +0100" MODIFIED_BY="Liz Doney" NAME="Fivenson 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-09-02 11:58:00 +0100" MODIFIED_BY="Liz Doney" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fivenson DP, Breneman DL, Rosen GB, Hersh CS, Cardone S, Mutasim D</AU>
<TI>Nicotinamide and tetracycline therapy of bullous pemphigoid</TI>
<SO>Archives of Dermatology</SO>
<YR>1994</YR>
<VL>130</VL>
<NO>6</NO>
<PG>753-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Guillaume-1993" MODIFIED="2010-09-02 12:02:53 +0100" MODIFIED_BY="Liz Doney" NAME="Guillaume 1993" YEAR="1993">
<REFERENCE MODIFIED="2010-09-02 12:02:53 +0100" MODIFIED_BY="Liz Doney" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guillaume JC, Vaillant L, Bernard P, Picard C, Prost C, Labeille B, et al</AU>
<TI>Controlled trial of azathioprine and plasma exchange in addition to prednisolone in the treatment of bullous pemphigoid</TI>
<SO>Archives of Dermatology</SO>
<YR>1993</YR>
<VL>129</VL>
<NO>1</NO>
<PG>49-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Joly-2002" MODIFIED="2010-09-03 18:30:34 +0100" MODIFIED_BY="Laura  Prescott" NAME="Joly 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-09-03 18:29:20 +0100" MODIFIED_BY="Laura  Prescott" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Joly P, Benichou J, Lok C, Hellot MF, Saiag P, Trancrede-Bohin E, et al</AU>
<TI>Prediction of survival for patients with bullous pemphigoid. A prospective study</TI>
<SO>Archives of Dermatology</SO>
<YR>2005</YR>
<VL>141</VL>
<PG>691-98</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-09-03 18:30:34 +0100" MODIFIED_BY="Laura  Prescott" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Joly P, Roujeau JC, Benichou J, Picard C, Dreno B, Delaporte E, et al</AU>
<TI>A comparison of oral and topical corticosteroids in patients with bullous pemphigoid</TI>
<SO>New England Journal of Medicine</SO>
<YR>2002</YR>
<VL>346</VL>
<NO>5</NO>
<PG>321-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Joly-2009" MODIFIED="2010-09-03 18:31:54 +0100" MODIFIED_BY="Laura  Prescott" NAME="Joly 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-09-03 18:31:54 +0100" MODIFIED_BY="Laura  Prescott" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Joly P, Roujeau JC, Benichou J, Delaporte E, D'Incan M, Dreno B, et al</AU>
<TI>A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: A multicenter randomized study</TI>
<SO>Journal of Investigative Dermatology</SO>
<YR>2009</YR>
<VL>129</VL>
<NO>7</NO>
<PG>1681-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-09-03 18:30:59 +0100" MODIFIED_BY="Laura  Prescott" PRIMARY="NO" TYPE="CORRESPONDENCE">
<AU>Joly P</AU>
<TI>Personal communication</TI>
<SO>Email communication clarifying the published report.</SO>
<YR>30 January 2010</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2006" MODIFIED="2010-09-03 18:33:32 +0100" MODIFIED_BY="Laura  Prescott" NAME="Liu 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-09-03 18:33:32 +0100" MODIFIED_BY="Laura  Prescott" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu BG, Li ZY, Du M</AU>
<TI>Effects of Jingui Shenqi Pill combined prednisone on expression of glucocorticoid receptor and its clinical effect in treating bullous pemphigoid patients</TI>
<SO>Chinese Journal of Integrated Traditional and Western Medicine</SO>
<YR>2006</YR>
<VL>26</VL>
<NO>10</NO>
<PG>881-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morel-1984" MODIFIED="2010-09-03 18:35:16 +0100" MODIFIED_BY="Laura  Prescott" NAME="Morel 1984" YEAR="1984">
<REFERENCE MODIFIED="2010-09-03 18:35:16 +0100" MODIFIED_BY="Laura  Prescott" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morel P, Guillaume JC</AU>
<TI>Treatment of bullous pemphigoid with prednisolone only: 0.75 mg/kg/day versus 1.25 mg/kg/day. A multicenter randomized study</TI>
<SO>Annales de Dermatologie et de Vénéréologie</SO>
<YR>1984</YR>
<VL>111</VL>
<NO>10</NO>
<PG>925-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Roujeau-1984" MODIFIED="2010-09-03 18:38:28 +0100" MODIFIED_BY="Laura  Prescott" NAME="Roujeau 1984" YEAR="1984">
<REFERENCE MODIFIED="2010-09-03 18:38:28 +0100" MODIFIED_BY="Laura  Prescott" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roujeau JC, Guillaume JC, Morel P, Crickx B, Dalle E, Doutre MS, et al</AU>
<TI>Plasma exchange in bullous pemphigoid</TI>
<SO>Lancet</SO>
<YR>1984</YR>
<VL>2</VL>
<NO>8401</NO>
<PG>486-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES/>
<AWAITING_STUDIES/>
<ONGOING_STUDIES MODIFIED="2010-09-05 00:03:19 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-ACTRN12607000104459" MODIFIED="2010-09-04 23:40:10 +0100" MODIFIED_BY="[Empty name]" NAME="ACTRN12607000104459" YEAR="2007">
<REFERENCE MODIFIED="2010-09-04 23:40:10 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>ACTRN12607000104459</AU>
<TI>Rituximab in the adjuvant treatment of bullous pemphigoid: A prospective open-label pilot study in three patients to study remission of disease with rituximab</TI>
<SO>http://www.anzctr.org.au/ACTRN12607000104459.aspx</SO>
<YR>(accessed 27 July 2010)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-09-04 23:33:38 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ISRCTN13704604" MODIFIED="2010-09-05 00:03:19 +0100" MODIFIED_BY="[Empty name]" NAME="ISRCTN13704604" YEAR="2009">
<REFERENCE MODIFIED="2010-09-05 00:03:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>ISRCTN13704604</AU>
<TI>A randomised controlled trial to compare the safety and effectiveness of doxycycline (200 mg/day) with prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid</TI>
<SO>http://www.controlled-trials.com/ISRCTN13704604/Bullous+Pemphigoid</SO>
<YR>(accessed 20 April 2009)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-02-16 10:56:09 +0000" MODIFIED_BY="Laura "/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00286325" MODIFIED="2010-09-04 23:37:54 +0100" MODIFIED_BY="[Empty name]" NAME="NCT00286325" YEAR="2009">
<REFERENCE MODIFIED="2010-09-04 23:37:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00286325</AU>
<TI>Rituximab in the treatment of patients with bullous pemphigoid</TI>
<SO>http://www.clinicaltrials.gov/ct2/show/NCT00286325</SO>
<YR>(accessed 20 April 2009)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-09-04 23:37:54 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00472030" MODIFIED="2010-09-04 23:45:23 +0100" MODIFIED_BY="[Empty name]" NAME="NCT00472030" YEAR="2007">
<REFERENCE MODIFIED="2010-09-04 23:45:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00472030</AU>
<TI>An open label case series on the effects of Xolair (Omalizumab) in bullous pemphigoid</TI>
<SO>http://clinicaltrials.gov/show/NCT00472030</SO>
<YR>(accessed 20 April 2009)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-09-04 23:37:40 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00525616" MODIFIED="2010-09-04 23:45:04 +0100" MODIFIED_BY="[Empty name]" NAME="NCT00525616" YEAR="2008">
<REFERENCE MODIFIED="2010-09-04 23:45:04 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00525616</AU>
<TI>Assessment of rituximab efficiency and tolerance in treatment of bullous pemphigoid</TI>
<SO>http://www.clinicaltrials.gov/show/NCT00525616</SO>
<YR>(accessed 20 April 2009)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-09-04 23:41:39 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00802243" MODIFIED="2010-09-04 23:44:47 +0100" MODIFIED_BY="[Empty name]" NAME="NCT00802243" YEAR="2007">
<REFERENCE MODIFIED="2010-09-04 23:44:47 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00802243</AU>
<TI>Leflunomide associated with topical corticosteroids for bullous pemphigoid. An open prospective study</TI>
<SO>http://clinicaltrials.gov/show/NCT00802243</SO>
<YR>(accessed 20 April 2009)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-09-04 23:43:34 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00809822" MODIFIED="2010-09-04 23:48:32 +0100" MODIFIED_BY="[Empty name]" NAME="NCT00809822" YEAR="2008">
<REFERENCE MODIFIED="2010-09-04 23:48:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00809822</AU>
<TI>NPB-01 (intravenous immunoglobulin) therapy for patients with bullous pemphigoid unresponsive to corticosteroids: Randomized, double-blind, placebo control, parallel assignment study (phase II)</TI>
<SO>http://clinicaltrials.gov/show/NCT00809822</SO>
<YR>(accessed 20 April 2009)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-09-04 23:45:44 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2011-11-07 15:25:57 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2010-09-05 01:47:25 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Adam-1992" MODIFIED="2010-09-03 18:39:14 +0100" MODIFIED_BY="Laura  Prescott" NAME="Adam 1992" TYPE="JOURNAL_ARTICLE">
<AU>Adam BA</AU>
<TI>Bullous diseases in Malaysia: Epidemiological and natural history</TI>
<SO>International Journal of Dermatology</SO>
<YR>1992</YR>
<VL>31</VL>
<NO>1</NO>
<PG>42-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ahmed-1977" MODIFIED="2010-09-03 18:41:06 +0100" MODIFIED_BY="Laura  Prescott" NAME="Ahmed 1977" TYPE="JOURNAL_ARTICLE">
<AU>Ahmed AR, Maize JC, Provost TT</AU>
<TI>Bullous pemphigoid: Clinical and immunologic follow-up after successful treatment</TI>
<SO>Archives of Dermatology</SO>
<YR>1977</YR>
<VL>113</VL>
<NO>8</NO>
<PG>1043-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bernard-1995" MODIFIED="2010-09-03 18:42:44 +0100" MODIFIED_BY="Laura  Prescott" NAME="Bernard 1995" TYPE="JOURNAL_ARTICLE">
<AU>Bernard P, Vaillant L, Labeille B, Bedane C, Arbeille B, Denoeux JP, et al</AU>
<TI>Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Bullous Diseases French Study Group</TI>
<SO>Archives of Dermatology</SO>
<YR>1995</YR>
<VL>131</VL>
<NO>1</NO>
<PG>48-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Colbert-2004" MODIFIED="2010-09-03 18:45:24 +0100" MODIFIED_BY="Laura  Prescott" NAME="Colbert 2004" TYPE="JOURNAL_ARTICLE">
<AU>Colbert RL, Allen DM, Eastwood D, Fairley JA</AU>
<TI>Mortality rate of bullous pemphigoid in a US medical center</TI>
<SO>Journal of Investigative Dermatology</SO>
<YR>2004</YR>
<VL>122</VL>
<NO>5</NO>
<PG>1091-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Garg-1994" MODIFIED="2010-09-03 18:44:55 +0100" MODIFIED_BY="Laura  Prescott" NAME="Garg 1994" TYPE="JOURNAL_ARTICLE">
<AU>Garg V, Jusko WJ</AU>
<TI>Bioavailability and reversible metabolism of prednisone and prednisolone in man</TI>
<SO>Biopharmaceutics and Drug Disposition</SO>
<YR>1994</YR>
<VL>15</VL>
<NO>2</NO>
<PG>163-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gudi-2005" MODIFIED="2010-09-03 18:46:20 +0100" MODIFIED_BY="Laura  Prescott" NAME="Gudi 2005" TYPE="JOURNAL_ARTICLE">
<AU>Gudi VS, White MI, Cruickshank N, Herriot R, Edwards SL, Nimmo F, et al</AU>
<TI>Annual incidence and mortality of bullous pemphigoid in the Grampian Region of North-east Scotland</TI>
<SO>British Journal of Dermatology</SO>
<YR>2005</YR>
<VL>153</VL>
<NO>2</NO>
<PG>424-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hadi-1988" MODIFIED="2010-02-16 11:44:32 +0000" MODIFIED_BY="Laura " NAME="Hadi 1988" TYPE="JOURNAL_ARTICLE">
<AU>Hadi SM, Barnetson RS, Gawkrodger DJ, Saxena U, Bird P, Merrett TG</AU>
<TI>Clinical, histological and immunological studies in 50 patients with bullous pemphigoid</TI>
<SO>Dermatologica</SO>
<YR>1988</YR>
<VL>176</VL>
<NO>1</NO>
<PG>6-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hertl-2008" MODIFIED="2010-09-03 18:48:33 +0100" MODIFIED_BY="Laura  Prescott" NAME="Hertl 2008" TYPE="JOURNAL_ARTICLE">
<AU>Hertl M, Zillikens D, Borradori L, Bruckner-Tuderman L, Burckhard H, Eming R, et al</AU>
<TI>Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases</TI>
<SO>Journal der Deutschen Dermatologischen Gesellschaft</SO>
<YR>2008</YR>
<VL>6</VL>
<NO>5</NO>
<PG>366-373</PG>
<IDENTIFIERS MODIFIED="2010-06-07 16:17:37 +0100" MODIFIED_BY="Cathy Bennett">
<IDENTIFIER MODIFIED="2010-06-07 16:17:37 +0100" MODIFIED_BY="Cathy Bennett" TYPE="DOI" VALUE="DOI: 10.1111/j.1610-0387.2007.06602.x"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008" MODIFIED="2010-02-16 11:54:06 +0000" MODIFIED_BY="Laura " NAME="Higgins 2008" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996" MODIFIED="2010-09-03 18:49:34 +0100" MODIFIED_BY="Laura  Prescott" NAME="Jadad 1996" TYPE="JOURNAL_ARTICLE">
<AU>Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al</AU>
<TI>Assessing the quality of reports of randomized clinical trials: Is blinding necessary?</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1996</YR>
<VL>17</VL>
<NO>1</NO>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jin-1993" MODIFIED="2010-09-03 18:50:17 +0100" MODIFIED_BY="Laura  Prescott" NAME="Jin 1993" TYPE="JOURNAL_ARTICLE">
<AU>Jin P, Shao C, Ye G</AU>
<TI>Chronic bullous dermatoses in China</TI>
<SO>International Journal of Dermatology</SO>
<YR>1993</YR>
<VL>32</VL>
<NO>2</NO>
<PG>89-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Joly-2010" MODIFIED="2010-09-05 01:47:25 +0100" MODIFIED_BY="[Empty name]" NAME="Joly 2010" TYPE="CORRESPONDENCE">
<AU>Joly P, et al</AU>
<TI>Personal communication</TI>
<SO>Email communication clarifying the published report.</SO>
<YR>30 January 2010</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kirtschig-1994" MODIFIED="2010-09-03 18:52:21 +0100" MODIFIED_BY="Laura  Prescott" NAME="Kirtschig 1994" TYPE="JOURNAL_ARTICLE">
<AU>Kirtschig G, Wojnarowska F, Marsden RA, Edwards S, Bhogal B, Black MM</AU>
<TI>Acquired bullous disease of childhood: Re-evaluation of diagnosis by indirect immunofluorescence examination on 1 M NaCl split skin and immunoblotting</TI>
<SO>British Journal of Dermatology</SO>
<YR>1994</YR>
<VL>130</VL>
<NO>5</NO>
<PG>610-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lebrun_x002d_Vignes-1999" MODIFIED="2010-09-03 18:53:32 +0100" MODIFIED_BY="Laura  Prescott" NAME="Lebrun-Vignes 1999" TYPE="JOURNAL_ARTICLE">
<AU>Lebrun-Vignes B, Roujeau JC, Bernard P, Delaporte E, Joly P, Prost C, et al</AU>
<TI>Prednisone is more effective than prednisolone metasulfobenzoate in the treatment of bullous pemphigoid</TI>
<SO>Archives of Dermatology</SO>
<YR>1999</YR>
<VL>135</VL>
<NO>1</NO>
<PG>89-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lever-1953" MODIFIED="2010-09-03 18:54:32 +0100" MODIFIED_BY="Laura  Prescott" NAME="Lever 1953" TYPE="JOURNAL_ARTICLE">
<AU>Lever WF</AU>
<TI>Pemphigus</TI>
<SO>Medicine</SO>
<YR>1953</YR>
<VL>32</VL>
<NO>1</NO>
<PG>1-123</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Logan-1987" MODIFIED="2010-09-03 18:55:27 +0100" MODIFIED_BY="Laura  Prescott" NAME="Logan 1987" TYPE="JOURNAL_ARTICLE">
<AU>Logan RA, Bhogal B, Das AK, McKee PM, Black MM</AU>
<TI>Localization of bullous pemphigoid antibody - An indirect immunofluorescence study of 228 cases using a split-skin technique</TI>
<SO>British Journal of Dermatology</SO>
<YR>1987</YR>
<VL>117</VL>
<NO>4</NO>
<PG>471-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Morrison-1990" NAME="Morrison 1990" TYPE="BOOK_SECTION">
<AU>Morrison LH, Diaz L, Anhalt GJ</AU>
<TI>Bullous pemphigoid</TI>
<SO>Management of blistering diseases</SO>
<YR>1990</YR>
<PG>63-82</PG>
<ED>Wojnarowska F, Briggaman RN (Editors)</ED>
<PB>Chapman and Hall Medical</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nemeth-1991" MODIFIED="2010-09-03 18:57:12 +0100" MODIFIED_BY="Laura  Prescott" NAME="Nemeth 1991" TYPE="JOURNAL_ARTICLE">
<AU>Nemeth AJ, Klein AO, Gould EW, Schachner LA</AU>
<TI>Childhood bullous pemphigoid. Clinical and immunologic features, treatment, and prognosis</TI>
<SO>Archives of Dermatology</SO>
<YR>1991</YR>
<VL>127</VL>
<NO>3</NO>
<PG>378-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Orange-1989" MODIFIED="2010-09-03 18:58:19 +0100" MODIFIED_BY="Laura  Prescott" NAME="Orange 1989" TYPE="JOURNAL_ARTICLE">
<AU>Orange AP, van Joost T</AU>
<TI>Pemphigoid in children</TI>
<SO>Pediatric Dermatology</SO>
<YR>1989</YR>
<VL>6</VL>
<NO>4</NO>
<PG>267-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Parker-2008" MODIFIED="2010-09-03 18:59:33 +0100" MODIFIED_BY="Laura  Prescott" NAME="Parker 2008" TYPE="JOURNAL_ARTICLE">
<AU>Parker SR, Dyson S, Brisman S, Pennie M, Swerlick RA, Khan R, et al</AU>
<TI>Mortality of bullous pemphigoid: An evaluation of 223 patients and comparison with the mortality in the general population in the United States</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>2008</YR>
<VL>59</VL>
<NO>4</NO>
<PG>582-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Person-1977" MODIFIED="2010-03-01 20:40:13 +0000" MODIFIED_BY="Cathy Bennett" NAME="Person 1977" TYPE="JOURNAL_ARTICLE">
<AU>Person JR, Rogers RS</AU>
<TI>Bullous and cicatricial pemphigoid: Clinical, pathological, and immunologic collerations</TI>
<SO>Mayo Clinic Proceedings</SO>
<YR>1977</YR>
<VL>52</VL>
<PG>54-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reguia_x00ef_-2009" MODIFIED="2010-09-03 19:01:32 +0100" MODIFIED_BY="Laura  Prescott" NAME="Reguiaï 2009" TYPE="JOURNAL_ARTICLE">
<AU>Reguiaï Z, Tchen T, Perceau G, Bernard P</AU>
<TI>Efficacy of rituximab in a case of refractory bullous pemphigoid</TI>
<TO>Efficacite du rituximab dans une pemphigoide bulleuse en echec therapeutique.</TO>
<SO>Annales de dermatologie et de Vénéréologie</SO>
<YR>2009</YR>
<VL>136</VL>
<NO>5</NO>
<PG>431-4</PG>
<IDENTIFIERS MODIFIED="2010-06-03 17:02:39 +0100" MODIFIED_BY="Cathy Bennett">
<IDENTIFIER TYPE="PUBMED" VALUE="19442800"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Rollin-1993" MODIFIED="2010-09-03 19:03:16 +0100" MODIFIED_BY="Laura  Prescott" NAME="Rollin 1993" TYPE="JOURNAL_ARTICLE">
<AU>Rollin C, Chosidow O, Diquet B, Dutreuil C, Herson S, Revuz J, et al</AU>
<TI>Comparative study of availability of prednisolone after intestinal infusion of prednisolone metasulfobenzoate and prednisone</TI>
<SO>European Journal of Clinical Pharmacology</SO>
<YR>1993</YR>
<VL>44</VL>
<NO>4</NO>
<PG>395-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Roujeau-1998" MODIFIED="2010-09-03 19:04:01 +0100" MODIFIED_BY="Laura  Prescott" NAME="Roujeau 1998" TYPE="JOURNAL_ARTICLE">
<AU>Roujeau JC, Lok C, Bastuji-Garin S, Mhalla S, Enginger V, Bernard P</AU>
<TI>High risk of death in elderly patients with extensive bullous pemphigoid</TI>
<SO>Archives of Dermatology</SO>
<YR>1998</YR>
<VL>134</VL>
<NO>4</NO>
<PG>465-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Savin-1979" MODIFIED="2010-09-03 19:05:06 +0100" MODIFIED_BY="Laura  Prescott" NAME="Savin 1979" TYPE="JOURNAL_ARTICLE">
<AU>Savin JA</AU>
<TI>The events leading to the death of patients with pemphigus and pemphigoid</TI>
<SO>British Journal of Dermatology</SO>
<YR>1979</YR>
<VL>101</VL>
<NO>5</NO>
<PG>521-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Savin-1987" MODIFIED="2010-09-03 19:05:38 +0100" MODIFIED_BY="Laura  Prescott" NAME="Savin 1987" TYPE="JOURNAL_ARTICLE">
<AU>Savin JA</AU>
<TI>Death in bullous pemphigoid</TI>
<SO>Clinics in Dermatology</SO>
<YR>1987</YR>
<VL>5</VL>
<NO>1</NO>
<PG>52-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tham-1998" MODIFIED="2010-09-03 19:07:01 +0100" MODIFIED_BY="Laura  Prescott" NAME="Tham 1998" TYPE="JOURNAL_ARTICLE">
<AU>Tham SN, Thirumoorthy T, Rajan VS</AU>
<TI>Bullous pemphigoid: Clinico-epidemiological study of patients seen at a Singapore skin hospital</TI>
<SO>Australasian Journal of Dermatology</SO>
<YR>1998</YR>
<VL>25</VL>
<NO>2</NO>
<PG>68-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Venning-1992" MODIFIED="2010-09-03 19:07:37 +0100" MODIFIED_BY="Laura  Prescott" NAME="Venning 1992" TYPE="JOURNAL_ARTICLE">
<AU>Venning VA, Wojnarowska F</AU>
<TI>Lack of predictive factors for the clinical course of bullous pemphigoid</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>1992</YR>
<VL>26</VL>
<NO>4</NO>
<PG>585-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wojnarowska-1998" NAME="Wojnarowska 1998" TYPE="BOOK_SECTION">
<AU>Wojnarowska F, Eady RAJ, Burge SM</AU>
<TI>Bullous pemphigoid</TI>
<SO>Textbook of Dermatology</SO>
<YR>1998</YR>
<VL>3</VL>
<PG>1866-73</PG>
<EN>6</EN>
<ED>Champion RH, Burton JL, Burns DA, Breathnach SM</ED>
<PB>Blackwell Science Ltd</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wojnarowska-2002" MODIFIED="2010-09-03 19:09:04 +0100" MODIFIED_BY="Laura  Prescott" NAME="Wojnarowska 2002" TYPE="JOURNAL_ARTICLE">
<AU>Wojnarowska F, Kirtschig G, Highet AS, Venning VA, Khumalo NP</AU>
<TI>Guidelines for the management of bullous pemphigoid</TI>
<SO>British Journal of Dermatology</SO>
<YR>2002</YR>
<VL>147</VL>
<NO>2</NO>
<PG>214-221</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zillikens-1995" MODIFIED="2010-09-03 19:10:41 +0100" MODIFIED_BY="Laura  Prescott" NAME="Zillikens 1995" TYPE="JOURNAL_ARTICLE">
<AU>Zillikens D, Wever S, Roth A, Weidenthaler-Barth B, Hashimoto T, Bröcker EB</AU>
<TI>Incidence of autoimmune subepidermal blistering dermatoses in a region of central Germany (Comment)</TI>
<SO>Archives of Dermatology</SO>
<YR>1995</YR>
<VL>131</VL>
<NO>1</NO>
<PG>48-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zimmermann-1999" MODIFIED="2010-09-03 19:12:15 +0100" MODIFIED_BY="Laura  Prescott" NAME="Zimmermann 1999" TYPE="JOURNAL_ARTICLE">
<AU>Zimmermann R, Faure M, Claudy A</AU>
<TI>Prospective study of treatment of bullous pemphigoid by a class I topical corticosteroid</TI>
<SO>Annales de Dermatologie et de Vénéréologie</SO>
<YR>1999</YR>
<VL>126</VL>
<NO>1</NO>
<PG>13-6</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2011-11-07 15:25:57 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Khumalo-2002" MODIFIED="2010-09-05 13:52:46 +0100" MODIFIED_BY="[Empty name]" NAME="Khumalo 2002" TYPE="JOURNAL_ARTICLE">
<AU>Khumalo NP, Murrell DF, Wojnarowska F, Kirtschig G</AU>
<TI>A systematic review of treatments for bullous pemphigoid</TI>
<SO>Archives of Dermatology</SO>
<YR>2002</YR>
<VL>138</VL>
<NO>3</NO>
<PG>385-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Khumalo-2005" MODIFIED="2011-11-07 15:25:57 +0000" MODIFIED_BY="[Empty name]" NAME="Khumalo 2005" TYPE="COCHRANE_REVIEW">
<AU>Khumalo N, Kirtschig G, Middleton P, Hollis S, Wojnarowska F, Murrell DF</AU>
<TI>Interventions for bullous pemphigoid</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2011-11-07 15:25:55 +0000" MODIFIED_BY="Cathy Bennett">
<IDENTIFIER MODIFIED="2011-11-07 15:25:55 +0000" MODIFIED_BY="Cathy Bennett" TYPE="DOI" VALUE="10.1002/14651858.CD002292.pub3"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2011-11-07 12:18:05 +0000" MODIFIED_BY="Finola M Delamere">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2011-11-07 12:18:05 +0000" MODIFIED_BY="Finola M Delamere" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2011-11-07 12:18:05 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Beissert-2007">
<CHAR_METHODS MODIFIED="2010-09-05 13:23:20 +0100" MODIFIED_BY="[Empty name]">
<P>Multicentre in Germany, central randomisation, not blinded</P>
<P>2 parallel groups; initial dose was maintained until blister formation ceased and re-epithelialisation started. Corticosteroid dose was then reduced every 2 weeks; after discontinuation of corticosteroid, azathioprine, or mycophenolate mofetil (MMF) dose was maintained for 4 more weeks, then reduced (see taper regimen page 1537)</P>
<P>Follow-up of 720 days</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-10-08 16:03:36 +0100" MODIFIED_BY="Cathy Bennett">
<P>73 participants with bullous pemphigoid, confirmed by direct and indirect immunofluorescence on salt split skin</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-07 12:18:05 +0000" MODIFIED_BY="Laura  Prescott">
<P>A: 38/38 oral methylprednisolone 0.5 mg/kg/day plus azathioprine sodium 2 mg/kg/day.</P>
<P>B: 35/35 oral methylprednisolone 0.5 mg/kg/day plus mycophenolate mofetil 2000 mg/day (tapering described on page 1537).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-05 13:24:05 +0100" MODIFIED_BY="[Empty name]">
<P>Primary:</P>
<OL>
<LI>Complete healing (complete reepithelialisation of all lesions)</LI>
<LI>Cumulative steroid dose (until end of documentation &gt; 720 days) (Table 2)</LI>
</OL>
<P>Secondary:</P>
<OL>
<LI>Duration of remission (disease-free interval)</LI>
<LI>Safety profiles</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-09-06 14:08:31 +0100" MODIFIED_BY="[Empty name]">
<P>Cumulative corticosteroid dose: described as primary outcome until complete healing was achieved (page 1537); on page1539 the cumulative corticosteroid dose was defined as corticosteroid dose until the end of the documentation period (&gt; 720 days) (Table 2, Table 3). We presumed that calculated cumulative corticosteroid dose is calculated until the end of the documentation period.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-05 13:27:18 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Burton-1978">
<CHAR_METHODS MODIFIED="2010-09-05 13:26:51 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised but not blind</P>
<P>Intervention took place over 3 years, treatment maintained at starting doses until 'rash suppressed' at which point prednisone doses were gradually reduced in both groups. If rash did not recur then also azathioprine was gradually withdrawn in the azathioprine group</P>
<P>Follow-up: at the end of the 3-year treatment period<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-09-03 17:39:08 +0100" MODIFIED_BY="Laura  Prescott">
<P>25 participants with BP confirmed by IF studies</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-03 17:39:39 +0100" MODIFIED_BY="Laura  Prescott">
<P>A: 12/12 participants prednisone (30 to 80 mg/day) + azathioprine (2.5 mg/kg/day). </P>
<P>B: 13/13 participants prednisone (30 to 80 mg/kg/day).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-03 17:40:29 +0100" MODIFIED_BY="Laura  Prescott">
<P>Unclear outcome measures:</P>
<OL>
<LI>Whether azathioprine + prednisolone (synergistic immunosuppression) associated with increased risk of malignancy</LI>
<LI>Disease control</LI>
<LI>Cumulative dose of prednisone in both groups</LI>
<LI>Mortality</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-09-05 13:27:18 +0100" MODIFIED_BY="[Empty name]">
<P>After 1 week of prednisolone to suppress lesions, consultant decided whether to include in trial. Not clear how prednisolone dose decided or numbers of participants on lower or higher doses in each group</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-05 13:28:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dreno-1993">
<CHAR_METHODS MODIFIED="2010-09-05 13:28:08 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind</P>
<P>Disease control = reduction of blisters, redness &amp; itch &gt; 50%</P>
<P>Follow-up: 10 days (= treatment period)<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-09-03 17:43:01 +0100" MODIFIED_BY="Laura  Prescott">
<P>57 participants with BP confirmed by IF studies</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-03 17:43:57 +0100" MODIFIED_BY="Laura  Prescott">
<P>A: 29/29 participants prednisolone (1.16 mg/kg/day). </P>
<P>B: 28/28 participants methylprednisolone (1.17 mg/kg/day).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-03 17:44:52 +0100" MODIFIED_BY="Laura  Prescott">
<OL>
<LI>Number of blisters</LI>
<LI>Extent of erythema scale: 0 (absent) to 3 (severe)</LI>
<LI>The intensity of pruritus (itch), scale 0 (absent) to 3 (severe), at days 5 and 10</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-09-05 13:28:21 +0100" MODIFIED_BY="[Empty name]">
<P>Problem: 'scale' for measuring symptoms &amp; signs. Very short study duration<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-06 15:44:29 +0100" MODIFIED_BY="Finola M Delamere" STUDY_ID="STD-Fivenson-1994">
<CHAR_METHODS MODIFIED="2010-09-06 15:44:29 +0100" MODIFIED_BY="Finola M Delamere">
<P>Randomised open-label, but randomisation method not stated, not blind</P>
<P>Disease control after 8 weeks Rx: complete response = 100% clearing of all lesions, partial response &#8805; 50%, no response &lt; 25%. </P>
<P>Pruritus and physician's global assessment were also recorded.</P>
<P>Disease recurrence in the follow up period was recorded if: new blisters, urticarial lesions and/or crusts were noted.</P>
<P>Follow-up: 10 months (= treatment period)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-09-03 17:47:48 +0100" MODIFIED_BY="Laura  Prescott">
<P>20 participants with BP confirmed by IF studies</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-03 17:47:41 +0100" MODIFIED_BY="Laura  Prescott">
<P>A: 6/6 participants prednisone 40 to 80 mg/day. </P>
<P>B: 14/14 participants nicotinamide 1500 mg/day in 3 divided doses + tetracycline 2 g/day 4 divided doses.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-03 17:50:02 +0100" MODIFIED_BY="Laura  Prescott">
<OL>
<LI>Number of bullous, crusted, urticarial lesions as follows: none = 0, 1 to 5 = 1+, 6 to 10 = 2+, 11 to 20 = 3+, 20 to 40 = 4+, more than 40 lesions = 5+. All three of these recorded as less than or more than 1 cm in size. Total highest score possible on each visit per participant. Mean scores for each group used to calculate P values</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-09-05 13:30:55 +0100" MODIFIED_BY="[Empty name]">
<P>Not clear how the prednisone dose was decided or number of participants on higher or lower dose<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-06 15:45:29 +0100" MODIFIED_BY="Finola M Delamere" STUDY_ID="STD-Guillaume-1993">
<CHAR_METHODS MODIFIED="2010-09-05 13:31:44 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, not blind</P>
<P>Disease control = no new blisters for 4 weeks, prednisolone dose decreased gradually to 0.5 mg/kg at 3 months and 0.2 mg/kg at 6 months </P>
<P>Follow-up: 6 months ( = treatment period)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-09-03 17:55:13 +0100" MODIFIED_BY="Laura  Prescott">
<P>100 participants with BP confirmed by IF studies</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-06 15:45:29 +0100" MODIFIED_BY="Finola M Delamere">
<P>31/32 participants prednisolone 1 mg/kg/day versus 36/36 participants azathioprine + prednisolone 1 mg/kg/day versus 31/32 participants plasma exchange + prednisolone 1 mg/kg/day.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-03 17:55:07 +0100" MODIFIED_BY="Laura  Prescott">
<OL>
<LI>Disease control: No more than 1 new blister in the 4 weeks after starting treatment, these participants were followed up a further 6 months. Resolution of erythema and no more than minimal pruritus</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-09-05 13:31:55 +0100" MODIFIED_BY="[Empty name]">
<P>Trial stopped at interim period due to no appreciable benefit<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-05 13:33:18 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Joly-2002">
<CHAR_METHODS MODIFIED="2010-09-05 13:32:51 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, not blinded</P>
<P>Disease control = number of new blisters after 3 weeks (21 days) of treatment. (Not clear if participant kept record of new blisters daily or if all new blisters since previous visit were averaged out to get a daily rate)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-09-05 13:33:03 +0100" MODIFIED_BY="[Empty name]">
<P>341 participants with BP confirmed by IF studies</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-03 18:04:38 +0100" MODIFIED_BY="Laura  Prescott">
<P>Moderate disease: </P>
<P>A: 40 g topical clobetasol propionate cream twice daily to entire body 77/77 versus 0.5 mg/kg/day oral prednisone 76/76.</P>
<P>Extensive disease:</P>
<P>A: topical clobetasol 93/93 versus prednisone 1 mg/kg/day 95/95.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-05 13:33:10 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Major outcome: survival</LI>
<LI>Disease control at 3 weeks</LI>
<LI>Complications</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-09-05 13:33:18 +0100" MODIFIED_BY="[Empty name]">
<P>Originally there were 364 participants recruited: 14 did not meet the inclusion criteria, 8 did not give consent, 1 withdrew his consent in the beginning of the study: left with 341 study participants</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-08 08:09:59 +0100" MODIFIED_BY="Finola M Delamere" STUDY_ID="STD-Joly-2009">
<CHAR_METHODS MODIFIED="2010-09-03 18:06:42 +0100" MODIFIED_BY="Laura  Prescott">
<P>Multicentre in France, centrally randomised; not blinded</P>
<P>2 different regimens were applied. In the mild regimen participants received doses depending on their body weight; follow-up of 360 days</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-09-03 18:06:45 +0100" MODIFIED_BY="Laura  Prescott">
<P>312 participants with bullous pemphigoid; confirmed by direct immunofluorescence test</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-08 08:09:59 +0100" MODIFIED_BY="Finola M Delamere">
<P>Mild regimen: clobetasol propionate cream 10 to 30 g/day, until 15 days after disease control, thereafter corticosteroid tapering over 4 months (159)</P>
<P>moderate disease (&#8804;10 new blisters/day):</P>
<P>20 g/day if body weight &gt; 45 kg, 10 g/day if &lt; 45 kg</P>
<P>severe disease (&gt;10 new blisters/day):</P>
<P>30 g/day if body weight &gt; 45 kg, 20 g/day if &lt; 45 kg.</P>
<P>Standard regimen: clobetasol propionate cream 40 g/day initially, until 15 days after disease control, corticosteroid tapering over 12 months (page 1686) (153 participants).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-03 18:13:38 +0100" MODIFIED_BY="Laura  Prescott">
<P>Primary:</P>
<OL>
<LI>Complete healing (no new bullae for 3 consecutive days) after 21 days (<U>moderate disease - severe disease)</U>
</LI>
<LI>Death/event-free survival after 1 year (<U>moderate disease - severe disease)</U>
</LI>
</OL>
<P>Secondary end points:</P>
<OL>
<LI>Time to achieve disease control</LI>
<LI>Occurrence of severe (grade 3 or 4) side-effects (adverse events requiring hospitalisation or prolongation of hospitalisation or life-threatening events) during the follow-up year</LI>
<LI>Occurrence of relapses during follow-up</LI>
<LI>Cumulative doses of clobetasol propionate cream used during the study period</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-09-05 13:37:18 +0100" MODIFIED_BY="[Empty name]">
<P>Page 1686 typing error: should be 0.05% clobetasol propionate cream, not 0.005%</P>
<P>Discrepancy between the numbers of participants as follows: the numbers in figure 1 (153 participants randomised, 150 participants analysed), text (153 participants randomised, 150 participants analysed), and table 2 (153 randomised and 153 analysed) for the standard regimen do not match</P>
<P>Clarification from the study investigator (<LINK REF="REF-Joly-2010" TYPE="REFERENCE">Joly 2010</LINK>): numbers in table 2 on page 1684, are wrong, should be 150 in the standard regimen</P>
<P>Only 150 were analysed, therefore intention-to-treat (ITT) analysis is not fulfilled</P>
<P>Worst case scenario calculation (none of the 3 missing cases in the standard group had complete healing): - 156/159 v 150/153 (ITT analysis), <LINK REF="CMP-008.01" TYPE="ANALYSIS">Analysis 8.1</LINK>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-05 13:38:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liu-2006">
<CHAR_METHODS MODIFIED="2010-09-05 13:37:50 +0100" MODIFIED_BY="[Empty name]">
<P>Healing of skin lesions (complete, partial, or no healing depending on the area affected) after 4 weeks treatment</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-09-03 18:14:52 +0100" MODIFIED_BY="Laura  Prescott">
<P>30 participants with bullous pemphigoid; diagnosis confirmed by pathological tests</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-03 18:15:39 +0100" MODIFIED_BY="Laura  Prescott">
<P>A: Jingui Shenqi Pill (JSP) 1# bid plus prednisone 0.5 to 1.0 mg/kg/day (15 participants).</P>
<P>B: prednisone alone 0.5 to 1.0 mg/kg/day (15 participants).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-03 18:15:37 +0100" MODIFIED_BY="Laura  Prescott">
<OL>
<LI>Complete healing after 4 weeks</LI>
<LI>Partial healing</LI>
<LI>No response</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-09-05 13:38:03 +0100" MODIFIED_BY="[Empty name]">
<P>Article in Chinese. Translation obtained</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-05 13:38:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Morel-1984">
<CHAR_METHODS MODIFIED="2010-09-05 13:38:16 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised but not blind</P>
<P>Disease control = number new blisters between days 21 to 51</P>
<P>Follow-up: 51 days ( = treatment period)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-17 14:30:27 +0000" MODIFIED_BY="Cathy Bennett">
<P>50 participants with BP confirmed by IF studies.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-03 18:16:24 +0100" MODIFIED_BY="Laura  Prescott">
<P>A: 24/26 prednisolone 0.75 mg/kg/day. </P>
<P>B: 22/24 prednisolone 1.25 mg/kg/day.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-03 18:16:39 +0100" MODIFIED_BY="Laura  Prescott">
<OL>
<LI>New blister formation: at day 21 and 51</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-09-05 13:38:32 +0100" MODIFIED_BY="[Empty name]">
<P>2 dropouts in each group, no reasons given, and not included in analysis</P>
<P>Erythromycin used for infection but its anti-inflammatory effect not evaluated or commented upon<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-05 13:39:47 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Roujeau-1984">
<CHAR_METHODS MODIFIED="2010-09-05 13:38:56 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised but not blinded</P>
<P>Disease control = complete disappearance of blisters, itch, and erythema</P>
<P>Follow-up: 6 months ( = treatment period)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-09-03 18:17:55 +0100" MODIFIED_BY="Laura  Prescott">
<P>41 participants with BP confirmed by IF studies, age &gt; 80 years excluded</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-03 18:19:07 +0100" MODIFIED_BY="Laura  Prescott">
<P>A: 15/17 prednisolone 0.3 mg/kg/day. </P>
<P>B: 22/24 plasma exchange + prednisolone 0.3 mg/kg/day.</P>
<P>
<BR/>Both groups were treated with an identical protocol based on weekly dose adjustments according to the therapeutic results observed. Therapy was started at a dose of 0.3 mg/kg oral prednisolone daily for 1 week. If the treatment was ineffective, the dose was increased weekly to 1.5 mg/kg/day oral prednisolone, 2 mg/kg/day intramuscular methylprednisolone, and 2 mg/kg/day intramuscular methylprednisolone with (maximum permissible) 3 mg/kg/day oral cyclophosphamide.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-05 13:39:47 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Control of blister formation, erythema, and pruritus: number of participants controlled at certain doses of prednisolone (0.3 mg/day, 1.0 mg/day, &#8805; 1.5 mg/day); daily and cumulative dose of prednisolone needed to control disease (cumulative dose was calculated at the time point when no new blisters appeared, no more pruritus, erythema, urticae) was measured</LI>
<LI>Assessment of therapeutic response (page 487: The number of new bullae reported in the last 48 hours of a 7-day therapeutic period). Treatment was considered effective</LI>
<LI>Side-effects</LI>
<LI>Mortality</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-09-03 18:18:21 +0100" MODIFIED_BY="Laura  Prescott">
<P>-<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2010-09-05 13:43:09 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2010-09-05 00:52:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ACTRN12607000104459">
<CHAR_STUDY_NAME MODIFIED="2010-09-05 00:11:14 +0100" MODIFIED_BY="[Empty name]">
<P>Rituximab in the adjuvant treatment of bullous pemphigoid: A prospective open-label pilot study in three patients to study remission of disease with rituximab</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2010-09-05 00:11:25 +0100" MODIFIED_BY="[Empty name]">
<P>A prospective open-label pilot study in three participants to study remission of disease with rituximab</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-29 13:46:49 +0100" MODIFIED_BY="Cathy Bennett">
<P>Bullous pemphigoid</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-05 00:20:51 +0100" MODIFIED_BY="[Empty name]">
<P>Rituximab 375 mg m-2 weekly for 4 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-05 00:26:54 +0100" MODIFIED_BY="[Empty name]">
<P>Primary: </P>
<OL>
<LI>Participants response rate. Measured at 1 and 3 months after rituximab administration and 3-monthly thereafter until completion of study. Completion of study was at 17 months post-rituximab but in 1 participant, follow-up was ceased at 13 months post-rituximab when they demonstrated clinical remission</LI>
</OL>
<P>Secondary: </P>
<OL>
<LI>Complete or partial response</LI>
<LI>Response duration</LI>
<LI>Per cent of participants able to discontinue steroids</LI>
<LI>Toxicity</LI>
<LI>Reduction in skin antibody levels</LI>
</OL>
<P>These secondary outcomes were measured at 1 and 3 months post-rituximab and 3-monthly thereafter until study completion. Completion of study was at 17 months post-rituximab but in 1 participant, follow-up was ceased at 13 months post-rituximab when they demonstrated clinical remission</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2010-07-29 13:48:01 +0100" MODIFIED_BY="Cathy Bennett">
<P>February 2007</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2010-09-05 00:52:53 +0100" MODIFIED_BY="[Empty name]">
<P>Professor H. Miles Prince (miles.prince@petermac.org)<BR/>Chair, Haematology Services<BR/>Peter MacCallum Cancer Centre<BR/>Locked Bag 1, A'Beckett St, East Melbourne<BR/>Victoria 8006<BR/>Australia</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2010-09-05 00:12:54 +0100" MODIFIED_BY="[Empty name]">
<P>-</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2010-09-05 01:11:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ISRCTN13704604">
<CHAR_STUDY_NAME MODIFIED="2010-09-05 00:21:36 +0100" MODIFIED_BY="[Empty name]">
<P>A randomised controlled trial to compare the safety and effectiveness of doxycycline (200 mg/day) with prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2010-09-05 00:27:34 +0100" MODIFIED_BY="[Empty name]">
<P>Prospective, 2-arm, single-blind, parallel group, multicentre randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-09-05 00:21:48 +0100" MODIFIED_BY="[Empty name]">
<P>256 participants with bullous pemphigoid, confirmed by immunofluorescence tests</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-05 00:21:51 +0100" MODIFIED_BY="[Empty name]">
<P>Doxycycline (200 mg/day) versus prednisolone (0.5 mg/kg/day)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-05 01:11:21 +0100" MODIFIED_BY="[Empty name]">
<P>Primary:</P>
<OL>
<LI>Proportion of participants classed as treatment success (3 or less significant blisters present on examination) at 6 weeks</LI>
<LI>Number of reported grade 3, 4, and 5 (mortality) adverse events for 1 year</LI>
</OL>
<P>Secondary:</P>
<P>Differences in the 2 treatment arms in the:</P>
<OL>
<LI>Proportion of participants classed as treatment success (3 or less significant blisters present on examination) at 6 weeks and are alive at 1 year</LI>
<LI>Proportion of participants classed as treatment success (3 or less significant blisters present on examination) after 3 and 12 months of treatment</LI>
<LI>Proportion of participants who have a further episode of bullous pemphigoid during their participation in the study after previously being classed as a treatment success</LI>
<LI>Number of reported grade 1 and 2 adverse events for 1 year following the start of study treatment</LI>
<LI>Quality of life</LI>
<LI>Cost-effectiveness</LI>
</OL>
<P>Tertiary:</P>
<P>Differences in the 2 treatment arms in the:</P>
<OL>
<LI>Proportion of participants who, on examination at 6 weeks, are completely blister-free</LI>
<LI>Proportion of participants who are alive 1 year after the start of study treatment</LI>
<LI>Proportion of participants in each treatment arm who, on examination at 3 weeks, are classed as treatment success (3 or less significant blisters present)</LI>
<LI>Difference in the amount of potent and super-potent topical corticosteroids used</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2009-09-03 12:42:20 +0100" MODIFIED_BY="[Empty name]">
<P>March 2009</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2010-09-05 00:54:16 +0100" MODIFIED_BY="[Empty name]">
<P>Mrs Caroline Onions (<A HREF="mailto:blister@nottingham.ac.uk">blister@nottingham.ac.uk</A>)<BR/>Clinical Trials Unit Office, B39<BR/>Medical School<BR/>Queens Medical Centre<BR/>Nottingham NG7 2UH<BR/>England</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2010-09-05 00:22:10 +0100" MODIFIED_BY="[Empty name]">
<P>-</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2010-09-05 00:41:04 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00286325">
<CHAR_STUDY_NAME MODIFIED="2010-09-05 00:39:54 +0100" MODIFIED_BY="[Empty name]">
<P>Rituximab in the treatment of participants with bullous pemphigoid</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2010-09-05 00:40:02 +0100" MODIFIED_BY="[Empty name]">
<P>Non-randomised, open label, active control, single group assignment, safety/efficacy study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-09-05 00:38:09 +0100" MODIFIED_BY="[Empty name]">
<P>Bullous pemphigoid</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-05 00:39:50 +0100" MODIFIED_BY="[Empty name]">
<P>Infusion of 1000 mg of rituximab on day 0 and day 14</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-05 00:41:04 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>To determine the safety of rituximab for treatment of participants with bullous pemphigoid (time frame: 1 year) (designated as safety issue: yes)</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2010-09-05 00:39:21 +0100" MODIFIED_BY="[Empty name]">
<P>March 2005</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2010-09-05 00:38:58 +0100" MODIFIED_BY="[Empty name]">
<P>Russell Hall, III, MD<BR/>Duke University Medical Center<BR/>Durham, North Carolina 27710<BR/>United States</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2010-09-05 00:35:14 +0100" MODIFIED_BY="[Empty name]">
<P>-</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2010-09-05 13:42:46 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00472030">
<CHAR_STUDY_NAME MODIFIED="2010-09-05 00:42:13 +0100" MODIFIED_BY="[Empty name]">
<P>An open label case series on the effects of Xolair (Omalizumab) in bullous pemphigoid</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2010-09-05 00:41:56 +0100" MODIFIED_BY="[Empty name]">
<P>An open label case series on the effects of Xolair (Omalizumab) in bullous pemphigoid</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-09-05 00:40:25 +0100" MODIFIED_BY="[Empty name]">
<P>Bullous pemphigoid</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-05 00:41:18 +0100" MODIFIED_BY="[Empty name]">
<P>Subcutaneous administration of omalizumab, dose dependent on weight and circulating levels of IgE. Omalizumab will be administered every 4 weeks for 12 weeks. Additional injections will be given on weeks 2, 6,10, and 14 if required based on weight and IgE levels</P>
<P>Versus prednisone</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-05 13:42:46 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Assessment of total and new blister numbers over the 16-week period. Time to the cessation of new blister formation. The total dose of prednisone (mg/kg/day) during the 16-week treatment period. Parameters will be compared to the controls (time frame: 24 total week) (designated as safety issue: no)</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2010-09-05 00:40:49 +0100" MODIFIED_BY="[Empty name]">
<P>August 2007</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2010-09-05 00:55:18 +0100" MODIFIED_BY="[Empty name]">
<P>Janet A Fairley (janet-fairley@uiowa.edu) &amp; Debra S Brandt (debra-brandt@uiowa.edu)<BR/>Department of Dermatology<BR/>University of Iowa<BR/>USA<BR/>
</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2010-09-05 00:50:13 +0100" MODIFIED_BY="[Empty name]">
<P>
<A HREF="mailto:janet-fairley%40uiowa.edu?subject=NCT00472030,%20100569,%20Efficacy%20and%20Safety%20of%20Omalizumab%20in%20Bullous%20Pemphigoid">janet-fairley@uiowa.edu</A>
</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2010-09-05 13:43:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00525616">
<CHAR_STUDY_NAME MODIFIED="2010-09-05 00:43:09 +0100" MODIFIED_BY="[Empty name]">
<P>Assessment of rituximab efficiency and tolerance in treatment of bullous pemphigoid</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2010-09-05 00:43:15 +0100" MODIFIED_BY="[Empty name]">
<P>Non-randomised, open label, uncontrolled, single group assignment, safety/efficacy study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-09-05 00:43:17 +0100" MODIFIED_BY="[Empty name]">
<P>20 participants with bullous pemphigoid</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-05 00:43:25 +0100" MODIFIED_BY="[Empty name]">
<P>2 IV perfusions of 1000 mg at 15 day intervals</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-05 13:43:09 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcomes:</P>
<OL>
<LI>Clinical and biological controls of bullous pemphigoid were estimated every 7 days during a period of 1 month and every month during a period of 2 years (time frame: 2 years) (designated as safety issue: yes)</LI>
</OL>
<P>Secondary outcomes:</P>
<OL>
<LI>Adverse reactions will be estimated during all the period of this clinical trial (time frame: 3 years) (designated as safety issue: yes)</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2009-09-04 17:54:04 +0100" MODIFIED_BY="[Empty name]">
<P>December 2008</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2010-09-05 00:56:23 +0100" MODIFIED_BY="[Empty name]">
<P>Pascal Joly, MD, PhD (pascal.joly@chu-rouen.fr)<BR/>Rouen University Hospital<BR/>Direction de la Recherche et de l'Innovation<BR/>Rouen 76031<BR/>France</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2010-09-05 00:55:51 +0100" MODIFIED_BY="[Empty name]">
<P>
<A HREF="mailto:pascal.joly%40chu-rouen.fr?subject=NCT00525616,%202006/101/HP,%20Efficiency%20and%20Tolerance%20of%20Rituximab%20%28mabth%C3%A9ra%29%20in%20Bullous%20Pemphigoid">pascal.joly@chu-rouen.fr</A>
</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2010-09-05 00:57:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00802243">
<CHAR_STUDY_NAME MODIFIED="2010-09-05 00:57:10 +0100" MODIFIED_BY="[Empty name]">
<P>Leflunomide associated with topical corticosteroids for bullous pemphigoid. An open prospective study</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2010-09-05 00:45:12 +0100" MODIFIED_BY="[Empty name]">
<P>Open label, uncontrolled, single group assignment, efficacy study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-09-05 00:45:13 +0100" MODIFIED_BY="[Empty name]">
<P>54 participants with bullous pemphigoid</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-05 00:57:15 +0100" MODIFIED_BY="[Empty name]">
<P>40 g topical clobetasol propionate cream per day plus 20 mg leflunomide per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-05 00:45:49 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcomes:</P>
<OL>
<LI>Stage 1: complete clinical remission after 6 months treatment for 9 participants at least among 15 appraisable participants</LI>
<LI>Stage 2: complete clinical remission after 6 months treatment for 27 participants at least among 43 appraisable participants</LI>
</OL>
<P>Secondary outcomes:</P>
<OL>
<LI>To determine the rate of clinical complete remission at M9 and M12</LI>
<LI>To estimate the number of participants with immunological remission at M6, M9, and M12</LI>
<LI>To evaluate monthly the tolerance of leflunomide</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2009-09-04 16:44:58 +0100" MODIFIED_BY="[Empty name]">
<P>September 2007</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2010-09-05 00:51:11 +0100" MODIFIED_BY="[Empty name]">
<P>Christophe Bedane (christophe.bedane@chu-limoges.fr)<BR/>Limoges University Hospital<BR/>Limoges 87042 <BR/>France</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2010-09-05 00:46:56 +0100" MODIFIED_BY="[Empty name]">
<P>Christophe</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2010-09-05 01:09:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00809822">
<CHAR_STUDY_NAME MODIFIED="2010-09-05 00:58:16 +0100" MODIFIED_BY="[Empty name]">
<P>NPB-01 (intravenous immunoglobulin) therapy for patients with bullous pemphigoid unresponsive to corticosteroids: Randomized, double-blind, placebo control, parallel assignment study (phase II)</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2010-09-05 00:58:20 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind (subject, investigator), placebo-control, parallel assignment, safety/efficacy study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-17 14:51:09 +0000" MODIFIED_BY="Cathy Bennett">
<P>20 participants with bullous pemphigoid</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-17 14:11:17 +0000" MODIFIED_BY="Cathy Bennett">
<P>NPB-01 Intravenous immunoglobulin versus placebo physiological saline</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-05 01:08:27 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Skin lesion area (%), number of new blisters/day, pemphigoid activity score, pemphigus disease area Index(PDAI), anti-BP180 and -BP230 antibody titers, steroid dose, time to escape from the protocol and its ratio (time frame: 57 days) (designated as safety issue: no)</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2009-09-04 16:26:57 +0100" MODIFIED_BY="[Empty name]">
<P>December 2008</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2010-09-05 01:09:36 +0100" MODIFIED_BY="[Empty name]">
<P>Yasumasa Ogawa (kaihatsu@nihon-pharm.co.jp)<BR/>Nihon Pharmaceutical Co. Ltd <BR/>Japan<BR/>
</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2010-09-05 00:51:07 +0100" MODIFIED_BY="[Empty name]">
<P>-</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2010-09-08 08:11:06 +0100" MODIFIED_BY="Finola M Delamere">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2010-09-05 13:39:56 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-03 17:35:31 +0100" MODIFIED_BY="Laura  Prescott" RESULT="YES" STUDY_ID="STD-Beissert-2007">
<DESCRIPTION>
<P>Quote: "Randomisation was stratified according to the clinical centre and performed centrally with the use of random number of three for each stratum." (Page 1537)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 15:56:04 +0100" MODIFIED_BY="Cathy Bennett" RESULT="UNKNOWN" STUDY_ID="STD-Burton-1978">
<DESCRIPTION>
<P>No details given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-05 17:16:15 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dreno-1993">
<DESCRIPTION>
<P>The study was randomised.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-08 15:47:47 +0100" MODIFIED_BY="Cathy Bennett" RESULT="UNKNOWN" STUDY_ID="STD-Fivenson-1994">
<DESCRIPTION>
<P>No details given. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-03 17:56:09 +0100" MODIFIED_BY="Laura  Prescott" RESULT="YES" STUDY_ID="STD-Guillaume-1993">
<DESCRIPTION>
<P>Randomised. Quote: "According to pre-established randomisation lists equilibrated in blocks of 3 for each center." (Page 50)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-03 18:05:10 +0100" MODIFIED_BY="Laura  Prescott" RESULT="YES" STUDY_ID="STD-Joly-2002">
<DESCRIPTION>
<P>Quote: "Randomization was performed centrally with the use of random numbers in permuted blocks of four within each stratum." (Page 322)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-03 18:14:22 +0100" MODIFIED_BY="Laura  Prescott" RESULT="YES" STUDY_ID="STD-Joly-2009">
<DESCRIPTION>
<P>Quote: "Randomization was performed centrally with the use of random numbers in permuted blocks of four within each stratum." (Page 1686)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-17 14:30:06 +0000" MODIFIED_BY="Cathy Bennett" RESULT="UNKNOWN" STUDY_ID="STD-Liu-2006">
<DESCRIPTION>
<P>No randomisation details in English abstract; nor in paper.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-05 13:38:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morel-1984">
<DESCRIPTION>
<P>Quote: "using a single table of pre-established and balanced randomisation for all 8 patients." (Translation, page 926).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-05 13:39:56 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Roujeau-1984">
<DESCRIPTION>
<P>Randomised. Quote: "Assigned to groups according to lists drawn by microcomputer for each participating centre and equilibrated after every 4 patients." (Page 487)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2010-09-03 17:56:12 +0100" MODIFIED_BY="Laura  Prescott" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-08 12:58:16 +0100" MODIFIED_BY="Cathy Bennett" RESULT="UNKNOWN" STUDY_ID="STD-Beissert-2007">
<DESCRIPTION>
<P>Allocation concealment is not well described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-03 17:41:51 +0100" MODIFIED_BY="Laura  Prescott" RESULT="UNKNOWN" STUDY_ID="STD-Burton-1978">
<DESCRIPTION>
<P>Quote: "Once included, each participant was randomly assigned ......by the ward sister who drew a marked paper from an envelope." (Page 1190)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-17 14:25:35 +0000" MODIFIED_BY="Cathy Bennett" RESULT="UNKNOWN" STUDY_ID="STD-Dreno-1993">
<DESCRIPTION>
<P>Unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-03 17:50:26 +0100" MODIFIED_BY="Laura  Prescott" RESULT="UNKNOWN" STUDY_ID="STD-Fivenson-1994">
<DESCRIPTION>
<P>Unclear; no details given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-03 17:56:12 +0100" MODIFIED_BY="Laura  Prescott" RESULT="UNKNOWN" STUDY_ID="STD-Guillaume-1993">
<DESCRIPTION>
<P>Unclear. No details given about how the allocation was concealed from the study investigator. Quote: "After determining a patient's eligibility, the attending physician telephoned the study co-ordinator who assigned the patient." (Page 50)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-08 17:56:46 +0100" MODIFIED_BY="Cathy Bennett" RESULT="UNKNOWN" STUDY_ID="STD-Joly-2002">
<DESCRIPTION>
<P>Allocation concealment is not well described. Probably adequate as it was done centrally.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-08 17:56:21 +0100" MODIFIED_BY="Cathy Bennett" RESULT="YES" STUDY_ID="STD-Joly-2009">
<DESCRIPTION>
<P>Allocation concealment is not well described. Probably adequate as it was done centrally.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-17 14:30:08 +0000" MODIFIED_BY="Cathy Bennett" RESULT="UNKNOWN" STUDY_ID="STD-Liu-2006">
<DESCRIPTION>
<P>No details in English abstract; nor in paper.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-08 18:37:12 +0100" MODIFIED_BY="Cathy Bennett" RESULT="UNKNOWN" STUDY_ID="STD-Morel-1984">
<DESCRIPTION>
<P>No details given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 11:15:17 +0100" MODIFIED_BY="Cathy Bennett" RESULT="UNKNOWN" STUDY_ID="STD-Roujeau-1984">
<DESCRIPTION>
<P>Probably done as randomisation was computerised.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2010-09-05 13:35:11 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-09-03 17:36:04 +0100" MODIFIED_BY="Laura  Prescott" RESULT="NO" STUDY_ID="STD-Beissert-2007">
<DESCRIPTION>
<P>Intentionally not blinded by trial investigators. </P>
<P>Quote: "Since complete healing was a primary outcome measure, blinding was not considered necessary." (Page 1537)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-10-08 13:26:23 +0100" MODIFIED_BY="Cathy Bennett" RESULT="UNKNOWN" STUDY_ID="STD-Burton-1978">
<DESCRIPTION>
<P>Unclear. Unlikely as the intervention group (azathioprine) were monitored by frequent blood testing.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-09-05 13:35:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dreno-1993">
<DESCRIPTION>
<P>Yes: double-blind.</P>
<P>Quote: "Taking into account the difference in presentation between the 2 products, the supply of the products to the participants was made by a person other than the investigator; additionally clinical follow-up after the end of the study was done by a masked (blinded) investigator." (Translation, page 518)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-09-03 17:50:38 +0100" MODIFIED_BY="Laura  Prescott" RESULT="NO" STUDY_ID="STD-Fivenson-1994">
<DESCRIPTION>
<P>Not blind, described as "open-label" (page 753).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-09-03 17:59:12 +0100" MODIFIED_BY="Laura  Prescott" RESULT="NO" STUDY_ID="STD-Guillaume-1993">
<DESCRIPTION>
<P>The study was not blind. See "Treatment Groups", page 50. "Techinically difficult and theoretically debatable to perform 'sham' plasma exchanges".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-10-08 17:56:42 +0100" MODIFIED_BY="Cathy Bennett" RESULT="NO" STUDY_ID="STD-Joly-2002">
<DESCRIPTION>
<P>The study was not blinded. A nurse not otherwise associated with the study assessed the number of new bullae, daily.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-09-03 18:14:31 +0100" MODIFIED_BY="Laura  Prescott" RESULT="NO" STUDY_ID="STD-Joly-2009">
<DESCRIPTION>
<P>Intentionally not blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-12-17 15:45:44 +0000" MODIFIED_BY="Cathy Bennett" RESULT="NO" STUDY_ID="STD-Liu-2006">
<DESCRIPTION>
<P>Not blinded, no details in English abstract; nor in paper.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-10-08 18:38:22 +0100" MODIFIED_BY="Cathy Bennett" RESULT="NO" STUDY_ID="STD-Morel-1984">
<DESCRIPTION>
<P>No. No details given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-09-03 18:20:42 +0100" MODIFIED_BY="Laura  Prescott" RESULT="NO" STUDY_ID="STD-Roujeau-1984">
<DESCRIPTION>
<P>Not blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2010-09-08 08:11:06 +0100" MODIFIED_BY="Finola M Delamere" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-09-08 08:11:06 +0100" MODIFIED_BY="Finola M Delamere" RESULT="YES" STUDY_ID="STD-Beissert-2007">
<DESCRIPTION>
<P>Yes. In <LINK REF="STD-Beissert-2007" TYPE="STUDY">Beissert 2007</LINK> 1 participant was lost, 2 died of treatment unrelated causes - they were included in the intention-to-treat analysis.</P>
<P>The same number of participants who started the trial were analysed at the end of the trial. (Figure 1, page 1538)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-09-08 08:11:01 +0100" MODIFIED_BY="Finola M Delamere" RESULT="UNKNOWN" STUDY_ID="STD-Burton-1978">
<DESCRIPTION>
<P>Unclear. The results section states that 25 participants completed a 3-year follow-up, but it is unclear how many were randomised to each group at the start. Table 1 page 1190 reports outcomes over 3 years for all 25 participants.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-09-03 17:46:10 +0100" MODIFIED_BY="Laura  Prescott" RESULT="YES" STUDY_ID="STD-Dreno-1993">
<DESCRIPTION>
<P>29/29 evaluated at both time points for prednisolone group. 27/28 evaluated at both times points for the methylprednisolone group. 1 participant dropped out (ceased treatment) after 8 days of treatment, due to a coma unrelated to the treatment (page 519).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-09-08 08:09:36 +0100" MODIFIED_BY="Finola M Delamere" RESULT="UNKNOWN" STUDY_ID="STD-Fivenson-1994">
<DESCRIPTION>
<P>20 were randomised, 18 were treated.</P>
<P>2 were unavailable for follow up within the initial 8 weeks, both from the tetracycline/nicotinamide group. There was 1 death in the prednisone group due to sepsis complicated by aspiration pneumonia, the time point was not given but the participant was available for follow up at week 8 as the results for all 8 participants who received prednisolone is given in Table 1 (page 755).</P>
<P>At longer term follow-up, only n = 3 in the prednisolone group and n = 5 in the tetracycline/nicotinamide group are reported, no detail of the reasons for loss to follow up at this later follow-up were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-09-03 17:59:42 +0100" MODIFIED_BY="Laura  Prescott" RESULT="UNKNOWN" STUDY_ID="STD-Guillaume-1993">
<DESCRIPTION>
<P>Reasons for 2 dropouts not clear. Quote: "unavailable for follow-up after having withdrawn their consent" (page 51) (not clear if this was before or after starting treatment). Dropouts not included in the analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-10-08 17:47:46 +0100" MODIFIED_BY="Cathy Bennett" RESULT="YES" STUDY_ID="STD-Joly-2002">
<DESCRIPTION>
<P>All participants and outcomes adequately reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-09-08 08:10:10 +0100" MODIFIED_BY="Finola M Delamere" RESULT="UNKNOWN" STUDY_ID="STD-Joly-2009">
<DESCRIPTION>
<P>Not all participants were accounted for at each stage of the trial. See Figure 1, page 1683, and Table 2, page 1686: typing error in table 2, only 150 participants were analysed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-12-17 14:30:13 +0000" MODIFIED_BY="Cathy Bennett" RESULT="YES" STUDY_ID="STD-Liu-2006">
<DESCRIPTION>
<P>Adequately reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-09-03 18:17:37 +0100" MODIFIED_BY="Laura  Prescott" RESULT="NO" STUDY_ID="STD-Morel-1984">
<DESCRIPTION>
<P>2 dropouts in each group, no reasons given, and not included in analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-09-05 13:40:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Roujeau-1984">
<DESCRIPTION>
<P>41 randomised, 2 from each group were excluded from analysis, reasons accounted for in Results (page 487).</P>
<P>2 participants from each group withdrawn from study, before treatment was initiated (1 had no BP, 2 accidentally received higher initial doses of prednisolone, 1 no plasma exchange). Dropouts not included in the analysis (they were randomised, but did not really start proper trial treatment and were excluded).</P>
<P>Outcomes (disease control) are reported for the remaining 37 participants the groups they were randomised to. (Table 2, page 488). Side-effects and mortality are reported in the text. (Table II and III).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2010-09-05 13:26:05 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-05 13:26:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Beissert-2007">
<DESCRIPTION>
<P>Outcomes reported for both outcome measures.</P>
<P>Primary: </P>
<OL>
<LI>Complete healing</LI>
</OL>
<P>Secondary: </P>
<OL>
<LI>Cumulative corticosteroid doses used</LI>
</OL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-08 16:06:30 +0100" MODIFIED_BY="Cathy Bennett" RESULT="UNKNOWN" STUDY_ID="STD-Burton-1978">
<DESCRIPTION>
<P>Outcome measures were not clearly stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-03 17:46:18 +0100" MODIFIED_BY="Laura  Prescott" RESULT="YES" STUDY_ID="STD-Dreno-1993">
<DESCRIPTION>
<P>All outcomes (number of blisters, itching, and redness) reported on at 5 and 10 days of treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-29 15:29:34 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fivenson-1994">
<DESCRIPTION>
<P>All outcomes reported at each time point.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-03 17:59:57 +0100" MODIFIED_BY="Laura  Prescott" RESULT="UNKNOWN" STUDY_ID="STD-Guillaume-1993">
<DESCRIPTION>
<P>Controlled disease was stated to be no more than 1 new blister occurring 4 weeks after starting treatment, resolution of erythema, and no more than minimal pruritis. Only the composite measure of controlled disease was reported (Table 2, page 52).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-08 17:48:34 +0100" MODIFIED_BY="Cathy Bennett" RESULT="YES" STUDY_ID="STD-Joly-2002">
<DESCRIPTION>
<P>Adequately reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-08 18:11:18 +0100" MODIFIED_BY="Cathy Bennett" RESULT="YES" STUDY_ID="STD-Joly-2009">
<DESCRIPTION>
<P>All outcomes reported adequately.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-17 14:30:15 +0000" MODIFIED_BY="Cathy Bennett" RESULT="YES" STUDY_ID="STD-Liu-2006">
<DESCRIPTION>
<P>Outcome is adequately reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-17 14:30:39 +0000" MODIFIED_BY="Cathy Bennett" RESULT="YES" STUDY_ID="STD-Morel-1984">
<DESCRIPTION>
<P>New blister formation at days 21 and 51 reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-03 18:21:38 +0100" MODIFIED_BY="Laura  Prescott" RESULT="YES" STUDY_ID="STD-Roujeau-1984">
<DESCRIPTION>
<P>Yes. Control of blister formation, erythema, and pruritus, although this is only reported as a composite when bullae, pruritis, and erythema has resolved; this was reported as disease control.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2010-09-06 15:59:57 +0100" MODIFIED_BY="Finola M Delamere" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-08 18:12:21 +0100" MODIFIED_BY="Cathy Bennett" RESULT="YES" STUDY_ID="STD-Beissert-2007">
<DESCRIPTION>
<P>No other bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-06 15:59:57 +0100" MODIFIED_BY="Finola M Delamere" RESULT="UNKNOWN" STUDY_ID="STD-Burton-1978">
<DESCRIPTION>
<P>Only those participants who were likely to attend for follow up were recruited. Elibility was also determined by the consultant doctor after baseline testing.</P>
<P>Baseline imbalance: There were more participants with severe disease in the azathioprine group, 53% had &#8805; 20% body surface area involvement compared to only 27% in the MMF group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-03 17:46:23 +0100" MODIFIED_BY="Laura  Prescott" RESULT="UNKNOWN" STUDY_ID="STD-Dreno-1993">
<DESCRIPTION>
<P>Short study duration. Non-validated assessment scales.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-08 16:05:49 +0100" MODIFIED_BY="Cathy Bennett" RESULT="UNKNOWN" STUDY_ID="STD-Fivenson-1994">
<DESCRIPTION>
<P>Unclear if the participant groups were equivalent with respect to disease severity or demographics at the start of the therapy.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-03 18:00:57 +0100" MODIFIED_BY="Laura  Prescott" RESULT="UNKNOWN" STUDY_ID="STD-Guillaume-1993">
<DESCRIPTION>
<P>Trial stopped early. Quote: "Our trial was interrupted after the interim analysis showed no appreciable benefit resulting from the addition of azathioprine or plasma exchange to prednisolone in the initial (at 4 weeks) and maintenance (at 6 months) treatments of BP" (page 52).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-05 01:20:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Joly-2002">
<DESCRIPTION>
<P>Quote: "In accordance with the study protocol, the investigators switched three patients with moderate bullous pemphigoid and four with extensive bullous pemphigoid from the oral-prednisone group to the topical-corticosteroid group because of side-effects of treatment." (Page 324) 'Compliance with treatment and adverse effects'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-08 18:12:09 +0100" MODIFIED_BY="Cathy Bennett" RESULT="YES" STUDY_ID="STD-Joly-2009">
<DESCRIPTION>
<P>No other bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-03 18:15:58 +0100" MODIFIED_BY="Laura  Prescott" RESULT="UNKNOWN" STUDY_ID="STD-Liu-2006">
<DESCRIPTION>
<P>Few details about any methods in translated paper. Precise method of diagnosis not specified (referred to as 'clinical' and 'pathological' tests). No further details available from the trial investigator.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-29 13:30:41 +0100" MODIFIED_BY="Cathy Bennett" RESULT="UNKNOWN" STUDY_ID="STD-Morel-1984">
<DESCRIPTION>
<P>Some participants that could have been recruited were excluded on the grounds that they were able to take part in a parallel study involving plasma exchanges.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-08 19:15:45 +0100" MODIFIED_BY="Cathy Bennett" RESULT="YES" STUDY_ID="STD-Roujeau-1984">
<DESCRIPTION>
<P>No other bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2011-11-07 15:07:14 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2011-11-07 15:07:14 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2010-06-17 19:09:51 +0100" MODIFIED_BY="Cathy Bennett">Adverse events in the included studies</TITLE>
<TABLE COLS="8" ROWS="22">
<TR>
<TD>
<P>
<B>Study ID</B>
</P>
</TD>
<TD>
<P>
<B>Drug and dose</B>
</P>
</TD>
<TD>
<P>
<B>Infection /Low WCC</B>
</P>
</TD>
<TD>
<P>
<B>Organ impairment</B>
</P>
</TD>
<TD>
<P>
<B>Cardiovascular</B>
</P>
</TD>
<TD>
<P>
<B>Other</B>
</P>
</TD>
<TD>
<P>
<B>Total adverse events</B>
</P>
</TD>
<TD>
<P>
<B>Death</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>
<LINK REF="STD-Beissert-2007" TYPE="STUDY">Beissert 2007</LINK>
</P>
</TD>
<TD>
<P>Oral methylprednisolone 0.5 mg/kg/day plus azathioprine 2 mg/kg/day (n = 38)</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>7</P>
<P>(1 hyperglycaemia 6 liver)</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>11</P>
<P>(grade 3/4)</P>
</TD>
<TD>
<P>2</P>
</TD>
</TR>
<TR>
<TD>
<P>Oral methylprednisolone 0.5 mg/kg/day plus mycophenolate mofetil 2000 mg twice/day (n = 35)</P>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P>6</P>
<P>(5 hyperglycaemia 1 liver)</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>13</P>
<P>(grade 3/4)</P>
</TD>
<TD>
<P>0</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>
<LINK REF="STD-Burton-1978" TYPE="STUDY">Burton 1978</LINK>
</P>
</TD>
<TD>
<P>Prednisone 30 to 80 mg/kg/day<BR/>(n = 13)</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>4</P>
</TD>
</TR>
<TR>
<TD>
<P>Azathioprine 2.5 mg/kg + prednisone 30 to 80 mg/kg/day<BR/>(n = 12)</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>3</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>
<LINK REF="STD-Dreno-1993" TYPE="STUDY">Dreno 1993</LINK>
</P>
</TD>
<TD>
<P>Prednisolone (average) 1.16 mg/kg/day<BR/>(n = 29)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>0</P>
</TD>
</TR>
<TR>
<TD>
<P>Methylprednisolone (average) 1.17 mg/kg/day<BR/>(n = 28)</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>0</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>
<LINK REF="STD-Fivenson-1994" TYPE="STUDY">Fivenson 1994</LINK>
</P>
</TD>
<TD>
<P>Prednisone 40 to 80 mg/kg/day<BR/>(n = 6)</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>8</P>
</TD>
<TD>
<P>1</P>
</TD>
</TR>
<TR>
<TD>
<P>Tetracycline 500mg 4x/day + nicotinamide (n = 14)</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P>0</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="3">
<P>
<LINK REF="STD-Guillaume-1993" TYPE="STUDY">Guillaume 1993</LINK>
</P>
</TD>
<TD>
<P>Prednisolone 1 mg/kg/day<BR/>(n = 31)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>5</P>
</TD>
</TR>
<TR>
<TD>
<P>Prednisolone 1 mg/kg/day + azathioprine 100 to 150 mg/day (n = 36)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>6</P>
</TD>
</TR>
<TR>
<TD>
<P>Prednisolone 1 mg/kg/day + plasma exchange (n = 31)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>6</P>
</TD>
<TD>
<P>3</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>
<LINK REF="STD-Joly-2002" TYPE="STUDY">Joly 2002</LINK>
</P>
</TD>
<TD>
<P>Moderate disease:<BR/>topical steroids (n = 77)</P>
<P>Prednisone 0.5 mg/kg/day (n = 76)</P>
</TD>
<TD>
<P>11<BR/>
<BR/>
<BR/>16</P>
</TD>
<TD>
<P>5<BR/>
<BR/>
<BR/>14</P>
</TD>
<TD>
<P>15<BR/>
<BR/>
<BR/>16</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>31<BR/>
<BR/>
<BR/>46</P>
</TD>
<TD>
<P>23<BR/>
<BR/>
<BR/>23</P>
</TD>
</TR>
<TR>
<TD>
<P>Extensive disease:<BR/>topical steroids (n = 93)<BR/>
<BR/>Prednisone 1 mg/kg (n=95)</P>
</TD>
<TD>
<P>8<BR/>
<BR/>
<BR/>22</P>
</TD>
<TD>
<P>6<BR/>
<BR/>
<BR/>23</P>
</TD>
<TD>
<P>16<BR/>
<BR/>
<BR/>20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>30<BR/>
<BR/>
<BR/>65</P>
</TD>
<TD>
<P>22<BR/>
<BR/>
<BR/>39 P = 0.02</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>
<LINK REF="STD-Joly-2009" TYPE="STUDY">Joly 2009</LINK>
</P>
</TD>
<TD>
<P>Mild regimen topical steroids (n = 159)</P>
</TD>
<TD>
<P>27</P>
</TD>
<TD>
<P>18 (DM)</P>
</TD>
<TD>
<P>21</P>
</TD>
<TD>
<P>41%</P>
<P>(skin)</P>
</TD>
<TD>
<P>194</P>
<P>(grade 3/4)</P>
</TD>
<TD>
<P>60</P>
</TD>
</TR>
<TR>
<TD>
<P>Standard regimen topical steroids (n = 150)</P>
</TD>
<TD>
<P>32</P>
</TD>
<TD>
<P>34 (DM)</P>
</TD>
<TD>
<P>35</P>
</TD>
<TD>
<P>52%</P>
<P>(skin)</P>
</TD>
<TD>
<P>227</P>
<P>(grade 3/4)</P>
</TD>
<TD>
<P>58</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>
<LINK REF="STD-Liu-2006" TYPE="STUDY">Liu 2006</LINK>
</P>
</TD>
<TD>
<P>Jingui Shenqi Pill (JSP) 1# bid plus prednisone 0.5 to 1.0 mg/kg/day (n = 15)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>not mentioned</P>
</TD>
<TD>
<P>not mentioned</P>
</TD>
</TR>
<TR>
<TD>
<P>Prednisone alone 0.5 to 1.0 mg/kg/day (n = 15)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>not mentioned</P>
</TD>
<TD>
<P>not mentioned</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>
<LINK REF="STD-Morel-1984" TYPE="STUDY">Morel 1984</LINK>
</P>
</TD>
<TD>
<P>Prednisolone 0.75 mg/kg/day<BR/>(n = 26)</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>2</P>
</TD>
</TR>
<TR>
<TD>
<P>Prednisolone 1.25 mg/kg/day<BR/>(n = 26)</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>3</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>
<LINK REF="STD-Roujeau-1984" TYPE="STUDY">Roujeau 1984</LINK>
</P>
</TD>
<TD>
<P>Prednisolone 0.3 mg/kg/day (n = 17)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>7</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>7</P>
</TD>
<TD>
<P>0</P>
</TD>
</TR>
<TR>
<TD>
<P>Plasma exchange + prednisolone 0.3 mg/kg/day (n = 24)</P>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>7</P>
</TD>
<TD>
<P>7</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>7</P>
</TD>
<TD>
<P>0</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2010-09-05 00:08:38 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2010-09-05 00:05:58 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Higher dose prednisolone (1.25 mg/kg p/solone) versus lower dose prednisolone (0.75 mg/kg p/solone)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="38" EVENTS_2="30" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-09-05 00:05:58 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="66" TOTAL_2="71" WEIGHT="0.0" Z="0.0">
<NAME>Disease control</NAME>
<GROUP_LABEL_1>1.25 mg/kg p/solone</GROUP_LABEL_1>
<GROUP_LABEL_2>0.75 mg/kg p/solone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 0.75 mg/kg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 1.25 mg/kg</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="14" EVENTS_2="14" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-09-05 00:05:29 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="24" WEIGHT="0.0" Z="0.0">
<NAME>Healing of skin lesions at day 21: excluding dropouts</NAME>
<DICH_DATA CI_END="1.8696841849118513" CI_START="0.7701835484413058" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" LOG_CI_END="0.2717682544866311" LOG_CI_START="-0.11340576239138143" LOG_EFFECT_SIZE="0.07918124604762482" ORDER="25960" O_E="0.0" SE="0.22625312415627807" STUDY_ID="STD-Morel-1984" TOTAL_1="20" TOTAL_2="24" VAR="0.05119047619047618" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="12" EVENTS_2="8" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-09-05 00:05:51 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="23" WEIGHT="0.0" Z="0.0">
<NAME>Healing of skin lesions at day 51: excluding dropouts</NAME>
<DICH_DATA CI_END="3.35168843872463" CI_START="0.8877988077949966" EFFECT_SIZE="1.725" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" LOG_CI_END="0.525263641333115" LOG_CI_START="-0.051685442514529056" LOG_EFFECT_SIZE="0.23678909940929294" ORDER="25961" O_E="0.0" SE="0.3389027477961312" STUDY_ID="STD-Morel-1984" TOTAL_1="20" TOTAL_2="23" VAR="0.11485507246376811" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="12" EVENTS_2="8" I2="0.0" ID="CMP-001.01.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-09-05 00:05:58 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="24" WEIGHT="0.0" Z="0.0">
<NAME>Healing of skin lesions at day 51: ITT (assuming unknown = not healed)</NAME>
<DICH_DATA CI_END="2.7932396341139634" CI_START="0.6863570672201732" EFFECT_SIZE="1.3846153846153846" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" LOG_CI_END="0.446108195747208" LOG_CI_START="-0.1634498901542694" LOG_EFFECT_SIZE="0.1413291527964693" ORDER="25962" O_E="0.0" SE="0.35805743701971643" STUDY_ID="STD-Morel-1984" TOTAL_1="26" TOTAL_2="24" VAR="0.1282051282051282" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-07-29 14:02:13 +0100" MODIFIED_BY="Cathy Bennett" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="22" TOTAL_2="24" WEIGHT="0.0" Z="0.0">
<NAME>Mortality at day 51</NAME>
<GROUP_LABEL_1>1.25 mg/kg p/solone</GROUP_LABEL_1>
<GROUP_LABEL_2>0.75 mg/kg p/solone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 1.25 mg/kg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 0.75 mg/kg</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.895658519253885" CI_START="0.301010424873842" EFFECT_SIZE="1.6363636363636365" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9491781031442141" LOG_CI_START="-0.521418463254052" LOG_EFFECT_SIZE="0.21387981994508107" ORDER="25963" O_E="0.0" SE="0.8638357026727486" STUDY_ID="STD-Morel-1984" TOTAL_1="22" TOTAL_2="24" VAR="0.7462121212121212" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2010-08-09 11:49:13 +0100" MODIFIED_BY="Cathy Bennett" NO="2">
<NAME>Methylprednisolone (mp/solone) versus prednisolone (p/solone)</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.01" MODIFIED="2010-07-28 17:51:35 +0100" MODIFIED_BY="Cathy Bennett" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="28" TOTAL_2="29" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Disease control - number of blisters at day 10</NAME>
<GROUP_LABEL_1>Mp/solone</GROUP_LABEL_1>
<GROUP_LABEL_2>P/solone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours mp/solone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours p/solone</GRAPH_LABEL_2>
<CONT_DATA CI_END="7.553209231828845" CI_START="-21.553209231828845" EFFECT_SIZE="-7.0" ESTIMABLE="YES" MEAN_1="6.0" MEAN_2="13.0" ORDER="25964" SD_1="19.0" SD_2="35.0" SE="7.425243191519182" STUDY_ID="STD-Dreno-1993" TOTAL_1="28" TOTAL_2="29" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="22" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-08-09 11:49:13 +0100" MODIFIED_BY="Cathy Bennett" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="28" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>Overall improvement</NAME>
<GROUP_LABEL_1>Mp/solone</GROUP_LABEL_1>
<GROUP_LABEL_2>P/solone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours mp/solone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours p/solone</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7856941137189537" CI_START="0.8973734527119844" EFFECT_SIZE="1.2658730158730158" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="18" LOG_CI_END="0.2518070670377834" LOG_CI_START="-0.04702678248650938" LOG_EFFECT_SIZE="0.10239014227563702" MODIFIED="2010-08-09 11:49:07 +0100" MODIFIED_BY="Cathy Bennett" ORDER="89" O_E="0.0" SE="0.17553648246198178" STUDY_ID="STD-Dreno-1993" TOTAL_1="28" TOTAL_2="29" VAR="0.03081305667512564" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.03" MODIFIED="2010-07-29 14:04:37 +0100" MODIFIED_BY="Cathy Bennett" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="28" TOTAL_2="29" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Disease control - extent of erythema at day 10 (score out of 3)</NAME>
<GROUP_LABEL_1>Mp/solone</GROUP_LABEL_1>
<GROUP_LABEL_2>P/solone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours mp/solone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours p/solone</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.026043586844418598" CI_START="-0.7060435868444188" EFFECT_SIZE="-0.3400000000000001" ESTIMABLE="YES" MEAN_1="0.59" MEAN_2="0.93" ORDER="25965" SD_1="0.69" SD_2="0.72" SE="0.1867603638289906" STUDY_ID="STD-Dreno-1993" TOTAL_1="28" TOTAL_2="29" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.04" MODIFIED="2010-07-29 14:04:37 +0100" MODIFIED_BY="Cathy Bennett" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="28" TOTAL_2="29" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Quality of life - extent of itching (score out of 3)</NAME>
<GROUP_LABEL_1>Mp/solone</GROUP_LABEL_1>
<GROUP_LABEL_2>P/solone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours mp/solone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours p/solone</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.1454296514384097" CI_START="-0.6854296514384097" EFFECT_SIZE="-0.27" ESTIMABLE="YES" MEAN_1="0.59" MEAN_2="0.86" ORDER="25966" SD_1="0.8" SD_2="0.8" SE="0.21195779856939503" STUDY_ID="STD-Dreno-1993" TOTAL_1="28" TOTAL_2="29" WEIGHT="0.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2010-09-05 00:06:36 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Prednisone + azathioprine (p/sone+azathio) versus prednisone (p/sone)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="23" EVENTS_2="22" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-09-05 00:06:36 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="48" TOTAL_2="44" WEIGHT="0.0" Z="0.0">
<NAME>Disease control</NAME>
<GROUP_LABEL_1>P/sone+azathio</GROUP_LABEL_1>
<GROUP_LABEL_2>P/sone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours p/sone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours p/sone+azathio</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="14" EVENTS_2="13" I2="0.0" ID="CMP-003.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-09-05 00:06:36 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="36" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>Disease control at 6 months</NAME>
<DICH_DATA CI_END="1.6603656555334365" CI_START="0.5179454370433416" EFFECT_SIZE="0.9273504273504274" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" LOG_CI_END="0.2202037414695659" LOG_CI_START="-0.28571598859279257" LOG_EFFECT_SIZE="-0.03275612356161331" ORDER="25967" O_E="0.0" SE="0.2971797537816827" STUDY_ID="STD-Guillaume-1993" TOTAL_1="36" TOTAL_2="31" VAR="0.08831580605774154" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="9" EVENTS_2="9" I2="0.0" ID="CMP-003.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-03-19 13:39:01 +0000" MODIFIED_BY="Cathy Bennett" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="13" WEIGHT="0.0" Z="0.0">
<NAME>Disease control: well at 3 years, either needing or not needing further treatment</NAME>
<DICH_DATA CI_END="1.7646197563069483" CI_START="0.6650787553049282" EFFECT_SIZE="1.0833333333333333" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" LOG_CI_END="0.2466511371864514" LOG_CI_START="-0.1771269246680276" LOG_EFFECT_SIZE="0.03476210625921191" ORDER="25968" O_E="0.0" SE="0.24892933126855896" STUDY_ID="STD-Burton-1978" TOTAL_1="12" TOTAL_2="13" VAR="0.06196581196581197" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="15" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-07-28 18:24:29 +0100" MODIFIED_BY="Cathy Bennett" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="36" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>Mortality and severe adverse events at 6 months</NAME>
<GROUP_LABEL_1>P/sone+azathio</GROUP_LABEL_1>
<GROUP_LABEL_2>P/sone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours p/sone+azathio</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours p/sone</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.4496554319461663" CI_START="0.6810765122392293" EFFECT_SIZE="1.2916666666666667" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="10" LOG_CI_END="0.38910500088356315" LOG_CI_START="-0.16680409663822984" LOG_EFFECT_SIZE="0.11115045212266668" ORDER="25971" O_E="0.0" SE="0.3265437556787143" STUDY_ID="STD-Guillaume-1993" TOTAL_1="36" TOTAL_2="31" VAR="0.10663082437275986" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="9" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-07-28 18:24:29 +0100" MODIFIED_BY="Cathy Bennett" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="723.02" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="48" TOTAL_2="44" WEIGHT="0.0" Z="0.0">
<NAME>Mortality</NAME>
<GROUP_LABEL_1>P/sone+azathio</GROUP_LABEL_1>
<GROUP_LABEL_2>P/sone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours p/sone+azathio</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours p/sone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="5" I2="0.0" ID="CMP-003.03.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-02-05 17:22:51 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="36" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>Mortality at 6 months</NAME>
<DICH_DATA CI_END="3.0590527217798025" CI_START="0.34905504248927394" EFFECT_SIZE="1.0333333333333334" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.48558696197347695" LOG_CI_START="-0.4571060837442564" LOG_EFFECT_SIZE="0.014240439114610285" ORDER="25969" O_E="0.0" SE="0.5537425614604317" STUDY_ID="STD-Guillaume-1993" TOTAL_1="36" TOTAL_2="31" VAR="0.3066308243727599" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="4" I2="0.0" ID="CMP-003.03.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-02-05 17:22:56 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="13" WEIGHT="0.0" Z="0.0">
<NAME>Mortality at 3 years</NAME>
<DICH_DATA CI_END="2.907247435098709" CI_START="0.22707260552715425" EFFECT_SIZE="0.8125" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.4634819960376912" LOG_CI_START="-0.6438352567358672" LOG_EFFECT_SIZE="-0.09017663034908802" ORDER="25970" O_E="0.0" SE="0.6504436355879908" STUDY_ID="STD-Burton-1978" TOTAL_1="12" TOTAL_2="13" VAR="0.423076923076923" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2010-09-05 00:07:46 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Prednisolone plus plasma exchange (p/solone+plas/x) versus prednisolone</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="43" EVENTS_2="21" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-07-28 18:35:35 +0100" MODIFIED_BY="Cathy Bennett" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="647.0039136675884" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="75" TOTAL_2="61" WEIGHT="0.0" Z="0.0">
<NAME>Disease control</NAME>
<GROUP_LABEL_1>P/solone+plas/x</GROUP_LABEL_1>
<GROUP_LABEL_2>P/solone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours p/solone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours p/solone+plas/x</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="13" EVENTS_2="0" I2="0.0" ID="CMP-004.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-02-05 17:23:03 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Disease control at 1 month (controlled with 0.3 mg/kg prednisolone)</NAME>
<DICH_DATA CI_END="293.695076970364" CI_START="1.201199533384032" EFFECT_SIZE="18.782608695652176" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="0" LOG_CI_END="2.4678966667729725" LOG_CI_START="0.07961515482166587" LOG_EFFECT_SIZE="1.2737559107973193" ORDER="25972" O_E="0.0" SE="1.4028883823043474" STUDY_ID="STD-Roujeau-1984" TOTAL_1="22" TOTAL_2="15" VAR="1.9680958132045085" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="21" EVENTS_2="8" I2="0.0" ID="CMP-004.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-02-05 17:23:08 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Disease control at 1 month (controlled with 1.0 mg/kg prednisolone or less)</NAME>
<DICH_DATA CI_END="2.8984248006528475" CI_START="1.1051818265451432" EFFECT_SIZE="1.7897727272727273" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="8" LOG_CI_END="0.462162037125224" LOG_CI_START="0.04343373482567739" LOG_EFFECT_SIZE="0.2527978859754507" ORDER="25973" O_E="0.0" SE="0.2459630775092788" STUDY_ID="STD-Roujeau-1984" TOTAL_1="22" TOTAL_2="15" VAR="0.06049783549783548" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="9" EVENTS_2="13" I2="0.0" ID="CMP-004.01.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-02-05 17:23:13 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>Disease control at 6 months</NAME>
<DICH_DATA CI_END="1.378653405066739" CI_START="0.3476507866784694" EFFECT_SIZE="0.6923076923076923" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="13" LOG_CI_END="0.1394550978028505" LOG_CI_START="-0.45885678353787435" LOG_EFFECT_SIZE="-0.1597008428675119" ORDER="25974" O_E="0.0" SE="0.35145136079111994" STUDY_ID="STD-Guillaume-1993" TOTAL_1="31" TOTAL_2="31" VAR="0.12351805900192997" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-004.02" MODIFIED="2010-09-05 00:07:30 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="22" TOTAL_2="15" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Disease control at 1 month - cumulative steroid dose (g)</NAME>
<GROUP_LABEL_1>P/solone+plas/x</GROUP_LABEL_1>
<GROUP_LABEL_2>P/solone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours p/solone+plas/x</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours p/solone</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.6647488333390025" CI_START="-2.3952511666609975" EFFECT_SIZE="-1.53" ESTIMABLE="YES" MEAN_1="1.24" MEAN_2="2.77" ORDER="25975" SD_1="0.73" SD_2="1.6" SE="0.4414627888501974" STUDY_ID="STD-Roujeau-1984" TOTAL_1="22" TOTAL_2="15" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-07-28 18:24:34 +0100" MODIFIED_BY="Cathy Bennett" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="31" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>Mortality and severe adverse events at 6 months</NAME>
<GROUP_LABEL_1>P/solone+plas/x</GROUP_LABEL_1>
<GROUP_LABEL_2>P/solone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours p/solone+plas/x</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours p/solone</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.448309194476435" CI_START="0.24856570777356715" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="0.16086128777293124" LOG_CI_START="-0.604558787005644" LOG_EFFECT_SIZE="-0.2218487496163564" ORDER="25979" O_E="0.0" SE="0.44961154081541166" STUDY_ID="STD-Guillaume-1993" TOTAL_1="31" TOTAL_2="31" VAR="0.2021505376344086" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-004.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-09-05 00:07:46 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="538.86" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="77" TOTAL_2="63" WEIGHT="0.0" Z="0.0">
<NAME>Mortality</NAME>
<GROUP_LABEL_1>P/solone+plas/x</GROUP_LABEL_1>
<GROUP_LABEL_2>P/solone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Mortality p/solone+plas/x</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Mortality p/solone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-004.04.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-09-05 00:07:40 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Mortality at 1 month: excluding dropouts</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="25976" O_E="0.0" SE="0.0" STUDY_ID="STD-Roujeau-1984" TOTAL_1="22" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-004.04.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-09-05 00:07:46 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>Mortality at 1 month: ITT worst case</NAME>
<DICH_DATA CI_END="4.545047475196923" CI_START="0.11039183063525043" EFFECT_SIZE="0.7083333333333334" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.6575384239954707" LOG_CI_START="-0.9570630646621348" LOG_EFFECT_SIZE="-0.14976232033333206" MODIFIED="2010-08-11 09:26:42 +0100" MODIFIED_BY="[Empty name]" ORDER="25977" O_E="0.0" SE="0.9484249068437463" STUDY_ID="STD-Roujeau-1984" TOTAL_1="24" TOTAL_2="17" VAR="0.8995098039215687" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="5" I2="0.0" ID="CMP-004.04.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-02-05 17:25:31 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>Mortality at 6 months</NAME>
<DICH_DATA CI_END="2.295994708530964" CI_START="0.1567947864437097" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.36097088282939777" LOG_CI_START="-0.8046683820621104" LOG_EFFECT_SIZE="-0.2218487496163564" ORDER="25978" O_E="0.0" SE="0.6847022742046907" STUDY_ID="STD-Guillaume-1993" TOTAL_1="31" TOTAL_2="31" VAR="0.4688172043010753" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2010-07-28 17:53:11 +0100" MODIFIED_BY="Cathy Bennett" NO="5">
<NAME>Prednisolone plus azathioprine (p/solone+azathio) versus prednisolone plus plasma exchange (p/solone+plas/x)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="14" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-07-28 17:52:58 +0100" MODIFIED_BY="Cathy Bennett" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="36" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>Disease control at 6 months</NAME>
<GROUP_LABEL_1>P/solone+azathio</GROUP_LABEL_1>
<GROUP_LABEL_2>P/solone+plas/x</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours p/solone+plas/x</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours p/solone+azathio</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.6599282940425977" CI_START="0.6745583296714261" EFFECT_SIZE="1.3395061728395061" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="9" LOG_CI_END="0.42486992914183025" LOG_CI_START="-0.1709804905300332" LOG_EFFECT_SIZE="0.12694471930589854" ORDER="25980" O_E="0.0" SE="0.350005486022399" STUDY_ID="STD-Guillaume-1993" TOTAL_1="36" TOTAL_2="31" VAR="0.12250384024577574" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-07-28 17:53:05 +0100" MODIFIED_BY="Cathy Bennett" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="36" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>Mortality at 6 months</NAME>
<GROUP_LABEL_1>P/solone+azathio</GROUP_LABEL_1>
<GROUP_LABEL_2>P/solone+plas/x</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours p/solone+azathio</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours p/solone+plas/x</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.319597508356486" CI_START="0.4693415013842265" EFFECT_SIZE="1.7222222222222223" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.8006894191896435" LOG_CI_START="-0.32851104172771023" LOG_EFFECT_SIZE="0.23608918873096663" ORDER="25981" O_E="0.0" SE="0.6632979403752836" STUDY_ID="STD-Guillaume-1993" TOTAL_1="36" TOTAL_2="31" VAR="0.4399641577060932" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="15" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-005.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-07-28 17:53:11 +0100" MODIFIED_BY="Cathy Bennett" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.06" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="36" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>Mortality and adverse events at 6 months</NAME>
<GROUP_LABEL_1>P/solone+azathio</GROUP_LABEL_1>
<GROUP_LABEL_2>P/solone+plas/x</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours p/solone+azathio</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours p/solone+plas/x</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.86794902611585" CI_START="0.9520338310098675" EFFECT_SIZE="2.1527777777777777" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="6" LOG_CI_END="0.6873460219424743" LOG_CI_START="-0.021347618464428314" LOG_EFFECT_SIZE="0.33299920173902303" ORDER="25982" O_E="0.0" SE="0.41629015246511236" STUDY_ID="STD-Guillaume-1993" TOTAL_1="36" TOTAL_2="31" VAR="0.17329749103942652" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2010-09-05 00:08:08 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Nicotinamide plus tetracycline (nicot+tetracy) versus prednisone (p/sone)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="15" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-09-05 00:08:08 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="209.2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="24" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>Disease control</NAME>
<GROUP_LABEL_1>Nicot+tetracy</GROUP_LABEL_1>
<GROUP_LABEL_2>P/sone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours p/sone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours nicot+tetracy</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="1" I2="0.0" ID="CMP-006.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-09-05 00:08:02 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>Complete response at 8 weeks: excluding dropouts</NAME>
<DICH_DATA CI_END="16.888405475320265" CI_START="0.3700763822335619" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.2275886474419597" LOG_CI_START="-0.43170863009788446" LOG_EFFECT_SIZE="0.3979400086720376" ORDER="25983" O_E="0.0" SE="0.9746794344808964" STUDY_ID="STD-Fivenson-1994" TOTAL_1="12" TOTAL_2="6" VAR="0.9500000000000001" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="10" EVENTS_2="6" I2="0.0" ID="CMP-006.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-09-05 00:08:08 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>Complete or partial response at 8 weeks: excluding dropouts</NAME>
<DICH_DATA CI_END="1.2165861914276732" CI_START="0.6218968792371309" EFFECT_SIZE="0.8698224852071006" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.08514288279861414" LOG_CI_START="-0.20628162252960905" LOG_EFFECT_SIZE="-0.06056936986549744" ORDER="25984" O_E="0.0" SE="0.17118419700436519" STUDY_ID="STD-Fivenson-1994" TOTAL_1="12" TOTAL_2="6" VAR="0.02930402930402931" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-006.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-07-28 17:53:26 +0100" MODIFIED_BY="Cathy Bennett" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="621.81" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="12" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>Mortality at 6 months</NAME>
<GROUP_LABEL_1>Nicot+tetracy</GROUP_LABEL_1>
<GROUP_LABEL_2>P/sone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours nicot+tetracy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours p/sone</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.850593985877188" CI_START="0.00836640988855751" EFFECT_SIZE="0.1794871794871795" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.5855277281815319" LOG_CI_START="-2.0774608622060167" LOG_EFFECT_SIZE="-0.7459665670122424" ORDER="25985" O_E="0.0" SE="1.564252679999765" STUDY_ID="STD-Fivenson-1994" TOTAL_1="12" TOTAL_2="6" VAR="2.4468864468864466" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" MODIFIED="2010-09-05 00:08:23 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Clobetasol propionate cream (clobetasol) versus oral prednisone (oral p/sone)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="169" EVENTS_2="158" I2="0.0" I2_Q="0.0" ID="CMP-007.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-07-28 17:53:39 +0100" MODIFIED_BY="Cathy Bennett" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="170" TOTAL_2="171" WEIGHT="0.0" Z="0.0">
<NAME>Disease control at day 21</NAME>
<GROUP_LABEL_1>Clobetasol cream</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral p/sone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral p/sone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clobetasol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="77" EVENTS_2="72" I2="0.0" ID="CMP-007.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-02-05 17:32:27 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="77" TOTAL_2="76" WEIGHT="0.0" Z="0.0">
<NAME>Prednisone 0.5 mg/kg for moderate disease</NAME>
<DICH_DATA CI_END="1.118758957411896" CI_START="0.9953667090883515" EFFECT_SIZE="1.0552608311229001" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="72" LOG_CI_END="0.048736525543172954" LOG_CI_START="-0.0020168887085367866" LOG_EFFECT_SIZE="0.023359818417318084" ORDER="25986" O_E="0.0" SE="0.029812806764906673" STUDY_ID="STD-Joly-2002" TOTAL_1="77" TOTAL_2="76" VAR="8.888034472016651E-4" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="92" EVENTS_2="86" I2="0.0" ID="CMP-007.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-02-05 17:27:55 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="93" TOTAL_2="95" WEIGHT="0.0" Z="0.0">
<NAME>Prednisone 1 mg/kg for extensive disease</NAME>
<DICH_DATA CI_END="1.1701527409784176" CI_START="1.0205105796640976" EFFECT_SIZE="1.0927731932983247" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="86" LOG_CI_END="0.06824255425432137" LOG_CI_START="0.008817511419479089" LOG_EFFECT_SIZE="0.038530032836900235" ORDER="25987" O_E="0.0" SE="0.03490656431989253" STUDY_ID="STD-Joly-2002" TOTAL_1="93" TOTAL_2="95" VAR="0.0012184682326187943" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="52" EVENTS_2="80" I2="0.0" I2_Q="0.0" ID="CMP-007.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-07-28 17:54:06 +0100" MODIFIED_BY="Cathy Bennett" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="170" TOTAL_2="171" WEIGHT="0.0" Z="0.0">
<NAME>Severe complications</NAME>
<GROUP_LABEL_1>Clobetasol cream</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral p/sone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clobetasol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oral p/sone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="25" EVENTS_2="29" I2="0.0" ID="CMP-007.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-02-05 17:28:21 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="77" TOTAL_2="76" WEIGHT="0.0" Z="0.0">
<NAME>Prednisone 0.5 mg/kg for moderate disease</NAME>
<DICH_DATA CI_END="1.3092088979063774" CI_START="0.5529944943711925" EFFECT_SIZE="0.8508732646663681" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="29" LOG_CI_END="0.11700894828468994" LOG_CI_START="-0.2572791925219079" LOG_EFFECT_SIZE="-0.07013512211860898" ORDER="25990" O_E="0.0" SE="0.21985870666597343" STUDY_ID="STD-Joly-2002" TOTAL_1="77" TOTAL_2="76" VAR="0.04833785089683455" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="27" EVENTS_2="51" I2="0.0" ID="CMP-007.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-02-05 17:28:34 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="93" TOTAL_2="95" WEIGHT="0.0" Z="0.0">
<NAME>Prednisone 1 mg/kg for extensive disease</NAME>
<DICH_DATA CI_END="0.7818251761526125" CI_START="0.3740751323120127" EFFECT_SIZE="0.540796963946869" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="51" LOG_CI_END="-0.10689034862862663" LOG_CI_START="-0.42704116177944623" LOG_EFFECT_SIZE="-0.2669657552040364" ORDER="25991" O_E="0.0" SE="0.18805817241687542" STUDY_ID="STD-Joly-2002" TOTAL_1="93" TOTAL_2="95" VAR="0.03536587621277524" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="45" EVENTS_2="62" I2="0.0" I2_Q="0.0" ID="CMP-007.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-09-05 00:08:23 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="170" TOTAL_2="171" WEIGHT="0.0" Z="0.0">
<NAME>Mortality at 1 year</NAME>
<GROUP_LABEL_1>Clobetasol cream</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral p/sone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clobetasol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oral p/sone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="23" EVENTS_2="23" I2="0.0" ID="CMP-007.03.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-02-05 17:28:03 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="77" TOTAL_2="76" WEIGHT="0.0" Z="0.0">
<NAME>Prednisone 0.5 mg/kg for moderate disease</NAME>
<DICH_DATA CI_END="1.6004026465429135" CI_START="0.6087184613426447" EFFECT_SIZE="0.987012987012987" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="23" LOG_CI_END="0.20422926088868482" LOG_CI_START="-0.21558352667206587" LOG_EFFECT_SIZE="-0.005677132891690521" ORDER="25988" O_E="0.0" SE="0.24660010951999867" STUDY_ID="STD-Joly-2002" TOTAL_1="77" TOTAL_2="76" VAR="0.060811614015275336" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="22" EVENTS_2="39" I2="0.0" ID="CMP-007.03.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-02-05 17:28:13 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="93" TOTAL_2="95" WEIGHT="0.0" Z="0.0">
<NAME>Prednisone 1 mg/kg for extensive disease</NAME>
<DICH_DATA CI_END="0.8924496531801575" CI_START="0.3720606461446367" EFFECT_SIZE="0.5762338020402537" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="39" LOG_CI_END="-0.04941627489395994" LOG_CI_START="-0.4293862640448006" LOG_EFFECT_SIZE="-0.2394012694693803" ORDER="25989" O_E="0.0" SE="0.2231962525089846" STUDY_ID="STD-Joly-2002" TOTAL_1="93" TOTAL_2="95" VAR="0.049816567134054406" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" MODIFIED="2010-09-05 00:08:38 +0100" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Mild regimen clobetasol propionate cream (mild clobetasol) regimen versus standard clobetasol propionate cream (stnd clobetasol) regimen</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="312" EVENTS_2="300" I2="0.0" I2_Q="0.0" ID="CMP-008.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-09-05 00:08:38 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="318" TOTAL_2="306" WEIGHT="0.0" Z="0.0">
<NAME>Healing of skin lesions: complete (at day 21)</NAME>
<GROUP_LABEL_1>Mild clobetasol</GROUP_LABEL_1>
<GROUP_LABEL_2>Stnd clobetasol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours stnd clobetasol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours mild clobetasol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="156" EVENTS_2="150" I2="0.0" ID="CMP-008.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-09-05 00:08:38 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="159" TOTAL_2="153" WEIGHT="0.0" Z="0.0">
<NAME>Intention-to-treat analysis, all participants</NAME>
<DICH_DATA CI_END="1.032359897083645" CI_START="0.9701171136046565" EFFECT_SIZE="1.0007547169811322" ESTIMABLE="YES" EVENTS_1="156" EVENTS_2="150" LOG_CI_END="0.013831125653354029" LOG_CI_START="-0.01317583406149864" LOG_EFFECT_SIZE="3.2764579592771355E-4" MODIFIED="2010-02-23 15:21:20 +0000" MODIFIED_BY="Cathy Bennett" ORDER="50" O_E="0.0" SE="0.01586402182311113" STUDY_ID="STD-Joly-2009" TOTAL_1="159" TOTAL_2="153" VAR="2.5166718840414614E-4" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="68" EVENTS_2="63" I2="0.0" ID="CMP-008.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-05-12 13:54:34 +0100" MODIFIED_BY="Cathy Bennett" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="69" TOTAL_2="65" WEIGHT="0.0" Z="0.0">
<NAME>Moderate disease</NAME>
<DICH_DATA CI_END="1.0709714437997357" CI_START="0.9653557045353776" EFFECT_SIZE="1.0167931907062342" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="63" LOG_CI_END="0.029777891032101045" LOG_CI_START="-0.015312632715591263" LOG_EFFECT_SIZE="0.007232629158254876" MODIFIED="2010-05-12 13:54:34 +0100" MODIFIED_BY="Cathy Bennett" ORDER="296" O_E="0.0" SE="0.026486396851086762" STUDY_ID="STD-Joly-2009" TOTAL_1="69" TOTAL_2="65" VAR="7.015292181532587E-4" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="88" EVENTS_2="87" I2="0.0" ID="CMP-008.01.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-05-12 13:55:45 +0100" MODIFIED_BY="Cathy Bennett" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="90" TOTAL_2="88" WEIGHT="0.0" Z="0.0">
<NAME>Extensive disease</NAME>
<DICH_DATA CI_END="1.0276968076578015" CI_START="0.9517922341926299" EFFECT_SIZE="0.9890166028097063" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="87" LOG_CI_END="0.0118650074776566" LOG_CI_START="-0.021457842992868865" LOG_EFFECT_SIZE="-0.004796417757606142" MODIFIED="2010-05-12 13:55:45 +0100" MODIFIED_BY="Cathy Bennett" ORDER="297" O_E="0.0" SE="0.019574007317156767" STUDY_ID="STD-Joly-2009" TOTAL_1="90" TOTAL_2="88" VAR="3.831417624521067E-4" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="67" EVENTS_2="52" I2="0.0" I2_Q="0.0" ID="CMP-008.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-07-28 17:54:28 +0100" MODIFIED_BY="Cathy Bennett" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="11.96" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="159" TOTAL_2="153" WEIGHT="0.0" Z="0.0">
<NAME>Number of relapses</NAME>
<GROUP_LABEL_1>Mild clobetasol</GROUP_LABEL_1>
<GROUP_LABEL_2>Stnd clobetasol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours stnd clobetasol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours mild clobetasol</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6507624389128193" CI_START="0.9312085452839085" EFFECT_SIZE="1.2398403483309144" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="52" LOG_CI_END="0.21768457847622774" LOG_CI_START="-0.030953047349878488" LOG_EFFECT_SIZE="0.09336576556317461" MODIFIED="2010-05-12 14:26:08 +0100" MODIFIED_BY="Cathy Bennett" ORDER="299" O_E="0.0" SE="0.14605097218635232" STUDY_ID="STD-Joly-2009" TOTAL_1="159" TOTAL_2="153" VAR="0.021330886476578662" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="60" EVENTS_2="58" I2="0.0" I2_Q="0.0" ID="CMP-008.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-07-29 10:57:14 +0100" MODIFIED_BY="Cathy Bennett" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="159" TOTAL_2="153" WEIGHT="0.0" Z="0.0">
<NAME>Mortality</NAME>
<GROUP_LABEL_1>Mild clobetasol</GROUP_LABEL_1>
<GROUP_LABEL_2>Stnd clobetasol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours stnd clobestaol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours mild clobetasol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="19" EVENTS_2="21" I2="0.0" ID="CMP-008.03.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-07-29 10:50:30 +0100" MODIFIED_BY="Cathy Bennett" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="69" TOTAL_2="65" WEIGHT="0.0" Z="0.0">
<NAME>Moderate disease</NAME>
<DICH_DATA CI_END="1.4335239832273117" CI_START="0.5067481606998515" EFFECT_SIZE="0.852311939268461" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="21" LOG_CI_END="0.1564049632023846" LOG_CI_START="-0.29520781895336456" LOG_EFFECT_SIZE="-0.06940142787549003" MODIFIED="2010-07-29 10:50:30 +0100" MODIFIED_BY="Cathy Bennett" ORDER="300" O_E="0.0" SE="0.2652795837576127" STUDY_ID="STD-Joly-2009" TOTAL_1="69" TOTAL_2="65" VAR="0.07037325755861225" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="41" EVENTS_2="37" I2="0.0" ID="CMP-008.03.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-07-29 10:50:36 +0100" MODIFIED_BY="Cathy Bennett" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="90" TOTAL_2="88" WEIGHT="0.0" Z="0.0">
<NAME>Extensive disease</NAME>
<DICH_DATA CI_END="1.5122826773157576" CI_START="0.7762678741154366" EFFECT_SIZE="1.0834834834834834" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="37" LOG_CI_END="0.17963297749057397" LOG_CI_START="-0.10998838676340549" LOG_EFFECT_SIZE="0.034822295363584235" MODIFIED="2010-07-29 10:50:36 +0100" MODIFIED_BY="Cathy Bennett" ORDER="301" O_E="0.0" SE="0.17012502301166216" STUDY_ID="STD-Joly-2009" TOTAL_1="90" TOTAL_2="88" VAR="0.028942523454718577" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" MODIFIED="2010-07-28 17:54:42 +0100" MODIFIED_BY="Cathy Bennett" NO="9">
<NAME>Jingui Shenqi Pill (JSP) 1# bid plus prednisone (JSP pill+p/sone) versus prednisone (p/sone) alone</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="28" EVENTS_2="22" I2="0.0" I2_Q="0.0" ID="CMP-009.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-07-28 17:54:42 +0100" MODIFIED_BY="Cathy Bennett" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="45" TOTAL_2="45" WEIGHT="0.0" Z="0.0">
<NAME>Healing at 4 weeks</NAME>
<GROUP_LABEL_1>JSP pill+p/sone</GROUP_LABEL_1>
<GROUP_LABEL_2>P/sone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours p/sone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours JSP pill+p/sone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-009.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-02-05 17:28:40 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Complete healing</NAME>
<DICH_DATA CI_END="68.25874292736694" CI_START="0.13185124152633113" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8341582859242351" LOG_CI_START="-0.87991577648491" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2010-01-29 11:23:54 +0000" MODIFIED_BY="[Empty name]" ORDER="43" O_E="0.0" SE="1.5942605391424158" STUDY_ID="STD-Liu-2006" TOTAL_1="15" TOTAL_2="15" VAR="2.5416666666666665" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="13" EVENTS_2="11" I2="0.0" ID="CMP-009.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-02-05 17:28:58 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Partial healing</NAME>
<DICH_DATA CI_END="1.7007938080196618" CI_START="0.8212013756695701" EFFECT_SIZE="1.1818181818181819" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="11" LOG_CI_END="0.23065166607163215" LOG_CI_START="-0.08555033177440872" LOG_EFFECT_SIZE="0.07255066714861175" MODIFIED="2009-09-13 02:55:17 +0100" MODIFIED_BY="[Empty name]" ORDER="47" O_E="0.0" SE="0.1857386187598974" STUDY_ID="STD-Liu-2006" TOTAL_1="15" TOTAL_2="15" VAR="0.03449883449883451" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="14" EVENTS_2="11" I2="0.0" ID="CMP-009.01.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-01-29 12:16:17 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Overall healing - participants experiencing any degree of healing</NAME>
<DICH_DATA CI_END="1.7770537696175834" CI_START="0.9115282488567495" EFFECT_SIZE="1.2727272727272727" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="11" LOG_CI_END="0.24970056877036623" LOG_CI_START="-0.04022986773034031" LOG_EFFECT_SIZE="0.10473535052001298" MODIFIED="2010-01-29 12:16:17 +0000" MODIFIED_BY="[Empty name]" ORDER="152" O_E="0.0" SE="0.17030657357932197" STUDY_ID="STD-Liu-2006" TOTAL_1="15" TOTAL_2="15" VAR="0.029004329004329005" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-010" MODIFIED="2010-07-29 14:11:48 +0100" MODIFIED_BY="Cathy Bennett" NO="10">
<NAME>Azathioprine plus methylprednisolone (azathio+mp/solone) versus mycophenolate mofetil plus methylprednisolone (MMF+mp/solone)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="38" EVENTS_2="35" I2="0.0" I2_Q="0.0" ID="CMP-010.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-07-29 14:11:48 +0100" MODIFIED_BY="Cathy Bennett" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="34.36335416666263" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="76" TOTAL_2="70" WEIGHT="0.0" Z="0.0">
<NAME>Healing of lesions</NAME>
<GROUP_LABEL_1>Azathio+mp/solone</GROUP_LABEL_1>
<GROUP_LABEL_2>MMF+mp/solone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours MMF+p/solone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours azathio+p/solone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="35" EVENTS_2="35" I2="0.0" ID="CMP-010.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-02-05 17:29:13 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="38" TOTAL_2="35" WEIGHT="0.0" Z="0.0">
<NAME>Complete healing</NAME>
<DICH_DATA CI_END="1.0261909632860358" CI_START="0.8303240199939838" EFFECT_SIZE="0.9230769230769231" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="35" LOG_CI_END="0.011228185906688818" LOG_CI_START="-0.08075239842511268" LOG_EFFECT_SIZE="-0.03476210625921192" MODIFIED="2009-09-14 12:27:53 +0100" MODIFIED_BY="[Empty name]" ORDER="51" O_E="0.0" SE="0.054029850547735826" STUDY_ID="STD-Beissert-2007" TOTAL_1="38" TOTAL_2="35" VAR="0.0029192247502106694" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-010.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-02-05 17:29:18 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="38" TOTAL_2="35" WEIGHT="0.0" Z="0.0">
<NAME>Partial healing</NAME>
<DICH_DATA CI_END="120.81057650055304" CI_START="0.345594570436883" EFFECT_SIZE="6.461538461538462" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.0821049567582803" LOG_CI_START="-0.4614330892481906" LOG_EFFECT_SIZE="0.8103359337550449" MODIFIED="2010-02-05 10:24:35 +0000" MODIFIED_BY="[Empty name]" ORDER="50" O_E="0.0" SE="1.4940868389405892" STUDY_ID="STD-Beissert-2007" TOTAL_1="38" TOTAL_2="35" VAR="2.2322954822954824" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2010-09-08 08:11:07 +0100" MODIFIED_BY="Finola M Delamere">
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2010-09-08 08:11:07 +0100" MODIFIED_BY="Finola M Delamere" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAASUAAAJGCAIAAACSjQRJAAAbd0lEQVR42u2dvW4lxRaFj4R0ReDA
gZ+AZ3CEjogg4p1w6GAkJvRbIB4BMRAOE5EhBg8CBxMYyPhT3x58Lxx8+qe6u9Y+taq+LQfoMLPc
U2d/vauqq/fa7QiCiIyOIAh9wBtBwBtBwBtBEPBGEPBGEAS8EQS8EQS8EQQBbwQBb0RFOcHZI3gj
dwOuNuVDAt7I3a0XvPr/EvBG7hLwRvjcLMgNeCN34y6YagxvrrC55C68wRu8cc3wRlSau4cpQW7A
m9/4krsEvBEEvBGF5ARHuuCN3A1ec5Ib8OY0uHa5y/4kvFXCW8fzAFIC3sjdicsmN+DNFTnGmYA3
goA34kSlGHsJeCN3CXgjCALeiDw5QUGGN3I3ZiY8/QkBb+QuvMEbvBnm7uFFkhvw5opc4eOM3TS8
VbJsI3cJeCMIeCMIeCMIAt4IAt6ICnKCPR54I3cDLphvDd5cB5drJuCN3AU5eAO5IifApAe8kbsE
vBEEAW/ElrLMgMAbuRu34CQ94M1mcO1yV3rNVE54g7eIax5MswZzD96oFXLlaZGm0g/e/NZv1Ap4
I05WM41qBW4K8Eb8CwbdM3qcruDNNXcdawW8wZv9rDJ77ur2eOAN3qLXWiXnbkBPsUM11m9E7mE1
XAuRDPBWT33L/s0BCbwR9dwmpE/SWb8RNrnrvuZk/UbY5K6uVrA/CW/wFlorAh4YwhuhHF9y9+hq
mU8SfpWTLUp4I7xrxWE1JjfgzXI+6Tjly1U5A06TwhthOetjpgpv8BZXK+AN3uDtNHPg8js1wBtB
hs3cfSY+gTeiLZIDntHDG7xRK4Lef2sZNngLKj6OpxyNRgPeiNASxzcIb4Rl5ew4XwJvFeDRNXy+
hIA3crcq3lyWhfBG7npfs1d3d3gjd+NqRfY1p113d3hjnhN99yEfGAh7kh2d5URTCdZvhEHuBp8v
aXPeDm9xS7jyE/dYXNpQrMF3iOAtCDZF+sZUTvZU4a113hxPZgbkcfkXDG/cd2dgtlA2Sgl4474b
evfxqpzwRljWCsfu7vDmei/Pm2fWuxrZr9nICQTeImaS0x+2tqvRcnd3ePPOsJbXQvBGGJNs3fWA
81xEDYvPjLNf+pfAG8FMFd6I09UKr/6TdpUT3ghWhvBWae62fMqRNIM3vwyjVsTUZHiDt6BaIeoy
wjsN8MYkqoZZH7wRXSfeN9O9hW1aky1uGfBWSdlsEzm71Sy8wVtQTWaPB96ip5QWygS8UYUYDXgj
aswwxfMAnhnCm/2uhsLpSveuNGkGb67rN2mnPbVydgKNiie8eVdOC96CO6WX/JY3vMHblLjpY71i
GwfBmzADYly2+QbhjSCSJpbSuw+8cd/l+ZtBl0h4s7+R8yzL1E0B3ozrG6PRyfZ4OK9M2IOR/cyn
QtkogeHNfoegU54v6eiMAm/sENg971bT4pLD8Ga5YrFTVruXsH4jLHnrlB6RPKOHN+O9B86XwBtB
RN/OmE8STov42eUQXyW8tY6c+lmW0akr+k8SXRfSUdhrJyZmhJlPEsLiZsRbWD9z5pOEB2+OM1V4
Ix7f0TvNsyyjhIu5R8AbVajpN1Bi5sCs3wizs4gxPSAUM1W/+Q5sGN3RpWcRCXirYf3Gea6Y7rf4
mxKt3yPUT8l43k3Yz4Gz5258/0l4a71WOL4rzTXDm2utsLts6ZqT9RvhwZvijh62yqL/JLzZIEf/
SXgjFrDR7Ew18iQ0vBFEXP9J9ksIefEEY3iDCm1XVuJ4QJhPMn2Se/OWfI8I2Pl02UOCN+MdAutr
5nkA4VTffDujtIwcvIXuajAHFvGme48e3gjXe0TAa6yFV054s6eia367Et6I0VVWXvslOqPAGzG8
RFF0MWEX0WudDG9BsB1+UjJv7CLCG7ydYO/BiDf6vRJTVBQ+4AH7k53gTVZ4I4igOTD9XonQKsT7
ptQ3wnLFYnRSTNdtGt6IiEyKJDmjZsqH8EYUB0YdHsjMJ1tfZXVWveX44uDNuAQZvW+q9sdpvAcE
vMGb/ZoT3ggtb47pS5rBm+s63nTWR6bBGzFVky32eIwaTsMbUcOaU/TeE7wZbxJ4eRd67akOfgJv
7cJmtIDRudqHPaOHN3hrfcMgco+H+SRJtnM5X0LAGzG1yoJkeCPieOvcnAmarfbwFr1oaZY33WqW
/iVERK04/ArLv2x4gzdj3nxrsmJ86BdEWCLnuH6jXxAhzwOcU41TgoEwrUK86QNvhDFv6pqcl+q/
yzvzSSJi1mfUy5HTbfDmPevzeiU08nkA9Q3ebO7oYc2IRLNf5pPw5jTr8+2UznwS5IQnBr0SjvMl
8GZfOS1yLmDWx/kSwpU3x50Y1m/ECd5obq1yuqYEA8GyPmCVxZus8AZyp6lv0vdN4Y3QrrLKn6nq
RoPn3YQciQpqL7wR7c5L1T0bI+8+8EZ4IGe6q8H6jRA+5w3oZ07Am3cVavywslEVgrdKpnwtI+d4
Jgbe4E2bYZEzVfYnCY8ZlGPlhDd4o3LWcPcxWifDG7yNUmGKcckLOXgLSoXO5MSgaQ8Is3xgIKRV
yLGLFrzBG7xxzd5zYHhzzV3dDoHjYS6XewS8hS7lFbBRheCNCLqjG/EW4BEJb4RZ5ew8dz45z0U8
zi36l7hUIXhjv6SGmapj88m8d0x4g7ep9DXqo2rxDcIbvE2VoLzvyOpmqup3GuDNab7e7HJFzbDd
HRPe6kli6ZRMrd/IHRPevGequtya/pCAN3iTVE6FcrOza3gDOde1kOO8Hd7q2YFombeYk5ms35rb
1aigIBudn2R/kilfPXefBkmGN3Y1qJyp4swnG0Uu+KyG3bGY0q8TMLzWb+pTxROlIyPDvB9AeMwn
43unll80FCOc/R4Bb6zf7Hl7NCDUN5AzngNn/IfETCZLTml4C1288fxNdzMSjbDEuA82vLLW+nyJ
Ys3psg8Mb8R8WVakb5vdXODtBGuhwmtF5Ox647AEVPu89wh4M5tBqZ9lkQzScYY31xVL5GU3O84q
jGGj8TyYvq8XuzK0O7kCb5brt87wTZ/I0zal5wNgmFZOLxdSvjh4q4G3Ll//rLC9Ph3MJV8wvMWt
gkruQ3qqYSl/nSxZBUCI1323q8IJRKdcbOdmeAvNMINXIT2f7PG+KWHsQqquyeyXEGb33bAdgvJd
NWK+wY7zXFROBRWmNdnCGRze4M11LaSjAt4qmU+2TEVH/0l4C65CjIZ0DiztlM773fDmVJOZA8Ob
MXLWR66arf/wFlooyq8VPJWWVnt4Yy1kPA22OxMDb/AWVJNZDsCb696D79zMroryfoDf3bFlx+qw
OXDe8yX0C7LnrSv+/YDOfI+n/HGGNzPerL2dfM+X5LpHwFsccowz9zV4I6icQZsl8AYVJ774Rr8+
8liXW9L7peOsz/fuBm8GuXW47ydNi7z3CJeTmY9MIQvfUIW3CN6kqaZIL6N2jqJrHlNgv8Sjvokw
CzBeKvmkGLwRWt50C8KA+hY2zvAGb63XNy/eWL+Z8Rawa599/Sa6ZuloPJIq/FA4vNWDN+NgcyNm
IAgC3ggC3giCgDeCgDeCIOAty8ARxJLnHPC2njeUUV6qDG/kAcrwBm8owxtBhqEMb/CGMrzBG8oo
w1vMt3X/+/317fX+xf78i/PdZ7uzZ2eXzy+vXl69/u31RuU//7z/6afru7v9q1fn3323u709+/HH
y/v7qz//3Kr8+/397fX1i/3+i/Pzz3a7Z2dnzy8vX15d/fb6dbGj4aUMbxLebn64ufjyov+Sjn/6
L+/p909XK//yy82rVxc9Zsc/PX4//7xe+Yebmy8vLoYuedfj9/3TpwWOhp0yvOXnrb8FDn5Phz/9
n1mh3BexQdIOf/o/s0K5L2Jzl7zr/0xRo+GoDG+Zeevvi7Nf1cPP2D1yTLmvbLOwPfyMVbkx5b6y
pV3ybqzKxY+Go3I23ha9BqvAe1BzrANkyoez/6LBD/sZ/9gkZHBacvfrXaJyv2Y7nEZ+/vnuvfd2
b7/95ufDD3dfffV4YvnHH6nK/ZptbBo5OLH89e7u5KPhqJyZt5idn3TeBrtZpH+YAvPxh/3yOvGr
mpiTDCr/9NP1IVHvvPPmW/v0090nn7z5j3ffTZpVDirfXl8vueThWWXwaDgqB/E2WDpylaBHhWj2
8lbwtqhP0/7FfuBbeYihb+vy+WWi8t3dfnDq+M03b7T/85/Hn//4Y6ryi/1+EW/PLy9PPhqOyhG8
Tef3xhL0qEtMyuUt5S2F4cN42DhO/7bOnp0lKj9s/T/6+frr3fvvv9H++OPH/+v2NlX5Yes//efZ
2dnJR8NROWL9ls5b+uQtfR44/ccUvA1/T4dx9IUlKg8Wtw8+eCP50UfDuyaJysdZdDFzybuTj4aj
clB9O+ZwxXwyRacE3oLr21tvvRH+9tsB2Khvlde32fnblj2J9KK3aGGZCGTJ67exH9ZvrN/yr9+W
MqzmLWx/8uHnIdKferM/Wc/+5Ng+oXp/8njvZHZJmf4bl/IW9vxtmjeev1X+/K3B4HzJaUej6fMl
8HYYnJ+MGQ3OT8LbP/fI4Z2uvyYhT149Wa381/sB5+PvB6xX7qvc2F5l//mrJ08KHA07ZXiT8NaN
vz01OONfpDz2/tvgmm2R8tj7b4NrtkJGw0sZ3lS8oYwyvJEHKMMbvKEMbwQZhjK8wRvK8AZvKKMM
b7oxJQj8cahvKFPf4A1llOGNPEAZ3uANZXgjyDCU4Q3eUIa31nnTudig7KsMbxLedC42KFsrw1t+
3nRvYaPsrgxvmXnTdRlB2V05iLdF7jl5V7SDLfESrXCmLzjYxQZld+VQ3tZRtPHCplvcpXeYTW9Q
q3OxQdld+fS8TXRfHexePuGPM/ZLF/G2qPFrsIsNyu7K5fKW3ol51h8nnbfVlfAwdC42KLsrn379
pu5n3s0ZiSxd6c2Oqc7FBmV35aLnkyLeDkkLq29ZXGxQdldulLeNa7l1s//tLjYouysXxNusq1v2
+aSIN52LDcruykU8fzue3Y253iQu/1Y8f5sgauPzt4wuNii7K8fxVmVwogLlQs+XNMVbx4lBlOEt
krdO6WKDsrUyvEl465QuNij7KsObijeUUYY38gBleIM3lOGNIMNQhjd4Qxne4A1llOFNN6YEgT8O
9Q1l6hu8oYwyvJEHKMMbvKEMbwQZhjK8wRvK8NY6b46OMPe/31/fXu9f7M+/ON99tjt7dnb5/PLq
5dXr31pUxh/HhjdHR5ibH24uvrzoU/b4p0/lp9+3pYw/jg1vju8d9wVhMGsPf/o/04gy73fb8ObY
V6OvErOJ+/AzVjFqUq6kf8lql5y8VEy0CUv5cHpMHX1b+vXP2JRscJJ292vNyjX44wxeRMAvTfTH
Wdfcshrfluvb68TEnZihVaNcgz/ORKk5/I8VVjgTJSjdH2cdWtX4tuxf7Ady9CGGcvfyec3KNfjj
pPCWyzQnvagqeHP0bXnYRk/P3bNnNSvX4I+TWN+yT/m6NH+cadOc6v1xhrP2MI7St2LlGvxxlvI2
aLaYhbduxB9nzDQnS30r3LeF+hYzzgb1beM8sEv2x1Gv30r2bWH9FjPOBe1Pxs8nY/YnLXxb2J+M
GeeCnr/N7jpO/Pfs6+snfP5m4dvC87eYcY7mrbLgfEmtyvjjOPHWcX7SX5nzk068dZ6OMH3FGN73
+2tK9uRVW8r44zjx1nk6woy9Sza4/qleGX8cJ95QRhneyAOU4Q3eUIY3ggxDGd7gDWV4gzeUUYY3
3ZgSBP441DeUqW/whjLK8EYeoAxv8IYyvBFkGMrwBm8ow1vrvDn64/x+f397ff1iv//i/Pyz3e7Z
2dnzy8uXV1e/vW7R0wd/HBveHP1xfri5+fLiYvC9zR6/75+25emDP44Nb47vd/dFbLY1Qf9nirpm
3u+GN8v+JX1lS2x1NVblauq5Umj/ktnGrGVSsbQVV/X+OP2abWwaOTix/PWuZk+fcv1xyq+KW/xx
xhSm//mO/ji319dLWjkOzyqr8fQp1x8n0ZUml+tN+l8fu5IA3hz9cV7s94t4e35Zs6dPuf44i3jb
6HqT/tenL3IRbxOOAl1F/jgPW//pP8/Oavb0KdcfZ/DtgwlLt3SKpv8BYf44K3hz9Mc5zs+LGauZ
mj19yvXHmQZjzEJx1vWmS+5nLvXHWVo5J+6OhfvjBNe3wj19yvXHWcpbYtWaUMvCW/pvnH59sBp/
nPj1W8mePuX64yxCaKMxTbw/zjqSHf1xwvYnLTx9yvXHWVqyNrrepP/1cp6/WfjjhD1/s/D0wR+n
3Id7g59zviTmmvHHgbf/3305PxlyzZyfhLd/7pF2/jh9lRvbq+w/f/WkLU8f/HGceOs8/XHG3n8b
XLMVcs3448AbyijDG3mAMrzBG8rwRpBhKMMbvKEMb/CGMsrwpuWNIPDHob6hTH2DN5RRhjfyAGV4
gzeU4Y0gw1CGN3hDGd5a583Lt+UhHP1xvJThTcKbnW9L5+mPY6cMb/l5c3zv2PH9bkdleMvMm2Nf
Dcf+JY7Ky3ibPaty/PtO7puzpT/X9L+3Gt8WR38cR+VlvKU0n0sBLxi21f0n03vRHoajb4ujP46j
8gLeJrqgTifr2B9Lb1f+qP/50r6R2/u9LvrQ0bfF0R/HUXkTb4kZnNH+JlFq+srVvDn6tjj64zgq
r+QtxXMjcf22bkYX5o/TLfd/c/RtcfTHcVQ+/XxyO2+zbxyt9sexqG/N+uM4Kp+Gt+07Fov2YFb7
47is39r0x3FUzrM/mbjEmp68zVqWxvvjFL4/2bg/jqNytudvKWaFs5O3CZFuoZNOC8/fGvfHcVRe
zBuRMqacL4m55vrPlxCJY8r5yZhr5vwkvP1T5bx8WzpPfxw7ZXiT8Na5+bb8vZaz88fxUoY3FW8o
owxv5AHK8AZvKMMbQYahDG/whjK8wRvKKMObbkwJAn8c6hvK1Dd4QxlleCMPUIY3eEMZ3ggyDGV4
gzeU4a113vDHiRkNr3GGNwlv+OPEjIbdOMNbft54vztmNBzHGd4y80b/kpjRcBznonmbvqrEHn5b
WnHhj7OxP5duNBzHuXLeNraaxB9ne/9J3Wg4jrMTb2OWOokuWQq08Mc54Wg4jrMNb9NuVUXxhj9O
zGg4jnMNvHUjPm+zE8t03vDHWe2PoxsNx3GGt/y84Y9TZX2L9sc51ZptO28b/RaX2uvgj1Pr+i3a
H6dY3haVoHXGV+m84Y9T2f7kKf1xwpBLeRSWsskx+H57uv706/H447Tw/A1/nDXP4iJ/KedLYkaD
8yUNwdZxfrKA0eD8ZEOBP04Jo2E3zvCmqqv448SMhtc4w1tx81iUK1aGN/IAZXiDN5ThjSDDUIY3
eEMZ3uANZZThLdeYEgT+ONQ3lKlv8IYyyvBGHqAMb/CGMrwRZBjK8AZvKMNb67w5OsLo/HF0nj5e
4wxvEt4cHWF0/jg6Tx+7cYa3/Lw5vtGse79b96604zjDW2beHDt26PqX6HqBOI5zhz/O0g+nL8Cx
I5WuP5fOa8ZxnCvnrTJ/HJ2yrv+kzmvGcZydeIv3x1nHm2NHYV1/ZZ3XjOM42/B2En+cdbw5dszX
+QfovGYcx7kG3jqZX8fhf+yqdoTR+ePovGYcxxne5v0DJsSpb+vqWxavGeqbZM22nbeN/jis3xTr
t+1eM6zfTsZbp/HHYX8y+/5kRq8Z9idzIleCPw7P37I/f8voNcPzt3Kf1AX/Us6XHAbnS2rjrSl/
HM5Puo8z5yclnDs6wuj8cXSePnbjDG+quuroCKPzx9F5+niNM7wVN49FuWJleCMPUIY3eEMZ3ggy
DGV4gzeU4Q3eUEYZ3nKNKUHgj0N9Q5n6Bm8oowxv5AHK8AZvKMMbQYahDG/whjK8tc6bzhFGp6zz
x3F0C1KMM7xJeNM5wuiUdf44jm5BonGGt/y86d5o1inr3u92fAtbN87wlpk3XccOnbKuf4ljlxHd
OJfOW3ojuql/W6A/js4RRqes68/l2EVLN86uvK34u2H+ATpHGJ2yrv+kY5dI3Tjb17dEs47tvKVf
m84RRqes66/s2AVZN87wluS/s2g+qXOE0Snr/AMcu/zrxrkV3lb740zXumBHGJ2yzh/H0cVGN87w
ln/9pnOE0SlT32LGuQneVvvjrONN5wijU2b9FjPO9fCWbokYvD+Z0RFGp8z+ZMw4e/B2/Jp6oiXi
SfxxdI4wOmWev8WMswFvJQfnS1KUOV8Cb1reOs5P/js4PwlvWt46pSOMTlnnj+PoFiQaZ3iT8NYp
HWF0yjp/HEe3IMU4w5uKN5RRhjfyAGV4gzeU4Y0gw1CGN3hDGd7gDWWU4U03pgSBPw71DWXqG7yh
jDK8kQcowxu8oQxvBBmGMrzBG8rw1jpvXr4tD6Hzx3F03sEfx4Y3O9+WTumP4+i8gz+ODW+O7x3r
3u92fHOc97tteHPsq6HrX+LYGaXC/iXTneoyZv9E367ZD5cqd56+Lbr+XI6dv+r0xxnsUZedt0Gu
jv97otXk0n54jr4tuv6Tjp0t6/THmeZtsGlkd9Tgdbol62BfSjVvjr4tuv7Kjp2b6/THOYThmKVB
JNbZR23hbayT7MRvdPRt0fkHODoT1OmPs4K3dGZSeEtsuryUN0ffFp0/jqPzTp3+OBt5O37RaOl+
SfpvLLm+Fe6PU019s/fHyVXf1u0ipojPvj5YjW8L67eYcS7iecB0PdHNJ9NhLnN/0sIfp4L9yUr8
cWYxm95+TNmfrPv5m4U/TgXP3/DHKSU4X3JaZc6XwNv/gvOTMcqcn4S3f+6+Xr4tndIfx9F5B38c
J946N9+Wv1dcIn8cR+cd/HGceEMZZXgjD1CGN3hDGd4IMgxleIM3lOEN3lBGGd50Y0oQ+ONQ31Cm
vsEbyijDG3mAMrzBG8rwRpBhKMMbvKEMb63zhj9OzDXrxlmhDG8S3vDHiblm3TiLlOEtP2+83x1z
zbpx1inDW2be6F8Sc826cdYp5+Et/TBL/OIVf5xZZV0XLd0168ZZp5yTt7CdnxU3grELwx/nIXRd
InXXrBtnnXIQb9O9IhP7T6brPPoEf5xZZV0XZN0168ZZpxzBW3p+b/krHf44Rfrj6K5ZN8465Yj1
Wy7e0mFO5A1/nL9D52Kju2bdOOuUJfVtdT2ZNcqY9sTBH8elvmW55tbrWwp+W/I713xy0aQXfxzR
+m37NbN+W8PbYLFa91fwxyl/fzLjNbM/uWB/MmVSl/JXxj5s4fmbhT+O7pqbfv4mejBdeHC+5LTX
3O75kgZh6zg/WcA1c36yocAfp4Rr1o2zSBneVDUZf5yYa9aNs0IZ3oqbA6NcsTK8kQcowxu8oQxv
BBmGMrzBG8rwBm8oowxvucaUIPDHIYjib9MMBEHAG0HAG0EQ8EYQ8EYQBLwRBLwRRP28EQQRE/8F
8LdiuLpD83oAAAAASUVORK5CYII=
</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2010-08-10 09:43:12 +0100" MODIFIED_BY="Finola M Delamere">
<APPENDIX ID="APP-01" MODIFIED="2010-06-17 09:16:39 +0100" MODIFIED_BY="Finola M Delamere" NO="1">
<TITLE MODIFIED="2010-06-17 09:16:39 +0100" MODIFIED_BY="Finola M Delamere">CSG Specialised Register search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-03-16 14:55:52 +0000" MODIFIED_BY="Finola M Delamere">
<P>
<BR/>((bullous and pemphigoid) OR (pemphigoid AND NOT gestationis)) AND ((drug AND therapy) OR treatment* OR medication* OR predniso* OR corticosteroid* OR steroid* OR azathioprine OR immunosuppres* OR dapsone OR erythromycin* OR tetracyclin* OR nicotinamide OR cyclophosphamide OR cyclosporin* OR sulph* OR methotrexate OR plasmaph* OR (mycophenolate and mofetil))</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2009-03-16 14:28:24 +0000" MODIFIED_BY="Finola M Delamere" NO="2">
<TITLE MODIFIED="2009-03-16 14:28:21 +0000" MODIFIED_BY="Finola M Delamere">Cochrane Library search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-03-16 14:28:24 +0000" MODIFIED_BY="Finola M Delamere">
<P>#1(bullous pemphigoid) OR (pemphigoid NOT gestationis)<BR/>#2MeSH descriptor Pemphigoid, Bullous explode all trees in MeSH products<BR/>#3(#1 OR #2)<BR/>#4SR-SKIN in All Fields in all products<BR/>#5(#3 AND NOT #4)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2010-08-10 09:43:09 +0100" MODIFIED_BY="Finola M Delamere" NO="3">
<TITLE MODIFIED="2009-03-16 14:39:31 +0000" MODIFIED_BY="Finola M Delamere">MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2010-08-10 09:43:09 +0100" MODIFIED_BY="Finola M Delamere">
<P>1. randomised controlled trial.pt.<BR/>2. controlled clinical trial.pt.<BR/>3. randomized.ab.<BR/>4. placebo.ab.<BR/>5. clinical trials as topic.sh.<BR/>6. randomly.ab.<BR/>7. trial.ti.<BR/>8. 1 or 2 or 3 or 4 or 5 or 6 or 7<BR/>9. (animals not (human and animals)).sh.<BR/>10. 8 not 9<BR/>11. bullous pemphigoid.mp. or exp Pemphigoid, Bullous/<BR/>12. pemphigoid gestationis.mp. or exp Pemphigoid Gestationis/<BR/>13. 11 not 12<BR/>14. 13 and 10<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2010-08-10 09:43:12 +0100" MODIFIED_BY="Finola M Delamere" NO="4">
<TITLE MODIFIED="2009-03-16 14:52:13 +0000" MODIFIED_BY="Finola M Delamere">EMBASE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2010-08-10 09:43:12 +0100" MODIFIED_BY="Finola M Delamere">
<P>1. random$.mp.<BR/>2. factorial$.mp.<BR/>3. (crossover$ or cross-over$).mp.<BR/>4. placebo$.mp. or PLACEBO/<BR/>5. (doubl$ adj blind$).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name]<BR/>6. (singl$ adj blind$).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name]<BR/>7. (assign$ or allocat$).mp.<BR/>8. volunteer$.mp. or VOLUNTEER/<BR/>9. Crossover Procedure/<BR/>10. Double Blind Procedure/<BR/>11. Randomized Controlled Trial/<BR/>12. Single Blind Procedure/<BR/>13. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12<BR/>14. bullous pemphigoid.mp. or exp Bullous Pemphigoid/<BR/>15. pemphigoid gestationis.mp. or exp Pemphigoid Gestationis/<BR/>16. 14 not 15<BR/>17. 16 and 13<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>

<EXTENSION ID="AFF_16372_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS"><ALIAS ALIAS_ID="16372"><ADDRESS><DEPARTMENT>Centre of Evidence Based Dermatology</DEPARTMENT><ORGANISATION>Nottingham University Hospitals NHS Trust</ORGANISATION><CITY>Nottingham</CITY><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></ALIAS></EXTENSION></EXTENSIONS>
</COCHRANE_REVIEW>